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Abstract 
Cancer associated fibroblasts (CAFs) are known to influence tumour progression 
through the secretion of factors which influence tumour growth and invasion. 
Collagen production is a major aspect of the secretory CAF phenotype. High 
collagen content in breast cancer is a marker of poor prognosis and is known to 
promote tumour growth and metastasis, as well is impeding drug delivery to the 
tumour through reduced perfusion. Tumour metabolism is also well established as 
a hallmark of cancer, however, how the metabolism of CAFs influences their pro-
tumourigenic phenotype is not yet well understood. 
 
We investigated metabolic differences between paired CAFs and normal 
fibroblasts (NFs) from breast tissue. Using an unbiased phosphoproteomic analysis, 
we identified pyruvate dehydrogenase kinase 2 (PDK2) as the most downregulated 
kinase in CAFs. PDK2 phosphorylates and deactivates pyruvate dehydrogenase 
(PDH), which is a key metabolic protein that converts pyruvate to acetyl-CoA in 
the mitochondria, providing a key link between the major metabolic pathways of 
glycolysis and the TCA cycle. However, extensive metabolic profiling of CAFs and 
NFs did not reveal metabolic differences that could be attributed to PDH activity. 
 
Acetyl-CoA is also used for protein acetylation, and, using an MS-proteomic 
approach, we discovered increased histone acetylation in CAFs, which has 
epigenetic implications for how CAFs regulate their activated phenotype. Using a 
combination of proteomics, metabolomics, in vitro assays and imaging analyses 
we investigated the role of PDH-mediated histone acetylation in CAFs and 
uncovered the importance of histone acetylation in regulating collagen and ECM 
production by CAFs. PDH activity also regulated PYCR1 expression in CAFs, and we 
further discovered that proline production by PYCR1 is further required to 
maintain PDH-activity induced collagen synthesis in CAFs. Our findings open up 
new possibilities for targeting the desmoplastic stroma to reduce tumour growth 
and metastasis, and improve drug delivery. 
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Chapter 1 Introduction 
 
1.1 Cancer associated fibroblasts in the tumour 
microenvironment 
 
1.1.1 The tumour microenvironment 
 
Tumours do not exist only as an isolated mass of tumour cells, but must exist in 
an already present complex body; indeed tumours utilise their surrounding tissues 
to provide them with a wide range of factors which they require to grow and 
progress. Whereas initial research on cancer as a disease focussed on targeting 
the tumour cells themselves, in more recent decades it has become clear that the 
cells and tissue surrounding the tumour, known as the ‘tumour microenvironment’ 
(TME), is a key targetable feature of the tumour. The TME is inseparably 
intertwined with the fate of the tumour through a complex array of interactions 
and crosstalk between different cell types and extracellular matrix (ECM), such 
that a tumour can be considered as a new and separate organ, albeit an 
abnormally functioning one (Egeblad et al., 2010).  
 
Tumour cells recruit and activate cells from their surrounding tissue via the 
secretion of growth factors, chemokines and cytokines. For example, VEGF 
secreted by tumour cells stimulates blood vessel sprouting (Carmeliet, 2005), 
which is a critical step in tumour vascularization. Intratumoural blood vessels are 
important for tumour development because in order to grow the tumour needs to 
develop its own supply of oxygen and nutrients, as well as providing tumour cells 
with a means of dissemination into the blood stream to form distant metastases. 
Tumours also create an immunosuppressive environment to evade being targeted 
by the immune system. For example, secretion of cytokines, such as IL-23, CXCL5, 
CXCL7, IL-1β, IL-6, CCL2 and CCL9, recruit immunosuppressive macrophages, 
neutrophils and CD4+ T cells to the tumour, while repelling immunoactive NK, B 
and CD8+ T cells (Koyama et al., 2016, Rabinovich et al., 2007, Kortlever et al., 
2017). Additionally, tumours secrete factors including IL-4 and IL-13 to polarise 
macrophages from the immunoactive M1 phenotype to the immunosuppressive M2 
(Aras and Zaidi, 2017).  Finally, cancer associated fibroblasts (CAFs) are highly 
abundant in the TME. CAFs have a highly secretory phenotype themselves that 
15 
 
promotes tumour growth, progression, and metastasis, and have been shown to 
be recruited and activated through a combination of growth factors and cytokines 
including TGF-β, TNF-α, PDGF and FGF2 (LeBleu and Kalluri, 2018), as well as 
signalling proteins such as Wnt (Avgustinova et al., 2016) and integrin mediated 
interactions with the ECM (Franco-Barraza et al., 2017).  
 
Therapeutically, targeting the TME has a number of advantages. Since cells of the 
TME are more genetically stable than tumour cells, they are less likely to gain 
resistance to therapies. Furthermore, the tumour microenvironment may provide 
support to tumour cells which enables them to overcome traditional cytotoxic 
therapies, and also reduces efficient drug delivery due to the leaky vasculature 
and increased interstitial fluid pressure (Joyce, 2005). Combination therapies 
combining standard chemotherapy with tumour microenvironment targeting drugs 
have been particularly successful in the clinic. For example, using the anti-VEGF 
antibody Avastin to normalise the tumour vasculature in combination with 
standard chemotherapy has shown benefits and is an approved line of treatment 
in some colorectal, breast and non-small cell lung cancers (Sini et al., 2016, 
Hurwitz, 2004, Sandler et al., 2006), and the anti β1-integrin antibody P5, which 
targets interactions between tumour cells and the ECM, has reached stage III 
clinical trials in combination with cisplatin for treatment of non-small cell lung 
cancer (Kim et al., 2016). Of recent years, targeting the immune response in 
tumours has been a breakthrough in cancer treatment, with the recent completion 
of several phase II or III trials combining checkpoint inhibitors with standard 
chemotherapy in lung, HNSCC and breast cancers (Gandhi et al., 2018, Bauml et 
al., 2017, Schmidt, 2019). Two immunotherapies have also recently been 
approved for treatment of acute myeloid leukaemia and diffuse-large B cell 
lymphoma (Maude, 2018, Schuster and Investigators, 2019). Therefore 
understanding the mechanisms that regulate the pro-tumourigenic 
microenvironment has led to the development of important anti-cancer therapies, 
and is vital to gain insight into potential vulnerabilities of the tumour. During my 
PhD I focussed on how the pro-tumourigenic phenotype of CAFs is regulated, and 
therefore in the following sections I will describe in more detail the fundamental 
role of CAFs in the TME and the myriad of ways in which they promote tumour 
progression.  
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1.1.2 The origins and definition of cancer associated fibroblasts 
 
Fibroblasts are found throughout the body as cells whose primary function is to 
continuously secrete ECM to maintain the structure of connective tissues. 
Fibroblasts secrete components of the fibrillar ECM and basement membrane, 
including collagens, fibronectin and laminin (Tomasek et al., 2002, Rodemann and 
Muller, 1991), as well as matrix metalloproteases (MMPs) to regulate ECM turnover 
(Simian et al., 2001). Fibroblasts are also mediators of the wound healing 
response, providing new ECM deposition to act as a scaffold for wound closure, 
contractile forces to close the wound, pro-angiogenic factors to promote blood 
vessel formation and growth factors to promote cell proliferation (Darby et al., 
2014). In order to carry out these functions, fibroblasts in a wound become 
‘activated’, a state which is most often characterised by an increase in the 
cytoskeletal protein α-smooth muscle actin (αSMA) expression. A chronic wound 
healing response is also found in diseases of fibrosis and in tumours, since the 
continuously growing tumour causes persistent injury in the surrounding tissue. 
This has led to the description of tumours as ‘wounds that do not heal’ (Dvorak, 
2015). In accordance with this, activated fibroblasts make up a significant 
component of tumours, where their wound healing phenotype is co-opted by the 
tumour to provide a stroma that promotes tumour growth and development. 
 
The activation of quiescent fibroblasts into CAFs has been the subject of much 
study, with many different pathways being implicated. Undoubtedly the most 
widely known activating factor is transforming growth factor beta (TGF-β), which 
is produced initially by cancer cells and binds to the type 2 TGF-β receptor on 
CAFs, stimulating ECM production and secretion of paracrine signalling factors. 
TGF-β activation then is maintained by autocrine CAF signalling, creating a 
positive feedback loop of CAF activation (Ronnov-Jessen and Petersen, 1993, 
Kojima et al., 2010, Colak and Ten Dijke, 2017). Platelet derived growth factor 
(PDGF) is another CAF activating factor frequently secreted by tumour cells and 
has been shown to stimulate ECM production and fibroblast proliferation (Shao et 
al., 2000, Cadmuro et al., 2013). CAFs have also been shown to be activated by 
other secreted proteins including Wnt7a signalling (Avgustinova et al., 2016), and 
inflammatory TNFα, IL-1β and IL-6 signalling (Giannoni et al., 2010, Katanov et 
al., 2015). In recent years, several studies have shown that tumour derived micro-
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RNAs, which are transferred to CAFs via exosomes, also play a role in CAF 
activation (Fang et al., 2018, Pang et al., 2015, Dror et al., 2016). The physical 
alterations that occur in the tumour microenvironment can further contribute to 
CAF activation, such as increased mechanical stress, hypoxia and oxidative stress 
(Calvo et al., 2013, Toullec et al., 2010, Chiavarina et al., 2010, Martinez-
Outschoorn et al., 2010a). Interestingly, hypoxia has also been shown to 
deactivate fibroblasts via loss of PHD2 (Madsen et al., 2015), so the role of hypoxia 
in fibroblast activation has yet to be elucidated. Therefore there is no single 
pathway that activates CAFs from normal fibroblasts, and the specific mechanism 
may depend on the tumour cells and other factors of the TME for each individual 
cancer. 
 
In addition to being activated through a combination of different signalling 
pathways, CAFs can also be derived from a variety of different cell types. Although 
the majority of CAFs are likely to be derived from resident quiescent fibroblasts 
from the tissue of origin of the cancer, other cell types can also be recruited by 
the cancer and develop a CAF-like phenotype. Bone marrow mesenchymal stem 
cells are a popular source of CAFs, with reports showing that up to 20-25% of CAFs 
originate from the bone marrow in mouse models of pancreatic and gastric cancer 
(Ishii et al., 2003, Quante et al., 2011). In breast cancer models, bone marrow 
derived CAFs can form a separate CAF subpopulation which may even be more 
aggressive than CAFs derived from resident fibroblasts (Raz et al., 2018)  
Furthermore, Jotzu et al. demonstrated that adipocyte stem cells, which are 
known to interact with tumour cells, develop an αSMA positive, myofibroblast-like 
phenotype when treated with cancer cell conditioned media (Jotzu et al., 2010). 
TGF-β treatment of endothelial cells can induce a myofibroblastic phenotype 
(Zeisberg et al., 2007), and it has even been suggested that epithelial cells can 
develop into CAFs or activated fibroblasts through undergoing epithelial to 
mesenchymal transition (EMT) (Petersen et al., 2001, Iwano et al., 2002). 
 
With such a varied array of origins and activation pathways, it is unsurprising that 
there is no common consensus for defined markers of CAFs. αSMA is the most 
commonly used CAF marker, both because it is a hallmark of upregulated TGF-β 
signalling, which as mentioned previously is one of the most well-defined 
pathways of CAF activation, and because αSMA expression is often equated with 
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the contractile, ECM producing myofibroblast phenotype. However, it has been 
demonstrated that not all contractile fibroblasts are αSMA positive (Sun et al., 
2016). There are many other markers associated with activated fibroblasts 
including upregulation of vimentin, PDGFRα, fibroblast activating protein (FAP) 
and fibroblast specific protein (FSP-1), and downregulation of caveolin-1 (CAV1) 
and CD36. These markers do not always appear concurrently, and none of them 
are specific for cancer associated fibroblasts as they also label other cell types. 
Even αSMA is also highly expressed in pericytes (Kalluri, 2016). Therefore CAFs are 
a broad and heterogeneous group of cells, which can be recruited from a number 
of different cell types and activated by a combination of many different 
mechanisms. Perhaps this reflects the heterogeneity of the tumours themselves, 
as different tumours are likely to be able to utilise different pathways of CAF 
activation. 
 
1.1.3 The pro-tumourigenic phenotype of CAFs 
 
A multitude of studies have demonstrated that CAFs promote tumour progression, 
growth and metastasis. Early studies showed that isolated CAFs support tumour 
formation in vivo whereas normal fibroblasts do not (Olumi et al., 1999, Orimo et 
al., 2005) and are also more pro-invasive and pro-angiogenic (Dimanche-Boitrel et 
al., 1994, Fukumura et al., 1998) One of the key features of CAFs that distinguishes 
them from normal fibroblasts is their highly secretory phenotype which influences 
both tumour cells and other cell types of the TME (Fig. 1-1). CAFs have been shown 
to secrete several growth factors which stimulate tumour proliferation and 
metastasis. Among these are HGF, which has also been shown to promote 
chemoresistance, CTGF, EGF and IGF, secretion of which is upregulated under 
hypoxic conditions (Straussman et al., 2012, Ding et al., 2018, Tyan et al., 2011, 
Ren et al., 2015, Rozenchan et al., 2009) (Unger et al., 2017, Hirakawa et al., 
2016). CAFs can also fuel tumour growth through secretion of metabolites such as 
lactate, ketones and amino acids (Martinez-Outschoorn et al., 2010) and stimulate 
growth, EMT and cell migration through cytokines such as IL-6 (Wu et al., 2017, 
Kinoshita et al., 2013). 
 
A key group of secreted factors by CAFs is pro-angiogenic factors. CAFs are a major 
regulator of angiogenesis in the TME, which is vital to provide tumours with a 
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supply of oxygen and nutrients for growth, and also a means of metastasis. The 
excess of pro-angiogenic factors in the TME also creates a leaky and irregular 
network of blood vessels, which further promotes metastasis and impairs drug and 
oxygen delivery creating more aggressive tumours (Carmeliet and Jain, 2000). 
CAFs induce angiogenesis through secretion of VEGF, the most potent and well-
known pro-angiogenic factor, as well as TGF-β, PDGF, SDF-1 and IL-6 (Nagasaki et 
al., 2014, Ferrara, 2010, Gomes et al., 2013). ECM remodelling due to the 
increased contractility of CAFs also increases vascularisation (Sewell-Loftin et al., 
2017). Interestingly, stromal angiogenesis can preclude response to anti-VEGF 
treatment. A study found that tumours with blood vessels predominantly within 
the tumour cells responded better to the VEGF antibody bevacizumab either as a 
single therapy or in combination with traditional chemotherapy, as opposed to 
tumours with predominantly stromal blood vessels (Smith et al., 2013), suggesting 
that blood vessels stimulated by CAFs are more resistant to anti-angiogenic 
therapies. 
 
CAF protein secretion also influences the immune response. Secretome and 
proteomic analyses of CAFs have revealed a highly immunomodulatory secretome 
(Torres et al., 2013, Ge et al., 2012). More in depth studies have shown that 
secretion of growth factors, cytokines and chemokines such as TGF-β, CCL2, CCL5, 
CXCL14, CXCL12, SDF1 and IL-6 promote M2 macrophage differentiation, recruit 
neutrophils and inhibit cytotoxic T-cells and natural killer cells (Comito et al., 
2014, Takahashi et al., 2017, Castriconi et al., 2003, Ziani et al., 2018). 
Upregulated production and secretion of the prostaglandin PGE2 also inhibits the 
anti-tumour immune response (Kalinski, 2012). Moreover, CAFs may account for 
the failure of some patients to respond to immunotherapy. In a mouse model of 
pancreatic ductal adenocarcinoma (PDAC), it was found that CXCL12 produced by 
FAP+ CAFs was preventing response to two checkpoint inhibitor therapies, despite 
the presence of tumour suppressive CD8+ T cells. Simultaneously treating tumours 
with a CXCL12 receptor inhibitor and the checkpoint inhibitor α-PD-L1 caused 
rapid recruitment of T-cells to the tumour and reduced tumour size (Feig et al., 
2013). This study highlights the advantages of using combination therapies 
targeting the tumour microenvironment alongside the tumour cells to increase 
tumour sensitivity and response to drugs. 
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Another important aspect of the TME influenced by CAF secretion is the ECM, 
which I will expand upon in later sections. Briefly, CAFs upregulate secretion of 
ECM components including collagens, fibronectin and laminin, resulting in a 
thicker and stiffer desmoplastic stroma that promotes tumour growth and 
invasiveness (Naba et al., 2014, Alexander and Cukierman, 2016, Kai et al., 2019). 
Conversely, CAFs also secrete matrix metalloproteases (MMPs) which degrade the 
matrix and enable angiogenesis and tumour cell migration (Boire et al., 2005, 
Deryugina and Quigley, 2015). ECM also confers drug resistance through adhesion 
of cancer cells to the ECM and through compressing blood vessels so that perfusion 
is limited in the tumour (Hazlehurst and Dalton, 2001, Chauhan et al., 2013).  
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Figure 1-1 CAFs are highly secretory cells 
Diagram showing the wide variety of secreted factors from CAFs. Images were adapted from 
https://smart.servier.com/ 
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Although the majority of studies on CAFs demonstrate that they are pro-
tumourigenic, several works have also demonstrated an anti-tumour effect of 
CAFs. Two studies in PDAC demonstrated a tumour suppressive role for CAFs. 
Depleting sonic hedgehog, which is a CAF activator, in a mouse model of PDAC 
actually increased tumour aggressiveness and vascularisation, showing that a high 
stromal content is not necessarily pro-tumourigenic (Rhim et al., 2014). Similarly, 
depleting αSMA+ cells in PDAC also increased tumour aggressiveness, (Ozdemir et 
al., 2014) suggesting that αSMA is not necessarily a marker of the pro-tumourigenic 
CAF phenotype. Patient derived mammary fibroblasts have been shown to express 
high levels of SLIT-2, which suppresses breast cancer cell invasion and is a 
predictor of better clinical outcome in patients (Chang et al., 2012). Once again, 
the heterogeneity of CAFs is evident in their functionality in addition to their 
origins and activation mechanisms. 
 
In recent years, the heterogeneity of CAFs has been further expanded by the 
discovery of different subpopulations of CAFs which may co-exist in the same 
tumour. For example, Ohlund et al. distinguished between two spatially distinct 
subpopulations of contractile, αSMA high myCAFS and proinflammatory iCAFs in 
KPC tumours (Ohlund et al., 2017). Subsequent studies have identified four 
subpopulations in CAFs derived from breast tumours through the more high-
throughput analysis techniques of single cell RNA-sequencing and flow cytometry 
analysis (Costa et al., 2018, Bartoschek et al., 2018). Still, αSMA expression and 
modulation of the immune response remain key distinguishing features between 
the different subtypes. In the Costa et al. study, it was shown that enrichment in 
breast tumours for either or both of two of their four defined subtypes was a 
predictor for subsequent metastasis, demonstrating the prognostic power of the 
stroma. Another recent study identified a subset of CAFs driving tumour growth 
as well as promotion of cancer stem cells and chemoresistance in lung and breast 
cancer. Usefully, these CAFs could be identified by the cell surface markers CD10 
and GPR77, and were successfully targeted by an anti-GPR77 antibody, providing 
evidence that it may be possible to target specific tumour promoting CAF 
subpopulations (Su et al., 2018). There is also evidence to suggest that CAFs 
derived from different cell types contribute to functionally different 
subpopulations, as bone marrow derived CAFs and resident CAFs formed two 
distinct subpopulations defined by PDGFR expression in the MMTV-PyMT model 
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(Raz et al., 2018). In a review on CAFs, Kalluri postulates that there may be many 
subtypes including tumour restraining, tumour promoting, secretory and ECM-
remodelling CAFs (Kalluri, 2016). As this is a relatively recent field of CAF 
research, it will be interesting to see what future developments there are in 
identification of CAF subpopulations, and what the implications are for trying to 
pharmacologically target the CAF phenotype.  
 
So far, no drugs have been developed specifically to target CAFs, although 
pirfenidone has been approved to treat fibrotic fibroblasts, which have a similar 
activated, wound healing phenotype (Takeda et al., 2014). Drugs have also been 
developed that target aspects of the TME known to be regulated by CAFs, such as 
suramin, which targets ECM turnover and blocks FGF and PDGF signalling and has 
shown promising results in breast and prostate cancers (Cheng et al., 2019). Yet 
drugs specifically targeting CAF activation, such as Shh inhibitors and the anti-FAP 
antibody sibrotuzumab, have so far failed to show benefits in clinical trials. 
However, new therapies are constantly being developed. A vitamin D analogue 
which has been shown to deactivate CAFs in pancreatic cancer (Sherman et al., 
2014) is currently being tested in clinical trials in combination with standard 
chemotherapy. CAFs have also been targeted with nanoparticles which both 
deactivate the CAFs and cause apoptosis of surrounding tumour cells (Miao et al., 
2015). Therefore there is still much to be discovered about the pro-tumourigenic 
CAF phenotype and vulnerabilities for potential therapeutic treatment. 
 
1.1.4 CAFs in breast cancer 
 
During my PhD I focussed on mammary CAFs. Breast cancer is the most common 
cancer in women worldwide, and according to the world health organisation 
(WHO) over 600,000 women died from breast cancer in 2018. In high income 
countries such as Japan or the USA, the survival rate is around 80% due to early 
detection programmes as well as advances in diagnosis and treatment, whereas in 
low income countries the survival rate is halved to around 40%. However, even 
with up to 80% of patients able to be successfully treated, the 20% who are not 
are still make up a considerable number. In the UK, breast cancer accounts for 7% 
of all cancer deaths and worldwide for 15% of all cancer deaths, with the rate of 
breast cancer incidence and mortality increasing most rapidly in the developing 
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world. Therefore there is still a need for new targets and therapies, and for a 
greater understanding of the molecular mechanisms driving breast cancer. 
 
The current system of patient classification for therapy is based on the standard 
clinical factors of tumour size, grade and presence of metastases, but also on 
breast cancer specific molecular markers. These consist of three receptors: the 
oestrogen receptor (ER), the progesterone receptor (PR) and the human epidermal 
growth factor receptor 2 (HER2). The system of classification was developed about 
twenty years ago by comparing gene expression data with clinical data from 
patient tumours (Perou et al., 2000, Sorlie et al., 2001). Five subtypes were 
identified: Normal-like (ER+ PR+ HER2-), Luminal A (ER+ PR+ HER2-), Luminal B 
(ER+ PR+ HER2+/-), HER2-amplified (ER- PR- HER2+) and Triple negative (ER- PR- 
HER2-). The ER+ and PR+ tumours have the best predicted outcome (Dunnwald et 
al., 2007) and usually respond to hormonal therapies, such as tamoxifen. Triple 
negative breast cancer (TNBC) has the worst prognosis, and there are currently no 
targeted therapies; the only options are standard chemotherapy, radiotherapy and 
surgery.  
 
The stroma is an extremely important aspect of breast cancer. Breast cancers 
have a particularly high stromal component with up to 80% of fibroblasts being 
activated as defined by high αSMA expression (Sappino et al., 1988) and the 
presence of αSMA positive myofibroblasts is further correlated with decreased 
survival and higher proliferation of tumour cells in breast cancer (Surowiak et al., 
2007). Other studies have also shown a correlation with a higher proportion of 
stroma in breast tumours with a poorer clinical outcome, especially in TNBC (de 
Kruijf et al., 2011, Moorman et al., 2012, Kramer et al., 2019). Furthermore, the 
gene signature of breast cancer stroma can serve as a prognostic marker. Using 
microdissected stroma from 53 breast cancer patients, Finak et al. formulated a 
set of 26 prognostic genes which, when applied to other data from independent 
studies, successfully predicted patient outcome (Finak et al., 2008). Further 
stromal prognostic markers in breast cancer have been identified, such as PDGFR 
expression (Paulsson et al., 2009) and ERK phosphorylation, which predicts 
tamoxifen resistance (Busch et al., 2012). Interestingly, one of the studies on CAF 
subpopulations also connected different CAF subpopulations with the different 
molecular subtypes of breast cancer, with enrichment of the immunosuppressive 
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CAF-S1 subtype in TNBC and enrichment of the myofibroblastic CAF-S4 subtype in 
HER2+ tumours (Costa et al., 2018). This suggests that, for example, the CAF-S1 
subtype could be targeted to improve response to immunotherapies such as anti-
PD-L1 treatment. Another intriguing recent study suggested that the stroma may 
play an active role in determining the molecular subtype of breast cancer. 
Targeting the signalling between PDGF producing basal-like carcinoma cells and 
the corresponding PDGF-receptor expressing CAFs transformed the cancers into a 
hormone receptor positive state, increasing their sensitivity to hormone therapy 
that they had previously shown resistance to (Roswall et al., 2018). Therefore 
breast cancer stroma plays a significant role in controlling patient outcome and is 
a potential therapeutic target. 
 
The molecular mechanisms underpinning the pro-tumourigenic aspects of 
mammary CAFs have been studied in some detail. The classic tropes of high αSMA 
expression and TGF-β signalling are key features of mammary CAFs. 
Overexpression of TGF-β or HGF in mammary fibroblasts stimulated breast cancer 
initiation in mice (Kuperwasser et al., 2004), and TGF-β treatment of mammary 
fibroblasts resulted in increased expression of many ECM-remodelling and pro-
tumourigenic proteins, including hyaluron synthase 2, fibulin-5, CTGF, 
podocalyxin and EphA2 in a proteomic study (Groessl et al., 2014). As well as being 
activated by TGF-β secreted by tumour cells, CAFs also produce their own TGF-β, 
and it has been shown that Wnt7a produced by breast cancer cells stimulates TGF-
β production and signalling in CAFs (Avgustinova et al., 2016). After activation by 
TGF-β, mammary CAFs can maintain their myofibroblast activation through 
autocrine TGF-β and SDF1 signalling (Kojima et al., 2010). TGF-β signalling by 
mammary CAFs is an important aspect of their pro-tumourigenic phenotype. For 
example, TGF-β signalling is known to upregulate αSMA expression; and mammary 
CAFs overexpressing miR-200 to reduce αSMA expression and contractility formed 
smaller tumours in vivo (Tang et al., 2016). In co-culture experiments, TGF-β 
production by CAFs also stimulated EMT in breast cancer cell lines (Yu et al., 
2014), which increased their metastatic potential. Furthermore, TGF-β activation 
in mammary CAFs stimulated CAF metabolic reprogramming, with an increase in 
oxidative stress, autophagy and a more glycolytic metabolism, which in turn 
promoted tumour growth (Guido et al., 2012). TGF-β signalling has been further 
associated with regulating production of MMPs and chemokines in mammary CAFs 
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(Moore-Smith et al., 2017, Fang et al., 2015). However, targeting TGF-β in CAFs 
can simply lead to compensation by HGF, which also promotes tumour growth and 
invasion (Cheng et al, 2008). 
 
Mammary CAFs have been implicated in all of the pro-tumourigenic effects of CAFs 
on the TME. They promote angiogenesis through upregulation of VEGF signalling 
(Kugeratski et al., 2019), through deformation of the ECM (Sewell-Loftin et al., 
2017), and through secretion of factors such as the oxidoreductase CLIC3, which 
acts via TGM2 (Hernandez-Fernaud et al., 2017), and SDF-1, which additionally 
promotes tumour growth via CXCR4 (Orimo et al., 2005). Mammary CAFs also 
contribute to an immunosuppressive microenvironment (Cohen et al., 2017, Liao 
et al., 2009) and promote chemoresistance (Mao et al., 2014).  They have been 
further shown to promote breast cancer invasion and metastasis through a variety 
of secreted factors, including CLIC3, CXCL12, and IL-32 (Hernandez-Fernaud et 
al., 2017, Dvorak et al., 2018, Wen et al., 2019). 
 
In addition to secreting protein factors and metabolites, there is a growing field 
of research showing that CAFs, including mammary CAFs, also modulate the TME 
through secretion of extracellular vesicles containing proteins, metabolites and 
nucleic acids. Luga et al. first showed that CAFs from breast cancer patients 
produced CD81+ exosomes which increased breast cancer cell motility and 
metastasis through Wnt signalling activation (Luga et al., 2012). The transfer of 
Wnt10b by CAF-derived exosomes was also shown to increase breast cancer cell 
invasion (Chen et al., 2017). In addition to protein transfer, one of the key ways 
in which vesicles from mammary CAFs are able to influence cancer cells is through 
miRNA transfer. The miR221/222 secreted by CAFs was shown to induce 
hyperactive MAPK signalling in breast cancer cells, which is known to be associated 
with a higher risk of recurrence and poorer survival (Shah et al., 2015). Similarly, 
a combination of three miRNAs contained in CAF-derived exosomes promoted 
cancer cell stemness and EMT in breast cancer (Donnarumma et al., 2017). 
Mammary CAF-derived exosomes can also contain mitochondrial DNA, which has 
been shown to restore oxidative phosphorylation to breast cancer cells with 
impaired metabolism and enable therapy resistance (Sansone et al., 2017). 
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Therefore CAFs in breast cancer stroma play an extremely important role in 
tumour progression, and understanding the mechanisms involved in how CAFs 
create a pro-tumourigenic microenvironment could provide important information 
on how to therapeutically target breast cancer. In the following sections I will go 
into more detail about the crucial roles that CAF derived ECM and CAF metabolism 
play in creating a pro-tumourigenic TME. 
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1.2 The role of CAF-derived ECM in cancer 
 
1.2.1 Properties of the extracellular matrix 
 
The ECM is made up of a variety of proteins, glycoproteins, proteoglycans and 
polysaccharides (Ozbek et al., 2010). There are two types of ECM: the basement 
membrane and the interstitial matrix. The basement membrane separates 
epithelium from stromal cells and is very compact, whereas the interstitial matrix 
contributes to the tensile strength of tissues and is more porous. The basement 
membrane is composed primarily of collagen IV, fibronectin, laminins and linker 
proteins. The interstitial matrix also contains a high proportion of fibronectin and 
collagens, but additionally contains a greater amount of glycoproteins and 
proteoglycans (Egeblad et al., 2010). The ECM therefore contains a high degree of 
biophysical and biochemical diversity. 
 
Physically, the ECM’s orientation, stiffness, porosity and ability to act as a barrier 
determine the scaffolding and integrity of tissues. The orientation of fibres, the 
physical barrier and the availability of proteins for cell adhesion also regulate cell 
migration (Lu et al., 2012). Furthermore, ECM elasticity and stiffness is a key 
environmental regulator of cell behaviour. Focal adhesion complexes, which are 
plasma membrane-associated multi-protein complexes that interact with the ECM 
through receptors such as integrins, act as mechanosensing links between ECM 
stiffness and the cytoskeleton and cell signalling pathways. Their components can 
change conformation depending on the applied force (Sawada et al., 2006, del Rio 
et al., 2009). This leads to functional consequences for the cell, including 
regulation of cell fate, cell contractility, and conventional cell signalling pathways 
(Engler et al., 2006, Gehler et al., 2009, Maeda et al., 2011).  
 
Biochemically, the ECM is rich in signalling cues, acting as a reservoir of signalling 
molecules such as the growth factors FGF and VEGF, which bind to proteoglycans. 
It has been suggested that this can create growth factor gradients, which are 
important for determining cell fate in development, or that these growth factor 
reserves can be released when required by ECM degradation (Hynes, 2009). 
Integrins provide cells with the ability to anchor themselves to the ECM, and are 
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also key mediators of signalling pathways regulating cell growth and proliferation, 
metabolism and migration, such as the MAPK cascade (Ata and Antonescu, 2017, 
Schwartz and Assoian, 2001).  
 
Tissues can constantly make new ECM, degrade existing ECM via MMPs and 
rearrange or realign ECM fibres via crosslinking and covalent modifications, making 
the ECM a highly dynamic structure that is able to stimulate rapid changes in cell 
behaviour. 
 
1.2.2 An overview of collagen 
 
Collagen accounts for approximately a third of all proteins in humans and other 
animals, and is furthermore the most abundant protein in the ECM. Approximately 
28 different collagens have been identified in vertebrates (Gordon and Hahn, 
2010). It is primarily a structural protein, and all collagens contain three 
polypeptide α-chains which fold together to form a rod-like triple helix. Each chain 
consists of a repeating Gly-X-Y triplet amino acid motif, in which X and Y are most 
commonly proline or hydroxyproline, which is a derivative of proline produced by 
prolyl hydroxylases. This is because small, flexible amino acids are required to fit 
into the helix conformation, and in particular glycine is the only amino acid small 
enough to fit into the centre of the triple helix. Furthermore, the hydroxyproline 
residues can form hydrogen bonds along the helix to stabilise it. Some collagens 
contain interruptions or imperfections in the Gly-X-Y motif which destabilise the 
helix and thus give them increased flexibility. Collagens are heavily post-
translationally modified in the endoplasmic reticulum where lysyl hydroxylases 
and prolyl hydroxylases create hydroxylysine and hydroxyproline respectively on 
the nascent polypeptide. The hydroxylysine residues can be further glycosylated. 
After folding, the full length collagen chain or ‘procollagen’ consists of a 
collagenous NC1 domain and a non-collagenous NC2 domain, which keeps the NC1 
domain soluble in the cell. Upon secretion, the NC2 domain is cleaved by 
procollagen N-proteases, which causes a sudden decrease in solubility and the 
collagens form aggregates. Lysyl oxidases can further stabilise the fibrillar 
aggregates by covalently crosslinking adjacent fibrils (Boot-Handford and 
Tuckwell, 2003, Kadler et al., 2007). 
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There are three classes of collagens: fibrillar collagens which make up the 
interstitial matrix, network-forming collagens which are found in the basement 
membrane, and transmembrane collagens which are involved in cell adhesion 
(Shoulders and Raines, 2009, Franzke et al., 2003). Collagen I is the archetypal 
fibrillar collagen, although collagens II, III, V and VI are also common fibrillar 
collagens, while collagen IV is the most abundant network-forming collagen. 
 
1.2.3 Features and properties of CAF-derived ECM 
 
As discussed previously, the main function of quiescent fibroblasts is to maintain 
the ECM of connective tissue. Under normal activation in wound healing, ECM 
production is enhanced in order to produce new ECM to heal the wound and create 
a scaffold for the cells migrating and proliferating to close the gap. Therefore it 
is unsurprising that one of the main outputs of fibroblasts activated in the context 
of cancer is ECM production. Indeed CAFs are the main source of ECM in tumours 
(Bhowmick et al., 2004). CAF-derived ECM differs from normal ECM in its 
composition, turnover and stiffness, and in the alignment of fibres. 
 
One of the major differences between CAF and normal fibroblast (NF) derived ECM 
is simply that they make more of it. CAFs deposit large quantities of ECM proteins 
including fibronectin, hyaluronic acid and collagen, which is the most abundant 
ECM protein and makes up to 30% of the total protein mass of animals (Frantz et 
al., 2010). Many collagens are enriched in tumour ECM, including collagen I, II, III, 
IV, V, VI and XI (Kauppila et al., 1998, Nissen et al., 2019). In addition to producing 
more collagen, CAFs also induce higher rates of ECM turnover and remodelling of 
the basement membrane through increased expression of ECM degrading enzymes, 
the most prominent of which are the MMPs, paving the way for cancer cells to 
proliferate, migrate and for new blood vessel formation (Kessenbrock et al., 
2010). Furthermore, the presence of collagen degradation products in serum can 
distinguish between healthy and breast or ovarian cancer patients (Bager et al., 
2015). 
 
In addition to increasing ECM production and turnover, CAF-derived ECM is also 
stiffer, in part because there is more of it but also due to increased crosslinking 
of fibrillar proteins such as collagens and elastin by lysyl oxidase and 
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transglutaminase, expression of both of which are upregulated in CAFs (Levental 
et al., 2009, Lucero and Kagan, 2006). Fibres in the ECM produced by CAFs are 
also more directionally aligned and bundle together to create gaps in the 
basement membrane. Indeed, the alignment of collagen fibres in the ECM can be 
used to predict patient outcome in breast cancer (Bredfeldt et al., 2014, Conklin 
et al., 2011).  Ao et al. showed that the mechanical forces that CAFs exert on the 
ECM also cause alignment of fibronectin fibres (Ao et al., 2015). Interestingly, high 
Cav-1 expressing mouse fibroblasts also showed more fibronectin and collagen 
alignment via increased Rho-mediated contractile force (Goetz et al., 2011), 
despite the fact that other studies have claimed that loss of Cav-1 in CAFs is a 
marker of the TGF-β induced myofibroblastic phenotype (Guido et al., 2012, 
Martinez-Outschoorn et al., 2010a), again highlighting fibroblast heterogeneity 
and the many different opposing signalling pathways that fibroblasts can use to 
create a pro-tumourigenic microenvironment. Similarly, it was shown that CAFs 
expressing Snail-1, which induces RhoA and αSMA mediated contractility, 
increased anisotropic fibre organisation and matrix stiffness (Stanisavljevic et al., 
2015). CAF contractility was also shown to be necessary for matrix remodelling in 
gastric cancer, where cancer cells were able to invade matrigel that was being 
remodelled by CAFs (Yamaguchi et al., 2014). Therefore it seems that the 
myofibroblastic, contractile, αSMA positive CAF phenotype is key to ECM 
remodelling in the TME. 
 
1.2.4 CAF-derived ECM sustains and promotes tumour development 
 
Taken together, the increased ECM deposition and turnover as well as increased 
matrix stiffness and remodelling create a highly pro-tumourigenic environment. 
One of the hallmarks of cancer is sustained proliferation, and CAF-derived ECM 
sustains proliferation through several pathways. Firstly, as mentioned previously, 
the increased ECM deposition by CAFs enables integrin adhesion by cancer cells, 
which sustains proliferative signalling through Fak activation leading to Erk/PI3K 
signalling and cell cycle progression (Schwartz and Assoian, 2001). The increased 
stiffness of the ECM further upregulates integrin-mediated Fak phosphorylation 
and accelerates cell cycle progression (Bae et al., 2014, Provenzano and Keely, 
2011). Equally, integrin mediated adhesion to the ECM can inhibit tumour growth 
suppressors such as BRCA1 and p21 and allow cancer cells to circumvent these 
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pathways (Kim et al., 2008, O'Connell and Martin, 2000), as well as inducing anti-
apoptotic factors and blocking p53-mediated apoptosis to promote cell survival 
(Gilmore et al., 2000, Lewis et al., 2002). Furthermore, as discussed previously, 
the ECM can act as a reservoir of growth factors and signalling molecules such as 
FGF and Wnt. Enhanced degradation of the ECM by MMPs produced by CAFs can 
release these factors, stimulating tumour growth. Additionally, TGF-β, which is a 
key factor promoting tumour progression, is secreted in an inactive form and is 
subsequently activated by MMP cleavage or by mechanical stress, both of which 
are enhanced by CAFs (ten Dijke and Arthur, 2007). Interestingly, it has recently 
been shown that cancer cells can use the ECM for metabolic fuel; taking up and 
degrading collagen to satisfy their demand for amino acids and promote tumour 
growth and survival (Gouirand and Vasseur, 2018). In vivo, the effects of the ECM 
on tumour growth have been assessed in several studies. Ablation of Col6a1 or 
Col5a3 in the MMTV-PyMT mammary tumour model resulted in reduced hyperplasia 
and primary tumour growth (Iyengar et al., 2005, Huang et al., 2017). Conversely, 
mice which have been engineered to produce more collagen (Col1a1tm1jae) showed 
increased tumour growth in the MMTV-PyMT model (Esbona et al., 2016, 
Provenzano et al., 2008). Inhibition of production of other ECM components such 
as hyaluronan, fibronectin and tenascin-C also suppresses tumour initiation and 
growth (Udabage et al., 2005, Lingasamy et al., 2019). 
 
In addition to promoting tumour growth and survival, CAF-derived ECM is a key 
factor in determining the metastatic ability of tumours by promoting EMT, 
inducing invadopodia formation and providing cancer cells with escape routes. 
Increased ECM stiffness has been shown to promote hallmarks of EMT in cancer 
cells, such as TWIST1 activation, vimentin expression and β-catenin nuclear 
localisation (Wei et al., 2015, Rice et al., 2017). One of the many roles of TGF-β 
signalling is to promote EMT, and so the combination of increased matrix stiffness 
and enhanced MMP activity can further drive EMT through release and activation 
of TGF-β (Leight et al., 2012). Integrin binding to proteins enriched in CAF-derived 
ECM, such as collagen and laminins, also promotes EMT in tumour cells (Scott et 
al., 2019). The combination of increased ECM stiffness and integrin receptor 
binding to the ECM also regulates formation of invadopodia, which are membrane 
protrusions which enable cell migration and invasion. Increased stiffness caused 
by collagen crosslinking promoted integrin clustering in cancer cells to stimulate 
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focal adhesion assembly and promote PI3K signalling, which is required for 
invadopodia formation (Levental et al., 2009). Increased MMP remodelling, which 
can be stimulated by integrin signalling at focal adhesion complexes, also enables 
invadopodia formation (Jacob and Prekeris, 2015). Alternatively, CAFs can 
combine MMP remodelling with increased collagen directionality due to Rho-ROCK 
mediated contractile forces to create ‘tracks’ for cancer cells to migrate along 
(Gaggioli et al., 2007). This allows cancer cells to migrate while still maintaining 
epithelial properties so that there is no need for them to undergo EMT. Similarly, 
it was observed that CAFs invaded first into matrigel using MMPs, and the cancer 
cells followed the path taken by the CAFs (Li et al., 2016). In addition to providing 
paths for tumour cells to migrate along, the forces exerted by CAFs on the 
basement membrane create holes, increasing the leakiness of blood vessels and 
allowing cancer cells to escape the tumour boundary and enter the bloodstream 
(Egeblad et al., 2010, Glentis et al., 2017). 
 
Another important aspect of the CAF ECM is to induce angiogenesis, which also 
affects tumour metastasis by providing the tumour cells with a means of 
extravasation into the blood stream. As well as acting as a reservoir of factors that 
induce tumour growth, the ECM also stores VEGF and other pro-angiogenic factors, 
which can be released by matrix deformation and MMP remodelling. Both MMP-7 
and MMP-9 have been implicated in promoting angiogenesis in tumours (Littlepage 
et al., 2010). Conversely, anti-angiogenic factors could be released by the same 
means, so the ECM can also inhibit angiogenesis in some cases. Increased ECM 
stiffness was also shown to promote endothelial cell MMP activity and endothelial 
VEGF expression, which is required for blood vessel branching and growth 
(Bordeleaux et al., 2017, Mammoto et al., 2009). Stiffness-induced ROCK 
activation in cancer cells further promotes angiogenesis (Croft et al., 2004). 
 
CAF derived ECM also affects the immune response of the tumour. Integrin 
signalling can mediate avoidance of the anti-tumour immune response (Weaver et 
al., 2002). Collagen I has been specifically implicated in inhibiting T-cell 
proliferation and activation, and a collagen rich ECM promotes the 
immunosuppressive M2 macrophage phenotype, although conversely fibronectin 
rich ECM can promote M1 macrophage polarisation (Meyaard, 2008, Wesley et al., 
1998, Perri et al., 1982). This is perhaps in part due to collagen rich ECM being 
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stiffer due to collagen crosslinking, as a stiffer ECM has also been shown to 
promote M2 macrophage polarisation and T-cell activation (Patel et al., 2012, 
O'Connor et al., 2012). Collagen assembly has also been recently shown to impede 
T-cell access to the tumour (Mariathasan et al., 2018). This may explain why 
immune checkpoint inhibitors often fail to produce a response in stroma-rich 
tumours, and, indeed, combining checkpoint inhibitors with targeting CXCL12 
production by myofibroblastic CAFs has shown success in a mouse model of PDAC 
(Feig et al., 2013). The ECM can also regulate cytokine availability. MMPs such as 
MMP-12 can cleave and inactivate cytokines which would recruit neutrophils and 
inflammatory monocytes (Dean et al., 2008). TGF-β release and activation by the 
ECM can further modulate the immune environment by influencing T-cell 
differentiation to being pro or anti-inflammatory in a concentration dependent 
manner (Li and Flavell, 2008). 
 
Drug response and resistance in tumours is also affected by the ECM. The increased 
stiffness of tumour associated ECM increases interstitial fluid pressure, which has 
been shown to reduce the efficiency of drug delivery. Matrix composition and 
organisation also affects drug delivery as increased collagen content and 
alignment in ECM have been shown to impede drug transport (Heldin et al., 2004, 
Netti et al., 2000). Further to this, normalisation of tumour stroma has been shown 
to improve response to therapy (Liu et al., 2012a). Cancer cell-ECM interactions 
also play a key role in drug resistance. Integrin mediated fibronectin attachment 
has been shown to enhance drug resistance and integrin β1 has been implicated 
in resistance to radiotherapy and chemotherapy in head and neck, breast and lung 
cancer (Damiano, 2002, Eke et al., 2012, Huang et al., 2011). Cancer stem cells 
expressing integrins β4 and β3 have also all been found to be enriched after 
chemotherapy treatment and in relapsed tumours, suggesting that integrin-ECM 
interactions may mediate drug resistance through promoting cancer stem cell 
survival (Zheng et al., 2013, Seguin et al., 2015). 
 
Therefore the increase in ECM output by CAFs and the increase in stiffness due to 
collagen crosslinking and fibre alignment creates a pro-tumourigenic 
microenvironment by promoting tumour cell growth and survival, invasion and 
metastatic potential, angiogenesis, an immunosuppressive immune response and 
also contributes to drug resistance and tumour relapse. The ECM plays a key role 
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in breast cancer pathology, and in particular increased collagen deposition and 
crosslinking have been shown to contribute to breast cancer progression (Kaushik 
et al., 2016). 
 
36 
 
1.3 Epigenetic control of collagen and ECM production 
 
1.3.1 Epigenetics 
 
Epigenetics is defined as the heritable modification of gene function without 
alterations in the DNA sequence, either by DNA or histone modification or by 
changes in chromatin structure. Histone modification is a major source of 
epigenetic regulation in cells. Histones are the core component of nucleosomes, 
which compact chromatin by wrapping DNA around them. In general, nucleosome 
compaction is obstructive to gene transcription as it reduces DNA accessibility to 
the transcriptional machinery. However, post translational histone modification 
can further regulate chromatin accessibility as well as recruiting specific 
transcription factors. So far, observed histones modifications include methylation, 
acetylation, phosphorylation, ubiquitination, deamination, ribosylation and 
sumoylation (Lawrence et al., 2016). Lysine acetylation and methylation are the 
most widely studied histone modifications and as far as we know have the greatest 
impact on chromatin accessibility and regulation of gene transcription (Bartova et 
al., 2008). In general, it is thought that acetylation neutralises the positive charge 
on lysine, destabilising bonds with negatively charged DNA and causing chromatin 
to form a more open conformation, enabling transcription machinery access. 
Conversely, methylation is associated with increased chromatin compaction and 
repression of transcription (Margueron et al., 2005). There are several exceptions 
to this, for example, H3K4me3 is known to be a transcriptional activator marking 
transcriptional start sites (Schneider et al., 2004). Furthermore, lysine residues 
can be modified with up to 3 methyl groups, and different numbers of methyl 
groups can have different effects. For example, H3K27me3 represses transcription 
whereas H3K27me1 promotes transcription (Ferrari et al., 2014). Methylation and 
acetylation have been further shown to influence recruitment and binding of 
transcription factors and the transcriptional machinery to gene promoters 
(Vettese-Dadey et al., 1996, Wysocka, 2006, Lawrence et al., 2016). DNA itself 
can also be methylated, and methylation of CpG dinucleotides at transcriptional 
start sites is a marker of transcriptional repression (Edwards et al., 2017, Jones, 
2012). 
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1.3.2 Regulation of CAF activation and fibrotic collagen production by 
epigenetics 
 
Many factors have been shown to contribute to increased collagen synthesis by 
activated fibroblasts in fibrotic tissue, including cytokines such as TGF-β, IL-3 and 
IL-4, growth factors such as CTGF and PDGF and the Wnt and Notch signalling 
pathways, and miRNA mediated post-transcriptional regulation (Bhogal et al., 
2005, Leask, 2010, Beyer et al., 2013, Dees et al., 2011, Nijhuis et al., 2014). 
However, in recent years epigenetic regulation of fibroblast activation and fibrosis 
through altering histone modification patterns or DNA methylation has been shown 
to be an important and targetable point of regulation of collagen synthesis.  
 
Since CAF activation is accompanied by dramatic alterations in gene and protein 
expression, which leads to increased production and secretion of many factors, it 
is to be expected that epigenetic alterations underpin at least a part of the 
process of CAF activation. Furthermore, the fact that the CAF phenotype is self-
sustaining in culture (Kojima et al., 2010) and does not require the presence of 
cancer cells to maintain activation suggests that an epigenetic switch supports 
CAF activation. Initial studies showed that CAF DNA was overall hypomethylated 
in comparison to NF DNA, suggesting an overall increase in active transcription 
(Jiang et al., 2008, Hu et al., 2005, Vizoso et al., 2015). Recently, a more in depth 
analysis of global DNA methylation in paired prostate CAFs and NFs using whole 
genome bisulphite sequencing revealed that CAFs had many consistent differences 
in methylation compared to NFs, particularly in genes involved in stromal-
epithelial signalling and tissue development. These genes tended to be 
hypomethylated in comparison with NFs, which implies that they are more actively 
transcribed (Pidsley et al., 2018).  
 
TGF-β signalling is a hallmark of activated, ECM producing myofibroblasts and a 
potent fibrotic activator. The major downstream effectors of TGF-β are the 
transcriptional modulators Smad2 and Smad3, which translocate into the nucleus 
and recognise Smad binding elements to promote transcription of target genes 
(Feng and Derynck, 2005). Blocking Smad signalling reduces collagen transcription 
(Ding et al., 2013). In addition to regulating transcription factor translocation to 
the nucleus to regulate collagen transcription, TGF-β signalling has also been 
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found to promote expression of fibrotic genes via regulating histone modifications. 
In rat mesangial cells, TGF-β activation upregulated expression of fibrotic genes, 
including collagen I, by increasing H3K4 trimethylation, a marker of active 
transcription, and decreasing repressive H3K9 methylation at the promoters of 
these genes. Furthermore, TGF-β upregulated the expression and recruitment of 
the H3K4 methyltransferase SET7/9 to the collagen I promoter, again to activate 
its transcription (Sun et al., 2010). Additionally, the combination of the cytokines 
TGF-β, TNFα and IL1-β induced alterations in histone modification at the 
promoters of fibrotic genes in fibroblasts, including hyperacetylation of histone 3 
and hypermethylation of histone 4 at the Col1a2 promoter, increasing its 
expression at the mRNA level (Sadler et al., 2013). TGF-β signalling has also been 
implicated in decreasing DNA CpG methylation at collagen promoters and thereby 
activating transcription via downregulation of the DNA methyltransferases DNMT1 
and DNMT3 (Pan et al., 2013). Other studies have also demonstrated a decrease 
in DNA methylation in activated fibroblasts at the promoters of fibrotic genes 
including collagens due to DNMT inhibition (Hu et al., 2010, Ko et al., 2013). 
However, increased DNA methylation of certain genes stimulates CAF activation. 
For example, a study by Albrengues et al. demonstrated that methylation of the 
gene encoding protein phosphatase SHP-1 resulted in activated JAK1/STAT3 
signalling in fibroblasts, leading to a pro-invasive CAF phenotype (Albrengues et 
al., 2015). Therefore upregulation of the fibrotic response in CAFs, as stimulated 
by TGF-β, involves epigenetic alterations, and epigenetic regulation of collagen 
transcription is a key aspect of this. 
 
Many studies have shown that increased expression of collagen by fibroblasts 
activated during fibrotic diseases is also regulated at the epigenetic level. 
H3K27me3 is a well-known marker of transcriptional repression that recruits 
polycomb group proteins to target genes, creating repressive polycomb 
complexes. In fibrotic sclerosis, H3K27me3 was shown to be decreased in 
fibroblasts, causing loss of transcriptional repression of collagen (Kramer et al., 
2013). In glioma cells, increased collagen expression was associated with the 
presence of H3K4me2, H3 hyperacetylation, and a reduction in H3k27me3, 
showing that epigenetic regulation of collagen production at the histone 
modification level is not limited to fibroblasts (Chernov et al., 2010). At the DNA 
methylation level, Gotze et al. explored the role of DNA methylation in 
39 
 
fibrogenesis of hepatic stellate cells and found an increase in hypomethylated 
genes, similar to the findings in CAF activation, although collagen was not 
specifically studied (Gotze et al., 2015). 
 
Epigenetic therapies have had some success at treating collagen production in 
fibrosis and in CAFs. DNA methylation inhibition reduced collagen I and collagen 
III in human fibroblasts and in spontaneously hypertensive rats (Watson et al., 
2016). BET inhibitors and histone deacetylase (HDAC) inhibitors have been 
investigated as an effective combination therapy in mouse models of PDAC, and 
BET inhibitors were further shown to effectively target PDAC stroma (Mazur et al., 
2016). BET inhibitors inhibit BRD transcription factors, which bind acetylated 
histone motifs and recruit further transcription factors and chromatin 
remodellers. Kumar et al. showed that in pancreatic stellate cells and in an in vivo 
model of PDAC, BET inhibition reduced collagen I expression through inhibition of 
BRD4 (Kumar et al., 2017). BET inhibitors or BRD4 knockdown have also been 
shown to decrease fibrosis-driven collagen production in lung and renal fibroblasts 
(Tang et al., 2013, Xiong et al., 2016). This further shows that histone acetylation 
is required for activation of collagen production in fibroblasts. BRD4 is strongly 
associated with the H3K27ac motif, which is found at enhancer regions and is a 
powerful activator of transcription (Raisner et al., 2018, Lee et al., 2017). As 
mentioned earlier, loss of H3K27me3 and hyperacetylation of histone 3 are also 
associated with increased collagen production, suggesting that a switch from 
methylation to acetylation of H3K27 could be a key epigenetic alteration 
stimulating collagen production in CAFs. On the other hand, HDAC inhibitors also 
have shown effectiveness in reducing fibrotic ECM. In cardiac fibrosis, HDAC1 and 
HDAC2 inhibition reduced collagen I, III and fibronectin (Nural-Guvener et al., 
2015). Similarly, the HDAC inhibitor SAHA effectively inhibited fibrotic collagen 
production in lung fibroblasts (Wang et al., 2009). Thus, it is clear that epigenetic 
alterations are a crucial aspect of CAF activation, particularly with regard to 
collagen and ECM production, and can be targeted with already existing inhibitors, 
several of which have undergone testing in clinical trials. 
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1.4 CAF metabolism 
 
In the past decade, there has been increasing research into how the metabolic 
rewiring of CAFs contributes to their pro-tumourigenic phenotype. The majority 
of this research focusses on how CAFs produce metabolites which can be taken up 
by tumour cells and used as fuel to promote growth and invasion.  
 
One of the first observations about CAF metabolism was an increase in glycolysis 
in CAFs. This was initially demonstrated in mammary fibroblasts by the Lisanti 
group (Pavlides et al., 2009). Proteomic analysis of fibroblasts activated upon 
knockdown of caveolin-1 (Cav-1) showed a general upregulation of glycolytic 
proteins. Downregulation of Cav-1 has been further shown to be a marker of CAFs, 
and to promote tumour growth and metastasis. Cav-1 is downregulated in CAFs 
due to increased oxidative stress and HIF1α stabilisation, which are caused both 
by TGF-β activation in CAFs and by the reactive oxygen species (ROS) and the 
hypoxic microenvironment created by tumour cells (Martinez-Outschoorn et al., 
2010a). The authors hypothesised that the increase in lactate produced by 
glycolytic CAFs could be used to fuel oxidative phosphorylation in cancer cells. 
This metabolic cross talk has been termed ‘the Reverse Warburg effect’ because 
the stromal cells are highly glycolytic instead of the tumour cells, as was initially 
discovered by Otto Warburg. Transcriptomic analysis of breast tumours also 
showed evidence of upregulation of glycolytic enzymes in the stroma (Pavlides et 
al., 2010c), and it was shown that Cav-1 knockdown in mammary fibroblasts led 
to increased glycolysis (Pavlides et al., 2010b). TGF-β activation of mammary 
fibroblasts leading to oxidative stress, upregulated autophagy, HIF-1α stabilisation 
and Cav-1 loss caused increased glucose uptake and lactate secretion (Guido et 
al., 2012). Furthermore, in co-cultures with the MCF7 breast cancer cell line, 
fibroblasts upregulated the expression of the lactate transporter MCT4, and this 
was shown to be a result of increased oxidative stress. This was coupled with 
corresponding expression of the lactate importer MCT1 in the MCF7 cells, 
suggesting that they are able to utilise the fibroblast-produced lactate. The 
upregulation of MCT4 in the fibroblasts protected the cancer cells against cell 
death, showing that the metabolic reprogramming of CAFs is important for tumour 
cell survival (Whitaker-Menezes et al., 2011b). Other studies have also 
demonstrated that cancer cells rely on lactate from the tumour microenvironment 
41 
 
(Sonveaux et al., 2008), and that a similar transfer of lactate occurs between 
glycolytic hypoxic and oxidative normoxic tumour cells, suggesting that this 
metabolic coupling is a common mechanism promoting tumour survival (Allen et 
al., 2016). Furthermore, treatment of xenografts containing Cav-1 (-/-) fibroblasts 
cotransplanted with MDA-MB-231 breast cancer cells with glycolysis inhibitors 
reduced the positive effect on tumour growth of the Cav-1 (-/-) fibroblasts. 
However, whether the glycolysis inhibitors would have had a similar effect on 
tumours containing normal fibroblasts was not assessed (Bonuccelli et al., 2010). 
A Cav-1 independent pathway stimulating glycolysis in mammary CAFs was 
discovered by Yu et al. in which the G-protein coupled Oestrogen receptor (GPER) 
was translocated to the cytoplasm in CAFs, where it promoted glycolysis via PKB 
and CREB signalling. Pyruvate and lactate produced by the CAFs were then used 
to fuel mitochondrial metabolism in tumour cells (Yu et al., 2017). A recent study 
also showed that MYC driven breast cancers stimulated glycolysis in CAFs via miR-
105, which was secreted in tumour cell-derived extracellular vesicles. miR-105 
caused fibroblasts to upregulate genes involved in glycolysis and glutaminolysis 
(Yan et al., 2018). 
 
Another aspect of the reverse Warburg effect hypothesis is that oxidative stress 
drives increased autophagy in CAFs, leading to mitochondrial breakdown and 
secretion of autophagic breakdown metabolites, such as ketones and amino acids, 
which can also be used to drive oxidative phosphorylation in cancer cells. 
Therefore CAFs should show evidence of mitochondrial dysfunction whereas 
cancer cells should show evidence of upregulated mitochondrial activity. In 
sections of breast cancer tissue, it was demonstrated that the stroma had little 
mitochondrial activity as measured by cytochrome C oxidase, NADH and succinate 
dehydrogenase staining whereas adjacent cancer cells were highly positive 
(Whitaker-Menezes et al., 2011a). In vitro, co-cultures of mammary fibroblasts 
and MCF7 cells demonstrated that CAFs had decreased levels of intact 
mitochondria whereas the MCF7 cells increased their levels of intact mitochondria 
(Martinez-Outschoorn et al., 2010b). In support of an autophagic CAF phenotype 
catabolically producing metabolites, metabolic analysis of mammary fat pad 
fibroblasts from Cav-1 (-/-) mice demonstrated upregulated production of ketone 
bodies, amino acids and markers of the breakdown of collagen and other proteins 
(Pavlides et al., 2010a). It was further demonstrated that MBA-MB-231 breast 
42 
 
cancer cells take up and use lactate and ketone bodies to fuel mitochondrial 
metabolism, growth and metastasis (Bonuccelli et al., 2010). Cav-1 loss has been 
shown to promote mitophagy by enabling accumulation of nitric oxide (NO). NO 
accumulation inhibits cytochrome c oxidase which causes mitochondrial 
uncoupling and triggers mitophagy (Pavlides et al., 2010b).  Interestingly, Cav-1 
(-/-) mammary fibroblasts showed increased expression of the matrix remodelling 
factors PAI1 and PAI2, which activate plasmin and MMPs to degrade ECM proteins. 
Fibroblasts overexpressing PAI1/2 also demonstrated an increase in autophagy, 
suggesting that ECM remodelling and degradation may have an unexplored role in 
regulating stromal metabolism. It is possible that either the protein break down 
products or pro-autophagic factors released from the degraded ECM stimulate 
autophagy in mammary CAFs (Castello-Cros et al., 2011). Other ECM related 
proteins such as the growth factors CTGF and MSF, which is a truncated form of 
fibronectin, have also been shown to promote the reverse Warburg effect in 
mammary CAFs. CTGF led to HIF1α stabilisation and thereby increased autophagy 
and glycolysis, whereas MSF stimulated Akt and mTOR signalling to promote 
glycolysis in mammary CAFs (Capparelli et al., 2012, Carito et al., 2012). 
Interestingly the reverse Warburg effect has been further shown to enable drug 
resistance in breast cancer cells. Increased oxidative phosphorylation mediated 
by TIGAR enabled tamoxifen resistance in MCF7 cells. The cells could be 
resensitised to tamoxifen by treating them with anti-mitochondrial drugs such as 
metformin (Martinez-Outschoorn et al., 2011a). 
 
All the above studies were carried out using only mammary CAFs, however, 
aspects of the reverse Warburg effect, namely increased glycolysis and autophagy 
in CAFs, have been observed in other cancers. In prostate cancer, a similar 
coupling of lactate metabolism was observed with CAFs expressing high levels of 
MCT4 and tumour cells expressing MCT1. Also in fibroblasts derived from prostate 
cancer, activation by TGF-β or PDGF was demonstrated to increase glycolysis by 
causing downregulation of isocitrate dehydrogenase 3α (IDH3α). This led to an 
imbalance in the α-ketoglutarate-succinate ratio, causing inhibition of PDH2 and 
HIF1α stabilisation, thus mimicking the upregulation of glycolysis caused by the 
hypoxic response. IDH3α downregulation was also seen in the stroma of prostate 
cancer patients, suggesting that this mechanism occurs in vivo (Zhang et al., 
2015). In ovarian cancer, BRCA mutated ovarian cancer cells were shown to 
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produce hydrogen peroxide, stimulating oxidative stress and thereby autophagy, 
mitophagy and increased glycolysis including higher MCT4 expression in ovarian 
CAFs via upregulation of NFκB signalling (Martinez-Outschoorn et al., 2012). In 
pancreatic tumours, PDAC tumour cells stimulated autophagy in pancreatic 
stellate cells leading to stromal alanine secretion. Alanine was then used in 
preference to glucose and glutamine, which can be limited in the tumour 
microenvironment, to fuel the TCA cycle and amino acid and lipid synthesis in the 
tumour cells and also rescued the growth of PDAC cells under nutrient deprived 
conditions (Sousa et al., 2016). In another study, pancreatic CAFs had increased 
expression of glycolytic enzymes such as LDHA, MCT4 and PKM2 compared to NFs, 
and conditioned media from CAFs both stimulated mitochondrial biogenesis and 
upregulated expression of MCT1 and TCA cycle enzymes fumarate dehydrogenase 
and succinate dehydrogenase in pancreatic cancer cell lines (Shan et al., 2017). 
 
Upregulated glycolysis is not a feature of all CAFs, however. Although many of the 
aforementioned studies in breast cancer demonstrated the existence of the 
reverse Warburg effect in breast tumours, many of the co-culture and xenograft 
experiments were carried out using MCF7 cancer cells. ER+ breast cancer cells, 
such as MCF7, have previously been shown to rely more on mitochondrial 
metabolism whereas the more aggressive HER2+ and TNBC subtypes are more 
glycolytic (Choi et al., 2013, Lanning et al., 2017). The study by Choi et al. 
classified stromal-tumour metabolic relationships by using immunohistochemistry 
to determine whether the stromal and tumour compartments used predominantly 
glycolytic or oxidative metabolism. The authors found a mixture of traditional 
Warburg, reverse Warburg, mixed (both tumour and stroma are glycolytic) or null 
(both tumour and stroma are oxidative) metabolic relationships between tumour 
and stroma. Lower grade ER+ tumours displayed the highest proportion of the 
reverse Warburg phenotype, and TNBC and HER2+ tumours constituted the 
majority of traditional Warburg and mixed metabolism phenotypes. Therefore, 
targeting the reverse Warburg effect in breast cancer stroma might be more 
effective in ER+ patients. In support of this, a study showed that CAFs from the 
more aggressive basal-like breast cancers stimulated glucose uptake in both basal 
and luminal cancer cells, whereas CAFs derived from luminal breast cancers 
suppressed glucose uptake in cancer cells, which is more reminiscent of the 
reverse Warburg effect (Brauer et al., 2013).  
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Several other studies have demonstrated that the Reverse Warburg effect is not a 
feature of all CAFs. In prostate cancer, one study found that p62 is downregulated 
in prostate cancer stroma. The authors showed that p62 loss was involved in 
increased ROS production by the CAFs, which is consistent with the reverse 
Warburg effect, but that this was mediated through metabolic reprogramming 
involving a decrease in glutamine metabolism, as well as a decrease in glucose 
uptake and lactate secretion, which is directly in contradiction with the catabolic 
metabolism of the Reverse Warburg effect theory (Valencia et al., 2014). Another 
recent study demonstrated that in head and neck squamous cell carcinoma CAFs 
actually induced a more glycolytic phenotype in the tumour cells, and utilised the 
lactate produced by the glycolytic tumour cells for oxidative phosphorylation, 
which again is in opposition to the reverse Warburg effect (Kumar et al., 2018). 
Similarly, in co-cultures of lung cancer cells and fibroblasts, the fibroblasts were 
found to upregulate pyruvate dehydrogenase and the lactate importer MCT1, 
suggesting a more oxidative metabolism, whereas the tumour cells upregulated 
lactate dehydrogenase and decreased pyruvate hydrogenase activity which is in 
accordance with the glycolytic tumour phenotype of the traditional Warburg 
effect (Koukourakis et al., 2017). In a mass-spectrometry based analysis of 
metabolism in lung derived CAFs and NFs, although it was found that CAFs had 
metabolic markers of increased autophagy, such as dipeptides, the levels of these 
markers correlated with the glycolytic capacity of the tumour which the CAFs were 
derived from. Therefore in this study, increased autophagy in the CAFs did not 
seem to be related to mitochondrial metabolism in the tumours, and instead 
verified the original Warburg effect theory that more glycolytic tumours are more 
aggressive. Even without promoting a switch to mitochondrial metabolism in 
cancer cells, CAF autophagy can still provide cancer cells with nutrients, such as 
amino acids, lipids and nucleic acids, as well as protecting against oxidative 
damage (Kimmelman, 2011).  
   
Therefore although autophagy does seem to be a common feature of the CAF 
phenotype, providing tumour cells with metabolites to fuel growth and metastasis, 
the question of whether CAFs develop a glycolytic metabolism to fuel oxidative 
metabolism in tumour cells via lactate transfer has not been resolved. Given the 
high levels of heterogeneity in CAFs previously discussed, it is likely that the 
45 
 
reverse Warburg effect is present in some tumours but further stratification is 
needed to determine which tumours might respond to therapies targeting this 
aspect of tumour-stroma crosstalk. In breast cancer, it is likely that the reverse 
Warburg effect occurs predominantly in lower grade, ER+ tumours. 
 
Other mechanisms of metabolic coupling between CAFs and tumour cells have 
been discovered. In ovarian cancer, CAFs were shown to upregulate synthesis of 
glutamine, which was then taken up and used by the tumour cells to fuel 
glutamate synthesis. By simultaneously targeting glutamine synthase in CAFs and 
glutaminase in cancer cells in an orthotopic mouse model of ovarian CAFs the 
authors were able to reduce both tumour growth and metastasis (Yang et al., 
2016). Another study in ovarian cancer showed that glutathione and cysteine 
released by CAFs promotes resistance to platinum-based chemotherapy (Wang et 
al., 2016). In PDAC, activation of pancreatic stellate cells was recently shown to 
induce production and secretion of lipids, including lysophosphatidylcholines, 
which were used by the tumour cells to produce components of cell membranes, 
facilitating proliferation, and also to support migration and Akt activation 
(Auciello et al., 2019). CAFs can further provide tumour cells with nutrients 
through secretion of exosomes. In PDAC, pancreatic stellate cells produce 
exosomes containing amino acids including alanine, which, as discussed above, 
has been shown to be an important metabolite driving mitochondrial metabolism 
in PDAC cells (Zhao et al., 2016). The exosomes also contained glucose, glutamine, 
lactate, acetate, TCA cycle metabolites and lipids, all of which can be used to 
fuel tumour growth.  
 
Taken together, all of these studies show that, as with most other aspects of their 
phenotype, CAFs are metabolically highly diverse and promote tumour growth, 
metastasis and chemoresistance through upregulation of a variety of metabolic 
pathways. However, there is a common thread running through them in that the 
highly secretory phenotype of CAFs clearly extends to their metabolism, as all of 
these studies focus on how CAFs secrete metabolites to promote tumour 
progression. 
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1.5 The role of metabolism in collagen production 
 
Since both metabolism and upregulated ECM production have been shown to be 
vitally important aspects of the CAF phenotype, an interesting question that has 
been little explored is whether alterations in CAF metabolism regulate ECM 
production. The many studies discussed in the previous section on how CAFs rewire 
their metabolism predominantly focus on how this enables CAFs to secrete 
metabolites, which can be taken up and used as fuel by cancer cells, but little 
research has been done on how fibroblast metabolism might underpin other 
aspects of their activated phenotype. Since collagen is such a major part of the 
protein output of activated fibroblasts, it is reasonable to suggest that there may 
be energetic requirements necessary to maintain this, or requirements for amino 
acids to support the translational output. In recent years, a few studies have 
shown this to be the case. It was shown that fibroblasts require an increase in 
glucose uptake and glycolysis to maintain TGF-β-induced collagen production in 
fibrosis, demonstrating a need for increased energy to fuel protein synthesis 
(Nigdelioglu et al., 2016). At the amino acid level, two recent studies have 
demonstrated that upregulation of glycine and serine production is required to 
maintain upregulated collagen synthesis in fibrotic disease. As discussed 
previously, collagen is predominantly made up of the Gly-X-Y motif, meaning that 
approximately 1/3 of collagen amino acid residues are glycine. The first study 
demonstrated that TGF-β treatment of fibroblasts caused upregulation of enzymes 
involved in de novo synthesis of glycine and serine from glucose, such as PHDGH 
and SHMT2. PHDGH and SHMT2 are also upregulated in lungs from patients with 
idiopathic pulmonary fibrosis, and inhibition of PGDGH or SHMT2 by genetic or 
pharmacological means led to reduced collagen production by fibroblasts. Since 
glycine is synthesised from serine, this implies that upregulation of glycolysis in 
fibrosis is used to fuel the serine/glycine synthesis pathway and increased glycine 
production is required for collagen synthesis (Nigdelioglu et al., 2016). More 
recently, Selvarajah et al. elucidated the mechanism of this pathway and showed 
that canonical TGF-β signalling through Smad3 in fibroblasts enhanced expression 
of glycine synthesis enzymes via activation of mTORC1 leading to upregulation of 
the transcription factor ATF4. ATF4 induced transcription of the glucose importer 
GLUT1 and enzymes for synthesising serine and glycine from glucose. Inhibition of 
this pathway reduced glycine incorporation into collagen (Selvarajah et al., 2019). 
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These two studies demonstrated a need for amino acid synthesis to maintain the 
increased collagen output of activated fibroblasts, and discovered a further role 
for TGF-β activation of glycolysis in activated fibroblasts: to produce glycine for 
collagen synthesis. Although these studies were carried out in the context of lung 
fibrosis, since CAFs and fibroblasts in fibrotic disease share many similarities in 
the upregulation of ECM production the mechanism is likely to be relevant for CAFs 
as well. 
 
A requirement for glycine for collagen synthesis by fibroblasts has therefore been 
demonstrated, but a requirement for proline, the second most abundant amino 
acid in collagen, has been little studied. Some nutritional studies have shown that 
a diet supplemented with proline improves growth in young animals, which could 
be linked to an increased ability to synthesise proline-rich proteins such as 
collagens (Wu et al., 2011). A recent study of collagen synthesis in chondrocytes 
showed that supplementing media with proline, lysine or glycine, but not other 
amino acids, stimulated an increase in collagen production, although interestingly 
both proline and lysine had a greater effect at lower doses whereas glycine 
supplementation maintained a consistent level of collagen production at higher 
doses, suggesting that an excess of proline and lysine might adversely affect the 
cells (de Paz-Lugo et al., 2018).  
 
Another metabolic aspect of collagen synthesis is the requirement for prolyl and 
lysyl hydroxylases, which convert α-ketoglutarate to succinate as a by-product of 
the hydroxylation reaction. The α-KG:succinate ratio is therefore very important 
for prolyl hydroxylase function as an excess of α-KG activates the enzymes 
whereas an excess of succinate is inhibitory (Gorres and Raines, 2010). The impact 
of the α-KG:succinate ratio on prolyl hydroxylases has mostly been studied in the 
context of HIF-1α, which is targeted for degradation when hydroxylated 
(MacKenzie et al., 2007, Selak et al., 2005, Zhang et al., 2015). The requirement 
for α-KG by prolyl hydroxylases has also been linked to amino acid sensing by 
mTOR, since α-KG is a degradation product of several amino acids and the product 
of glutamine deamination (Duran et al., 2013). As previously discussed, mTOR 
activation has also been linked to collagen production through activation of 
glycine synthesis. It has further been shown that α-KG promotes collagen 
formation by fibroblasts, both by activation of mTOR and by proline hydroxylation 
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of procollagen (Ge et al., 2018). A more recent study demonstrated that HIF-1α 
activation in chondrocytes led to increased glutaminolysis and thereby 
accumulation of α-KG. This enhanced proline and lysine hydroxylation on collagen, 
making the matrix more resistant to degradation by MMPs and ultimately resulting 
in skeletal dysplasia (Stegen et al., 2019). Since HIF-1α signalling is also often 
activated in CAFs, this mechanism could also be relevant for increased collagen 
modification in the tumour microenvironment. Another recent study 
demonstrated that breast cancer cells require extracellular pyruvate to fuel α-KG 
synthesis and thus maintain activation of the prolyl hydroxylase P4HA. Inhibition 
of the pyruvate transporter MCT2 resulted in decreased collagen hydroxylation 
and functionality in vivo, and this could be rescued by α-KG. Furthermore 
succinate, which inhibits P4HA, also inhibited pyruvate driven proline 
hydroxylation. The authors also demonstrated that collagen hydroxylation was 
dependent on pyruvate and the α-KG:succinate ratio in CAFs but not in normal 
fibroblasts (Elia et al., 2019). 
 
Therefore, metabolic rewiring in CAFs is an important factor to maintain the 
increase in collagen synthesis that accounts for the majority of CAF-derived ECM. 
CAFs both increase the synthesis of specific amino acids to support translation of 
collagen and maintain the α-KG:succinate ratio to promote the activity of prolyl 
and lysyl hydroxylases, which are essential for the correct folding and stabilisation 
of collagen proteins. 
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1.6 An overview of PDH and PYCR1 and their roles in 
cancer 
 
1.6.1 Pyruvate dehydrogenase 
 
In my thesis, the first of the two key metabolic enzymes I investigated was 
pyruvate dehydrogenase (PDH). Pyruvate dehydrogenase is an extremely 
important metabolic enzyme because it sits at the centre of glucose and oxidative 
metabolism, connecting the two major metabolic pathways in the cell: glycolysis 
and the TCA cycle. For this reason it has been named the ‘mitochondrial 
gatekeeper’. Inhibition of PDH generally results in a more glycolytic metabolism 
and activation leads to oxidative, mitochondrial metabolism. The reaction 
catalysed by PDH involves the reduction of 3-carbon pyruvate to 2-carbon acetyl-
coA, with the release of carbon dioxide and the reduction of NAD+ to NADH. The 
pyruvate dehydrogenase complex (PDC) is made up of three subunits: E1 (Pyruvate 
dehydrogenase or PDH), E2 (Dihidrolipoyl transacetylase or DLAT) and E3 
(Dihydrolipoyl dehydrogenase or DLD). The E1 subunit catalyses the rate limiting 
step, which is the decarboxylation of pyruvate into an acetyl group and CO2, with 
vitamin B6 as a cofactor. The acetyl group reduces a lipoyl moiety linked to the 
E2 subunit. The E2 subunit then catalyses the transacylation reaction transferring 
the acetyl group to the thiol of coenzyme A producing acetyl-coA. Finally, the E3 
subunit restores the complex to the resting state by reoxidising the lipoyl 
moieties, mediated by the reduction of NAD+ to NADH with FAD as a cofactor (Fig. 
1-1).  
 
The conversion of pyruvate to acetyl-coA is irreversible, and therefore the flux 
through the pyruvate dehydrogenase complex is tightly regulated (Patel and 
Korotchkina, 2006). Since the E1 subunit catalyses the rate limiting reaction, it 
has been the most highly studied and is the subunit subject to most regulation at 
the post translational level and by allosteric binding. Allosterically, the products 
of the reaction, acetyl-coA and NADH, both inhibit PDH activity. At the post-
translational level, the major way that the E1 subunit is regulated is through 
inhibitory phosphorylation (Harris et al., 2001). The PDC has four regulatory 
phosphorylation sites. Three of these are on the E1 alpha subunit (PDHA1) and are 
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regulated by pyruvate dehydrogenase kinases (PDKs): S293, S232 and S300. The 
fourth, Y301, is on the E2 subunit and is thought to be phosphorylated by 
epidermal growth factor (EGF) and other tyrosine kinases (Fan et al., 2014), 
causing obstruction of pyruvate binding. The S293 site is the most well-studied 
and is also the most potent, as phosphorylation reduces PDH activity by over 97% 
by blocking the active site (Patel and Korotchkina, 2006).  
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Diagram showing the reaction catalysed by each of the three PDC subunits to 
produce acetyl-coA from pyruvate 
 
Figure 1-2 Reaction catalysed by PDC 
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1.6.2 Regulation of PDH phosphorylation 
 
There are four PDKs in mammals, named PDK1-4, which share ~70% homology. The 
different PDKs preferentially phosphorylate different sites. PDK1 is the only PDK 
known to phosphorylate all three sites of PDHA1, but all PDKs will phosphorylate 
S293 and S300 in vitro (Patel and Korotchkina, 2001). S293 is the site most rapidly 
phosphorylated in PDH isolated from mammalian tissues (Yeaman et al., 1978). 
PDK2 exhibits the highest affinity for the S293 phosphorylation site, followed by 
PDK4, PDK1 and PDK3 and therefore PDK2 activity has the greatest effect on PDH 
inhibition, at least in vitro. The different PDK isoforms further show differences 
in tissue distribution. In rat tissue, PDK1 and PDK4 are predominantly found in 
heart and skeletal muscle, PDK2 is expressed in most tissues and PDK3 is most 
highly expressed in the testes and lungs (Bowker-Kinley et al., 1998). In mouse 
tissues, PDK1 and PDK2 were ubiquitously expressed whereas PDK3 and PDK4 were 
more limited. PDK3 was found only in testes, lung, brain and heart. PDK4 was only 
expressed at very low levels in muscular tissues (Klyuyeva et al., 2019). 
 
Regulation of the PDKs is as diverse as the differential tissue expression. In 
general, all the PDKs can be activated by the outputs of the PDH-catalysed 
reaction: mitochondrial acetyl-coA and NADH. They can be additionally activated 
by ATP, as are many kinases. Conversely, pyruvate, NAD+ and ADP inhibit the PDKs 
(Pratt and Roche, 1979, Hansford, 1976, Cate and Roche, 1978). However, the 
combination of NADH and acetyl-coA increases the activity of PDK1 and PDK2 by 
200-300 fold, whereas PDK3 is unresponsive to NADH and PDK4 is unresponsive to 
acetyl-coA and only increases its activity 2 fold with NADH stimulation (Bowker-
Kinley et al., 1998). PDK1 has been shown in several studies to be upregulated by 
HIF1α signalling in hypoxia to promote a more glycolytic metabolism by blocking 
flux into the TCA cycle. This maintains ATP production whilst blocking ROS 
accumulation (Kim et al., 2007, Kim et al., 2006a, Papandreou et al., 2006). 
Another study demonstrated that under hypoxia, Akt accumulates in the 
mitochondria and phosphorylates PDK1 to activate it (Chae et al., 2016). 
Therefore hypoxia appears to be a major regulator of PDK1 activity. PDK3 has also 
been shown to be upregulated by hypoxia (Lu et al., 2008). Both PDK2 and PDK4 
have been shown to be upregulated by starvation and in diabetes (Huang et al., 
2002) and insulin decreases the expression of both PDK2 and PDK4 (Kim et al., 
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2006c). Little is known about how PDK2 is regulated by insulin, but the PDK4 
promoter contains insulin response sequences which are binding sequences for the 
FOXO1 and FOX3 transcription factors, which have been shown to upregulate PDK4 
transcription (Furuyama et al., 2003). The nuclear hormone receptors PPARs have 
also been associated with increased expression of PDK2, PDK3 and PDK4, possibly 
via FOXO activity, however the evidence suggests that PDK2 is probably not a 
direct target of PPARs (Degenhardt et al., 2007, Holness and Sugden, 2003). Other 
nuclear hormone receptors and factors that have been shown to upregulate PDK4 
expression include the glutocorticoid receptor, Estrogen-related receptors and 
Thyroid hormone receptors (Huang et al., 2002, Zhang et al., 2006, Attia et al., 
2010, Connaughton et al., 2010). However, none of these pathways have 
conclusively been shown to also upregulate PDK2 expression. Interestingly, p53 
has been shown to repress PDK2 activity which could contribute to metabolic 
alterations and increased glycolysis in tumours with p53 mutations (Contractor 
and Harris, 2012). Therefore PDK1 and PDK3 appear to be predominantly activated 
by hypoxia, whereas PDK2 and PDK4 are more responsive to metabolic stimuli such 
as starvation and insulin. The regulation of PDK4 is better understood than that of 
PDK2, despite PDK2 being the more ubiquitously expressed throughout the body. 
 
PDH phosphorylation by the PDKs is opposed by pyruvate dehydrogenase 
phosphatases of which there are two isoforms: PDP1 and PDP2. Little is known 
about their regulation in comparison to the PDKs. Both PDPs are activated by 
insulin, in contrast to the inhibitory effect of insulin on PDK2 and PDK4 (McLean 
et al., 2008). PDP1 activity is also known to be stimulated by Ca2+ ions, but PDP2 
is not. As with the PDKs, the PDPs are expressed in a tissue specific manner. PDP1 
is the predominant isoform in skeletal muscle, whereas PDP2 is more abundant in 
the liver and in adipocytes (Huang et al., 1998). PDHA1 phosphorylation has 
further been shown to be downregulated by PI3K/Akt signalling, although it is 
unclear which PDKs and/or PDPs are responsible for this (Cerniglia et al., 2015). 
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1.6.3 Regulation of PDH activity by acetylation 
 
Due to the high concentration of acetyl-coA, which is the substrate for protein 
acetylation, in the mitochondria, many proteins are auto-acetylated and this can 
impact on their activity. Acetylation in the mitochondria is predominantly 
regulated by deacetylases, the major mitochondrial deacetylase being SIRT3 
(Lombard et al., 2007). Although not so highly characterised as PDH 
phosphorylation, a few studies have investigated the role of PDH acetylation. 
K321, which is the lysine residue that binds the FAD cofactor, has been identified 
as a regulatory acetylation site on the E1 subunit that inhibits PDH activity when 
acetylated. Deacetylation by SIRT3 restored PDH activity (Ozden et al., 2014). 
Treatment with a SIRT3 inhibitor increased PDH acetylation and decreased its 
activity in myocardial tissue (Zhang et al., 2018). In a further study, both PDH and 
PDP1 were shown to be regulated by acetylation. Again, K321 acetylation was 
shown to inhibit PDH activity by recruiting PDK1, and PDP1 acetylation on K202 
caused PDP1 to dissociate from PDH, leading to an overall increase in glycolytic 
metabolism (Fan et al., 2014). PDH was also shown to be more acetylated in mice 
fed a high fat diet; it is possible that acetylation decreased PDH activity so that 
fatty acid oxidation could take over as the main source of acetyl-coA in the 
mitochondria (Thapa et al., 2017). Therefore acetylation, like phosphorylation, is 
an inhibitory modification for PDH, and can furthermore provide a mechanism to 
reduce PDH activity if there is an excess of acetyl-coA that is not converted to 
citrate, maintaining metabolic homeostasis. 
 
1.6.4 The varied roles of PDH 
 
The acetyl-coA produced by the PDH complex is a highly versatile metabolite. It 
consists of an acetyl group joined by a thioester bond to Coenzyme A, which is a 
derivative of vitamin B5 and cysteine. The thioester bond is high in energy, and 
therefore the acetyl group can easily be transferred to acceptor molecules such 
as metabolites or proteins. Acetyl-coA from PDH is one of two routes that pyruvate 
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can take to enter the TCA cycle and therefore controls the flux into the TCA cycle 
from glycolysis. Acetyl-CoA can then be exported out of the mitochondria either 
via citrate or acetylcarnitine, where it can be used for fatty acid, sterol and 
ketone body synthesis. PDH thus links glucose, oxidative and lipid metabolism (Fig. 
1-2). It is vital for an organism to be able to adapt nutrient usage to nutrient 
availability, that is, to be able to rapidly switch between using carbohydrates or 
lipids depending on supply, because the inability to do this leads to diseases such 
as diabetes, obesity and metabolic syndrome. PDH therefore sits at a central 
metabolic point.  Finally, acetyl-coA is the substrate for protein acetylation which 
is a key post-translational modification, especially in the nucleus where histone 
acetylation can drastically alter the epigenetic code.  
 
The majority of the studies on PDH activity have focussed on its ability to switch 
cell metabolism from glycolytic to oxidative and vice versa. The PDKs play a vital 
role in the metabolic flexibility of different organs, particularly PDK2 and PDK4. 
PDK4 is upregulated in skeletal muscle during and after exercise to inactivate the 
PDH complex and promote glycolysis. This enables increased ATP production 
during exercise to meet the higher energy demands and subsequently allows the 
cells to replenish glycogen stores to restore metabolic homeostasis (Pilegaard and 
Neufer, 2004). The PDH complex is also a crucial enzyme in the liver, which 
regulates blood glucose levels and the supply of other nutrients to tissues. In 
fasting conditions, the liver must produce glucose from non-carbohydrate sources 
by gluconeogenesis. Inactivation of PDH by upregulating PDK4 enables pyruvate 
derived from glucose to directly enter the TCA cycle via oxaloacetate rather than 
being used for fatty acid synthesis. This promotes the use of lipids for 
gluconeogenesis (Randle, 1986). In the liver, conversion of glucose to lipids is also 
important for storing energy. PDH knockdown decreased fatty acid synthesis in 
the liver. Interestingly, PDH knockdown also decreased expression of lipid 
synthesis genes, suggesting that acetyl-coA is not only a building block for lipid 
synthesis but also a regulator of gene expression, possibly through altering histone 
acetylation (Mahmood et al., 2016). As mentioned earlier, PDH plays an important 
role in the switch to glycolytic metabolism in hypoxia, via HIF-1α upregulation of 
PDK1 to phosphorylate and inhibit PDH activity. This is important to block access 
to the TCA cycle and initiate the switch to lactate production, increasing ATP 
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synthesis and reducing toxic ROS production in the mitochondria to prevent 
hypoxia-induced apoptosis (Kim et al., 2006a). 
 
Failure to correctly regulate PDH activity leads to disease. Pyruvate 
dehydrogenase deficiency leads to a build-up of lactate leading to acidosis and 
genetic disorders such as encelopathy, demonstrating the importance of PDH in 
regulating oxidative metabolism (Asencio et al., 2016). PDH activity also plays an 
important role in insulin resistance, which is characterised by an inability to switch 
from lipid to glucose oxidation when stimulated. Insulin resistant patients have 
increased PDK2 and PDK4 expression, and fail to reduce PDK4 expression in 
response to insulin, demonstrating the importance of regulating PDH activity to 
maintain metabolic flexibility (Kim et al., 2006c). Metabolic flexibility is also 
important in the heart, because the heart has to be able to rapidly oxidise glucose 
to meet energy demands. PDK4 is upregulated in cardiomyopathy, and 
overexpression of PDK4 in cardiac tissue in mice led to a decrease in glucose 
catabolism and increased hypertrophy and death (Zhao et al., 2008). Interestingly, 
PDH activity has also been linked to neurological disorders. The brain relies 
primarily on glucose oxidation for energy, which requires an active PDH. 
Alzheimers disease has been linked to dysfunctional glucose metabolism involving 
a reduction in PDH activity (Yao et al., 2009), and the expression of PDK1 and 
PDK2 is upregulated in the aging brain (Nakai et al., 2000). 
 
Although the PDH complex is a major source of acetyl-coA in cells and it is known 
that acetyl-coA is the substrate for protein acetylation, there are few studies 
showing that PDH activity has a direct impact on protein acetylation. Mitochondria 
are known to have a disproportionately high level of acetylated proteins, and this 
is thought to occur due to the high concentration of acetyl-coA in the mitochondria 
which stimulates autoacetylation of lysine residues (Baeza et al., 2016). 
Acetylation of mitochondrial proteins is generally inhibitory (Anderson and 
Hirschey, 2012). PDH activity could therefore regulate mitochondrial acetylation 
to control mitochondrial metabolism. Although PDH is typically a mitochondrial 
protein, studies have shown that PDH can be located in the nucleus in lung 
fibroblasts, where the acetyl-coA it produces is used to acetylate specific lysine 
residues on histones to enable cell cycle progression (Sutendra et al., 2014, Chen 
et al., 2018). Mitochondrial acetyl-coA production can also affect histone 
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acetylation. Recently, studies have shown that mitochondrial dysfunction leads to 
decreased histone acetylation. Under conditions of mitochondrial DNA depletion, 
the pool of mitochondrial acetyl-coA was reduced, leading to loss of histone 
acetylation, and particularly of H3K9 and H3K27 acetylation (Lozoya et al., 2019). 
However whether this is due specifically to loss of PDH activity or is a general 
response to mitochondrial dysfunction is unclear. Similarly, loss of the 
transcription factor TFAM, which is important for transcription of mitochondrial 
genes, led to decreased mitochondrial metabolism and a corresponding decrease 
in histone acetylation in erythroid cells (Liu et al., 2017). However, at present 
there is still no direct link between mitochondrial PDH activity and nuclear histone 
acetylation in the literature. 
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Diagram showing the production of acetyl-coA by PDH and the varied metabolic 
and acetylation pathways that acetyl-coA can be used for both inside and 
outside the mitochondria. 
 
Figure 1-3 Acetyl-coA is a central metabolite 
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1.6.5 PDH activity in cancer 
 
In addition to regulating metabolic diseases, PDH activity has been shown to play 
a critical role in cancers in many studies. One of the most well-known metabolic 
alterations in tumour cells is the Warburg effect, in which cancer cells become 
more glycolytic. PDH is a key player in this, and PDKs are upregulated in many 
cancers in order to inhibit oxidative metabolism and promote glycolysis. PDK1 is 
upregulated in several types of cancer and high PDK2 expression in cervical cancer 
cells is a prognostic factor for metastasis and poor survival (Lyng et al., 2006). 
PDK3 expression is increased in colorectal cancer and is associated with drug 
resistance and tumour relapse (Lu et al., 2011). PDK4 has been shown to be both 
up and downregulated in various cancers including lung, ovarian, breast and 
prostate tumours (Grassian et al., 2011, Ross et al., 2000). Therefore in some 
tumours an increase in PDH activity is required, possibly to produce acetyl-coA for 
fatty acid synthesis, which can be upregulated in cancer cells. Furthermore, as 
discussed previously, in the reverse Warburg effect some tumours rely more on 
lactate uptake to fuel oxidative phosphorylation than on glycolysis. This would 
require a more active PDH and therefore reduced PDK4 expression would be 
beneficial. The role of PDK1 in mediating metabolic adaptation to hypoxia is also 
important in the context of cancer, where hypoxia is a commonly occurring stress 
in the tumour microenvironment due to poor oxygenation by dysfunctional blood 
vessels. PDK-mediated inhibition of PDH activity has also been associated with 
metastasis. PDK4 upregulation enhanced the ability of mammary cancer cells to 
resist matrix detachment-induced apoptosis, otherwise known as anoikis, which is 
a barrier to metastasis (Kamarajugadda et al., 2012). 
 
Targeting PDH to increase its activity and reduce the Warburg effect has been 
proposed as a metabolic therapy for cancer. Several studies have shown that 
increasing PDH activity reduces cancer aggressiveness. For example, in BRAF 
driven melanoma, senescence was shown to be mediated by PDK1 downregulation 
and induction of PDP2 to activate PDH activity. Furthermore, PDK1 knockdown in 
BRAFV600E cell lines made them more sensitive to BRAF inhibitors (Kaplon et al., 
2013). Dichloroacetate (DCA), which activates PDH by inhibiting the PDKs, is the 
most well studied drug targeting PDH. It is already used clinically to target lactic 
acidosis, and was shown to have anti-tumour properties, causing apoptosis in 
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several cancer cell lines and reducing tumour growth in xenografts (Bonnet et al., 
2007, Michelakis et al., 2008). In breast and non-small cell lung cancer xenografts, 
inhibition of PDK2 with DCA also reduced angiogenesis and suppressed 
pseudohypoxic HIF signalling (Sutendra et al., 2013). DCA has shown additive or 
synergistic effects in pre-clinical experiments in combination with already existing 
therapies, including radiation, metformin, cisplatin and bevacizumab (Cao et al., 
2008, Florio et al., 2018, Kumar et al., 2013a, Kumar et al., 2013b). As a cancer 
therapy, DCA has been effective in treating some individual cases (Flavin, 2010a, 
Flavin, 2010b). In clinical trials however, its effectiveness has not been 
conclusively demonstrated so far. In a trial on glioblastoma patients, some 
patients showed a response, but a phase II clinical trial on breast and non-small 
cell lung cancer had to be halted due to safety concerns and DCA had no effect on 
head and neck cancer in phase II trials (Powell, 2015, Dunbar et al., 2014, Garon 
et al., 2014). Conversely, inhibiting PDH has shown great effectiveness in some 
cancers. CPI-613, which inhibits both PDH and α-ketoglutarate dehydrogenase to 
block mitochondrial metabolism, has been shown to improve response and 
enhance sensitivity to chemotherapy in AML, T-cell lymphoma and pancreatic 
cancer, and is currently in stage II and III clinical trials for treatment of pancreatic 
cancer patients (Pardee et al., 2018, Alistar, 2018, Lamar, 2016). Therefore it 
appears that PDH activity can have both positive and negative effects on tumour 
progression, and further investigation is needed in order to determine which 
tumours would benefit from PDH-targeting therapy and whether to inhibit or 
activate PDH. 
 
Although there has been much research on PDH activity in cancer cells, little is 
known about its role in the stroma. As discussed earlier, the metabolism of the 
stroma is often the opposite to that of the tumour, creating a metabolic symbiosis. 
Therefore if tumour cells have an inactive PDH to promote glycolysis, it is possible 
that PDH is more active in the stroma and promoting a more oxidative metabolism. 
In support of this, one study has found that PDH expression is upregulated in lung 
fibroblasts co-cultured with cancer cells, and, conversely, the cancer cells 
upregulate PDK1 expression to reduce PDH activity and promote glycolysis 
(Koukourakis et al., 2017). On the other hand, one of the studies demonstrating 
the existence of the reverse Warburg effect, PDH expression was found to be 
downregulated in CAFs in response to oxidative stress as part of the switch to 
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glycolytic metabolism (Martinez-Outschoorn et al., 2010). Therefore the role of 
PDH in the stroma is still an open question, and may depend on whether the 
tumour the CAFs are derived from has a more glycolytic or oxidative metabolism. 
 
1.6.6 PYCR1 and proline metabolism 
 
Pyrroline-5-carboxylate reductase 1 (PYCR1) is the second metabolic enzyme that 
I discovered regulated in mammary CAFs during my PhD. PYCR1 catalyses the final, 
rate limiting step in proline production from glutamate or ornithine in cells: the 
NAD(P)H dependent conversion of pyrroline-5-carboxylate (P5C) to proline. P5C is 
the intermediate linking the two pathways of proline synthesis, and is synthesised 
from glutamate by P5C synthase (P5CS or ALDH18A) or from ornithine by ornithine 
aminotransferase (OAT) (Fig. 1-4). Proline is an unusual amino acid because its α-
amino group is contained within its pyrrolidine ring, and therefore its metabolic 
pathways of synthesis and degradation are distinct from those of other amino 
acids. For example proline does not undergo decarboxylation, deamination and 
other pyridoxal phosphate (vitamin B6) catalysed reactions typical of other amino 
acids (Adams and Frank, 1980). 
 
There are three homologous PYCR genes: PYCR1, PYCR2 and PYCR3. De Ingeniis et 
al. showed that PYCR1 and PYCR2 are mitochondrial, whereas PYCRL is 
cytoplasmic. The authors also suggested that PYCR1 and PYCR2 mainly use 
glutamate as a source of proline whereas PYCR3 participates only in the conversion 
of ornithine to proline. However, these results were only demonstrated in 
melanoma cells, so whether they are also relevant in other cell lines is unknown. 
Other studies suggest that P5C is derived from either glutamate or ornithine in the 
mitochondria and can then be exported for conversion to proline by PYCR3 (Tanner 
et al., 2018). The three isoforms also differ in their response to product inhibition: 
PYCR2 is the most highly inhibited by proline, followed by PYCR1, and PYCR3 is 
not inhibited by proline within a physiological range (De Ingeniis et al., 2012). 
PYCR3 could therefore maintain a baseline level of proline synthesis even when 
cytosolic proline levels are high.  
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Diagram showing the production of proline from both ornithine and glutamate, with the final 
step being catalysed by PYCR1 
 
Figure 1-4 Proline synthesis pathway 
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Proline synthesis plays an important role in protecting cells from stress. The 
production of proline by PYCR1 oxidises NAPDH or NADH to NADP+/NAD+, which 
can support glycolysis and the pentose phosphate pathway (Liu et al., 2015). 
Equally, the interconversion of P5C and PYCR1 creates a shuttle of the redox 
equivalents NADPH/NAP+ between the mitochondria and cytosol, meaning that 
proline production plays a role in maintaining redox homeostasis (Hagedorn and 
Phang, 1983). Furthermore, the proline molecule itself protects against ROS via 
the secondary amine of the pyrrolidine ring and has also been reported to protect 
against photoxidative UVA damage (Wondrak et al., 2005). The importance of 
proline production to protect against ROS has been demonstrated in several 
studies. For example, treatment of mammalian cell lines with hydrogen peroxide 
resulted in increased PYCR1 expression, and higher PYCR1 expression was then 
found to protect cells from ROS-induced apoptosis. Conversely, overexpression of 
proline dehydrogenase (PRODH) resulted in decreased intracellular proline levels 
and decreased resistance to ROS (Krishnan et al., 2008). Interestingly, both PYCR1 
and PYCR2 have been found to interact with and promote the activity of RRM2B, 
a protein which promotes DNA damage repair in response to oxidative stress, in 
fibroblasts, showing that the anti-oxidant properties of PYCR1 are not solely due 
to its role in proline production but that it also plays a role in the wider cellular 
response to oxidative stress (Kuo et al., 2016). Further demonstrating the diverse 
roles of PYCR1 as a protection against cellular stresses are studies showing that 
proline produced by PYCR1 can protect against protein misfolding in vitro and in 
E.Coli and plants by acting as a molecular chaperone (Samuel et al., 2000). This 
is due to its properties as an osmolyte, which is a substance that can change the 
physical properties of biological fluids such as the viscosity or ionic strength, and 
can therefore influence protein stability, folding rate and aggregation (Fisher, 
2006). 
 
As an amino acid, a major role of proline is to contribute to protein synthesis, and 
another important aspect of proline synthesis is the fact that it makes up a 
considerable proportion of collagen, the most abundant protein in the body, as 
discussed earlier in this chapter. Although there is little evidence so far in the 
literature connecting proline synthesis to collagen production, it is interesting to 
note that collagen production is downregulated in response to oxidative stress 
caused by ROS, and this can be rescued by treating cells with reducing agents 
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(Tanaka et al., 1993). It is therefore possible that collagen can be a means of 
getting rid of excess reducing potential in the form of proline, again demonstrating 
the importance of proline as a reducing equivalent.  
 
Clinically, PYCR1 mutations are one of the causes of cutis laxa, a disorder with 
symptoms including wrinkled skin, premature aging, and developmental delay, 
showing the importance of maintaining proline levels during development, and in 
fibroblasts for maintenance of skin elasticity and turnover. Research into the role 
of proline in cutis laxa showed that PYCR1 mutant fibroblasts did not display a 
reduction in intracellular proline, although patients had slightly lower levels of 
proline in their serum. However, the morphology of mitochondria in the fibroblasts 
was abnormal and they were more susceptible to ROS induced apoptosis, again 
showing the importance of PYCR1 in maintaining redox balance across the 
mitochondrial membrane (Reversade et al., 2009). The presence of abnormal 
collagen fibres and a decrease in collagen bundle compactness, along with a 
significant decrease in elastin fibres, has also been reported in the ECM of some 
patients with PCYR1 mutations (Kretz et al., 2011). Additionally, a study on pycr1 
KO zebrafish found that the zebrafish had reduced ECM content and decreased 
levels of proline and hydroxyproline in their tissues (Liang et al., 2019). Although 
none of these studies conclusively linked proline levels to collagen production, it 
is reasonable to hypothesise that a reduction of proline production can affect 
collagen production since proline is such a crucial component of collagen. 
 
Therefore aside from its role as an amino acid for protein synthesis, proline is a 
highly important molecule for maintaining redox balance and protecting cells from 
stresses such as ROS or protein misfolding. Since these factors are critical in 
tumours, where there are higher levels of ROS and oxidative stress, it is 
unsurprising that PYCR1 expression is dysregulated in many cancers. 
 
1.6.7 PYCR1 in cancer  
 
Increased PYCR1 expression is a common feature of tumours. In a meta-analysis 
of the mRNA profiles of 2000 tumours spanning 19 types of tumour, PYCR1 was 
found to be one of the most consistently upregulated metabolic genes (Nilsson et 
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al., 2014). This is at least in part due to the fact that PYCR1 is a known target of 
cMyc and has also been shown to be linked to PI3K signalling; both of which are 
oncogenes that are commonly activated in cancer. In tumours where PYCR1 is 
upregulated by cMyc, there also is a corresponding increase in intracellular 
proline, showing that PYCR1 overexpression has a functional output. (Liu et al., 
2015, Liu et al., 2012b). Increased proline production by tumour cells has been 
reported in other studies. In a study profiling central carbon metabolism in breast 
cancer, a significant increase in proline synthesis was the main metabolic 
alteration observed in metastatic cells when compared to non-metastatic cells 
(Richardson et al., 2008). PYCR1 and proline synthesis upregulation is not merely 
a side effect of oncogenic tumour formation, however, but also contributes 
significantly to tumour development. PYCR1 knockdown inhibited tumour 
formation by xenografts in vivo (Possemato et al., 2011). In both prostate and 
non-small cell lung cancer, PYCR1 is overexpressed and has been shown to 
promote proliferation and inhibit apoptosis (Cai et al., 2018). PYCR1 appears to 
be the main regulator of tumourigenesis out of the PYCR enzymes, since a study 
comparing PYCR1 and PYCR2 expression in data from 2535 breast cancer patients 
found that PYCR1, but not PYCR2, was upregulated in breast cancer and 
corresponded with poor survival and metastasis (Ding et al., 2017). The pro-
tumourigenic effects of PYCR1 have mostly been found to involve maintaining 
redox homeostasis. In glioma cells, IDH1 mutations, which cause loss of reducing 
potential and alter the NADPH:NADP+ ratio, were shown to upregulate PYCR1 
expression. This provided a mechanism of NAD(P)H reduction to maintain redox 
balance, and the increased production of proline from glutamate led to partial 
TCA cycle uncoupling from respiration. This enabled oxygen-independent 
synthesis of TCA cycle-derived metabolites, such as citrate and aspartate, which 
would give the cells a metabolic advantage under hypoxia (Hollinshead et al., 
2018). PYCR1 has further been shown to contribute to the adaptation of cancer 
cells to hypoxia by promoting HIF-1α signalling. In hepatocellular carcinoma, 
HIF1α signalling under hypoxia stimulated proline production, leading to increased 
hydroxyproline production. Increased levels of hydroxyproline stabilised HIF1α and 
enhanced hypoxia-driven signalling (Tang et al., 2018). PYCR1 has also been shown 
to be important for the broader metabolic rewiring of tumours. Because proline 
production is a source of NAD+/NAPDH+, it can stimulate glycolysis through GAPDH 
activity and nucleotide synthesis through the pentose phosphate pathway, both of 
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which enable increased proliferation of cancer cells. Because proline is derived 
from glutamine, proline production by PYCR1 thus links the frequently observed 
reliance on glutamine by tumours with nucleotide synthesis and the Warburg 
effect to promote proliferation (Liu et al., 2015) (Fig. 1-5).  
 
Tumour cells are also dependent on proline for protein synthesis. Ribosome 
profiling revealed that proline was a limiting factor for protein synthesis in both 
kidney and breast cancers, and that this was dependent on high expression of 
PYCR1. Loss of PYCR1 increased ribosome stalling and inhibited tumour growth 
(Loayza-Puch et al., 2016). Proline synthesis was also shown to be required for 
protein synthesis in melanoma cells, where P5C synthase knockdown inhibited 
protein synthesis via EIF2AK4 activation (Kardos et al., 2015). The necessity for 
tumour cells to maintain proline levels is also highlighted by the fact that tumours 
have recently been shown to use degraded collagen from the ECM as a source of 
proline to maintain protein synthesis and redox homeostasis. In PDAC, 
upregulation of MMPs, which are involved in collagen degradation, and PRODH, 
the proline catabolism enzyme, enabled tumour cells to scavenge and utilise 
collagen from the tumour microenvironment in times of nutrient scarcity 
(Gouirand and Vasseur, 2018, Olivares et al., 2017). This again highlights the 
importance of CAF-derived collagen in the ECM to promote tumour growth and 
metastasis. Additionally, upregulated expression of PRODH in breast cancer cells 
supported growth by maintaining ATP levels in 3D culture and promoted the 
formation of lung metastases in orthotopic mouse models (Elia et al., 2017). This 
could mean that breast cancer cells are also able to scavenge collagen from their 
environment as a source of proline. However, in this study the PYCR enzymes were 
still required even with exogenous proline treatment; therefore although cancer 
cells may degrade proline as a source of energy, it is probably still necessary to 
continue synthesising proline to maintain the cellular redox balance. 
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Diagram showing the pathways affected by the products of the PYCR1-catalysed reaction  
 
 
Figure 1-5 Metabolic impact of proline synthesis 
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Despite the aforementioned significance of proline metabolism and synthesis in 
tumour development and progression, until recently there were no drugs or other 
therapeutic agents targeting PYCR1, so the relevance of these findings to the 
clinic has been untested. However, very recently a small molecule inhibitor has 
been developed against PYCR1 which reduced intracellular proline and inhibited 
growth in breast cancer cell lines (Milne et al., 2019). Although the drug is 
metabolised rapidly in mice, and therefore is unlikely to be suitable for clinical 
studies, it is a good starting point for the development of treatments targeting 
PYCR1. Much of the initial work on targeting tumour metabolism was done on 
‘core’ metabolic pathways such as glucose or glutamine metabolism, which are 
indeed highly dysregulated in tumours. However, targeting these pathways has 
proved difficult, since they are also vital pathways for all cells in the body, so 
pharmacological inhibition produced severe side effects. Therefore targeting 
metabolic pathways which are not universally required but are dysregulated in 
tumour cells and therefore provide therapeutic vulnerabilities has become a more 
promising strategy, and proline production by PYCR1 falls under this category. 
 
Finally, although many studies have linked PYCR1 expression to poor clinical 
outcome in tumours and demonstrated the relevance of PYCR1 in cancer cells, 
little research has been done on the role of PYCR1 in the tumour 
microenvironment. PYCR1 has been shown to be important for fibroblast 
functionality in the context of cutis laxa caused by PYCR1 mutations, but so far 
no studies have investigated whether PYCR1 is relevant in CAFs or, indeed, in any 
other cells of the TME. As any drug targeted towards the cancer cells will naturally 
also have an impact on the stroma, to determine if PYCR1 is a viable therapeutic 
target it is also important to know what effect, if any, it has in the stroma.  
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1.8 Objectives 
 
The primary objective of this study was to gain further insight into how the 
metabolic rewiring of CAFs contributes to their pro-tumourigenic function, with 
the aim of discovering new potential targets for therapies targeting the tumour 
microenvironment, or to inform on existing lines of treatment. Many studies have 
shown that CAFs rewire their metabolism to secrete metabolites to fuel tumour 
cells. However, how CAF metabolic rewiring might affect other aspects of the CAF 
phenotype has been little explored. In particular, ECM production, which is a 
major function of CAFs, is known to be affected by metabolite availability but as 
yet few studies have investigated ECM production from a metabolic perspective in 
CAFs. Targeting ECM production in the stroma can improve tumour perfusion and 
drug delivery as well as reducing tumour growth and metastasis. Furthermore, as 
metabolic targets and therapies are being discovered for tumour cells, it is 
important to have an understanding of whether these will also target the CAF 
phenotype and if so whether they might have a pro or anti-tumourigenic effect. 
To uncover metabolic differences between CAFs and NFs which contribute to the 
pro-tumourigenic CAF phenotype, I used a combination of mass spectrometry-
based proteomics and metabolomics and in vitro assays. Based on these results, I 
selected candidate metabolic enzymes that were differentially regulated between 
CAFs and NFs. In order to characterise these targets and determine how they 
affected pro-tumourigenic phenotype of CAFs I carried out further proteomic and 
metabolomic experiments as well as characterising the effects of overexpression 
and pharmacological or RNAi mediated inhibition of these targets, both using in 
vitro assays and in vivo characterisation of xenografts containing CAFs with 
impaired metabolism. 
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Chapter 2  Materials and Methods 
 
2.1 Materials 
 
2.1.1 Reagents and kits 
 
Table 2-1 Reagents and kits 
Reagent Supplier Catalogue # 
Acetic acid Sigma 32009 
Acetonitrile Sigma 34967 
Alexa Fluor 647 azide Life Technologies A10277 
Amaxa nucleofector kit R Lonza VCA-1001 
Ammonium bicarbonate Sigma 11213 
Ampicillin Sigma A0166 
Bradford reagent Biorad 500-0205 
BSA Sigma A2153 
BSA standard Biorad 500-0206 
Calcium phosphate transfection 
kit 
Invitrogen K278001 
Chloroacetamide Sigma C0267 
Click-iT™ EdU Alexa Fluor™ 647 
Flow Cytometry Assay Kit 
Life Technologies C10419 
D-Glucose Sigma G7021 
D-Glucose U-13C6 Cambridge Isotope 
laboratories 
CLM-1396 
Dialysed FBS Sigma F0392 
DMEM Gibco 11960044 
DMEM 1g/l glucose (low glucose) Gibco 21885025 
DMEM no glucose Gibco 11966025 
DMEM no pyruvate Gibco 11960044 
DMSO Fisher 10080110 
DNAse I recombinant, RNAse free Roche 4716728001 
DTT Sigma 43819 
Empore solid phase extraction 
disk (C18) 
3M 2215 
F12 medium Gibco 21765029 
FBS Gibco 10270 
Fluorescent mounting medium Dako S3032 
Fungizone Gibco 15290018 
Glutamine   
 
Life technologies  25030-024 
Glutamine U-13C5 Cambridge Isotope 
Laboratories 
CLM-182 
Glycine Sigma G7126 
HEPES Sigma H3537 
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Horse serum  
 
Gibco  26-050-070 
Hygromycin  
 
Sigma   
 
H3274 
iScript cDNA synthesis kit Biorad 170-8891 
iTaq Universal SYBR green 
supermix 
Biorad 172-5121 
Kanamycin sulphate Sigma 11815024 
L-Arginine hydrochloride 13C6 
15N4 (Arg10) 
Cambridge Isotope 
laboratories 
CNLM-539-H-PK 
L-Lysine hydrochloride 13C6 15N2 
(Lys8) 
Cambridge Isotope 
laboratories 
CNLM-291-H-PK 
L-Arginine hydrochloride (Arg0) Sigma A6969-25 
L-Lysine monohydrochloride Sigma L8662 
LysC   
Growth factor reduced Matrigel Corning 15585729 
Methanol Sigma 32213 
Methanol (HPLC grade) Sigma 34860 
MitoSOX Red Mitochondrial 
Superoxide Indicator 
Life Technologies M36008 
Nicotinamide Sigma 72340 
Nitrocellulose transfer membrane 
0.45 µm 
GE Healthcare 10600003 
Non-fat milk Marvel 5000354167508 
NP-40 Sigma NP40S 
NuPage 4-12% Bis-tris 
polyacrylamide gel 
Life Technologies NW04120 
NuPage LDS sample buffer Life Technologies NP0007 
NuPage running buffer (MOPS) Life Technologies NP0001 
NuPage running buffer (MES) Life Technologies NP0002 
NuPage transfer buffer Life Technologies NP0006-1 
Optiblot Bradford reagent abcam ab119216 
Palmitate U-13C16 Sigma 605573 
Paraformaldehyde Sigma 441244 
PBS with Mg2+ and Ca2+ Sigma D8662 
Penicillin/Streptomycin Life Technologies 15140122 
Phalloidin Life Technologies A12379 
Ponceau Red Sigma P7170 
Puromycin Gibco A1113802 
PVDF transfer membrane 0.45 µm Thermo Scientific 88518 
Pyruvate dehydrogenase enzyme 
activity microplate assay 
abcam ab109902 
Qiashredder kit Qiagen 79656 
RNAse free DNAse Qiagen 79254 
RNEasy mini kit Qiagen 74904 
Saponin Sigma 84510 
Seahorse XF base medium Agilent 102353-100 
Seahorse XF24 Fluxpak Agilent 100867-100 
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SILAC DMEM (no Arg/Lys) Gibco A14431-01 
Sodium acetate Sigma 241245 
Sodium butyrate Sigma B5887 
Sodium chloride Fisher S/3160/60 
Sodium deoxycholate Sigma D6750 
Sodium dodecyl sulphate (SDS) Fisher S/P530/53 
Sodium hydroxide Sigma S5881 
Sodium pyruvate Gibco 11360070 
Sodium pyruvate (U-13C3) Sigma 490733 
Sulforhodamine B Sigma 230162 
TCEP Sigma C4706 
TFA Sigma T6508 
Thiourea Sigma T8656 
TMRE Life Technologies T669 
Tris Melford B2005 
Triton-X-100 Sigma X100 
Trypsin Life Technologies 15090 
Trypsin (MS-grade) Promega V5280 
Urea Sigma U5128 
Western blotting detecting 
reagent Amersham ECL 
GE Healthcare RPN2109 
Western blotting detecting 
reagent Amersham ECL Prime 
GE Healthcare RPN2232 
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2.1.2 Buffers and solutions 
 
Table 2-2 Buffers and solutions 
Name Composition 
Buffer A 0.5% (v/v) formic acid in HPLC water 
Buffer A* 2% (v/v) ACN, 0.1% (v/v) TFA in HPLC 
water 
Buffer B 80% (v/v) ACN, 0.5% (v/v) formic acid 
in HPLC water 
IAP buffer 50 mM MOPS, 10 mM sodium 
phosphate, 50 mM sodium chloride in 
HPLC water 
PBS 0.8 % (w/v) Sodium chloride, 0.02 % 
(w/v) potassium chloride, 0.115 % 
(w/v) di-sodium hydrogen phosphate, 
0.02 % (w/v) potassium dihydrogen 
phosphate, pH 7.3 
RIPA 50 mM Tris-HCl pH 7.5, 150 mM sodium 
chloride, 1 mM EDTA, 1% (v/v) NP-40, 
0.1% (w/v) sodium deoxycholate 
SDS buffer 2% (w/v) SDS, 100 mM Tris-base pH 7.4 
TBST Tris buffered saline with 0.05 % Tween-
20 
Urea buffer 6M Urea, 2M thiourea, 40 µM CAA, 10 
µM TCEP 
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2.1.3 Antibodies 
 
Table 2-3 Antibodies and dilutions used 
 
Antibody Supplier Catalogue # Dilution 
αSMA Sigma A5288 1:10,000 WB, 1:1000 IF 
Acetylated 
H3K27 
Abcam ab4729 1:1000 
ACLY CST 4332S 1:1000 
Β-tubulin abcam ab6046 1:1000 
GAPDH Santa Cruz sc-47724 1:1000 
CD31 BioRad MCA1370Z 1:100 
PDHA1 Abcam ab110334 1:1000 WB, 1:100 IF 
Phospho-ACLY 
(S455) 
CST 4331S 1:1000 
Phospho-
PDHA1 (S293) 
Abcam 177461 1:2000 
Phospho-Smad 
2 
CST 3108 1:1000 
PYCR1 ProteinTech 22150-1-ap 1:1000 
Vimentin Santa Cruz sc-7557 1:2000 
Vinculin Sigma V9131 1:1000 
Anti-mouse 
HRP 
CST 7076S 1:5000 
Anti-rabbit 
HRP 
CST 7074S 1:5000 
Anti-mouse 
Alexa fluor 555  
Life 
Technologies 
A32773 1:500 
Anti-rabbit 
Alexa Fluor 555 
Life 
Technologies 
A32794 1:500 
Anti-mouse 
Alexa fluor 647  
Life 
Technologies 
A32787 1:500 
Anti-rabbit 
Alexa Fluor 647 
Life 
Technologies 
A32795 1:500 
Anti-hamster 
Alexa Fluor 647 
Life 
Technologies 
A-21451 1:200 
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2.1.4 Primers 
 
Table 2-4 List of primers  
 
 
Gene 
name 
Forward (5’-3’) Reverse (3’-5’) 
18S AGGAATTGACGGAAGGGCAC GGACATCTAAGGGCATCACA 
ACTB GGCATGGGTCAGAAGGATT ACATGATCTGGGTCATCTTCTC 
COL1A1 TGAAGGGACACAGAGGTTTCAG GTAGCACCATCATTTCCACGA 
COL6A1 AGCAAGTGTGCTGCTCCTTC CTTCCAGGATCTCCGGCTTC 
GAPDH AGCCACATCGCTCAGACA GCCCAATACGACCAAATCC 
PDK1 GAATGTTACTCAATCAGCACTCTT CCTAGCATTTTCATAGCCATCTTT 
PDK2 CGGGGACCACAACCAAAGTC GCTGGATCCGAAGTCCAGAAA 
PYCR1 CCCCGCCTACGCATTCACA GCGCGTTGGAAGTCCCATCT 
PYCR2 GTACACTGTAGCGCCTTCCTG GTACACTGTAGCGCCTTCCTG 
TBP2 AGTGACCCAGCATCACTGTTT TAAGGTGGCAGGCTGTTGTT 
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2.1.5 Small interfering RNA  
 
Table 2-5 List of small interfering RNAs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene name Sequences (5’-3’) Supplier Catalogue # 
Control pool UGGUUUACAUGUCGACUAA,  
UGGUUUACAUGUUGUGUGA,  
UGGUUUACAUGUUUUCUGA, 
UGGUUUACAUGUUUUCCUA 
Dharmacon D-001810-10-05 
(On Target plus 
non-targeting 
pool) 
PDK2 CCACGUACCGCGUCAGCUA, 
AAGGCGUGCUUGAGUACAA, 
CAACGUCUCUGAGGUGGUC, 
UGGCUAAGCUCCUGUGUGA 
Dharmacon LQ-005020-00-
0002 (Set of 4) 
PYCR1 GACCAACACUCCAGUCGUG, 
GAUGUGCUCUUCCUGGCUG, 
GCCCACAAGAUAAUGGCUA, 
GCGCCGACAUUGAGGACAG 
Dharmacon LQ-012349-00-
0002 (Set of 4) 
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2.1.6 Short hairpin RNA  
 
Table 2-6 Short hairpin RNAs and their targets 
 
 
Target 
Gene  
Sequence (5’-3’) Supplier Catalogue # 
Control CCGGCAACAAGATGAAGAGCACCA
ACTCGAGTTGGTGCTCTTCATCTT
GTTGTTTTT 
Sigma SHC002 
PDK2 ACTATATACACAGAAGGTC Dharmacon V2LHS_169815 
PYCR1-a CCGGGAGGGTCTTCACCCACTCCT
ACTCGAGTAGGAGTGGGTGAAGAC
CCTCTTTTTG 
Sigma TRCN000003898
1 
PYCR1-b CCGGTGAGAAGAAGCTGTCAGCGT
TCTCGAGAACGCTGACAGCTTCTT
CTCATTTTTG 
Sigma TRCN000003898
3 
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2.1.7 Plasmids 
 
Table 2-7 Plasmids 
 
Name Source Catalogue # 
WT PDK2 Prof. Angus McQuibben  
N255A PDK2 Prof. Angus McQuibben  
hTERT (Lentivirus) Dr. Fernando Calvo  
pET28a-mCherry-CNA35 Addgene 61607 
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2.2 Methods 
2.2.1 Cell lines and culture 
 
2.2.1.1 iCAFs and iNFs 
iCAFs and iNFs were kindly provided by Prof. Akira Orimo (Kojima et al., 2010). 
The iNFs are normal human mammary fibroblasts derived from reduction 
mammoplasty tissue and immortalised with a construct containing hTERT, GFP and 
puromycin resistance. hTERT is the catalytic subunit of human telomerase, which 
prevents telomere shortening and thereby the induction of telomere controlled 
senescence. hTERT expression has been shown to effectively immortalise cells 
without causing phenotypic changes or making the cells cancerous (Lee et al, 
2004).  A subsection of iNFs were transformed into iCAFs by two rounds of co-
injection subcutaneously with MCF7-hRAS cells into mice and subsequent 
reisolation of the fibroblasts by culturing the isolated tumours with puromycin for 
5 days.  
 
2.2.1.2 pCAFs and pNFs 
pCAFs and pNFs were isolated in house by Lisa Neilson from matched normal and 
breast cancer tissue from patients obtained through NHS Greater Glasgow and 
Clyde Biorepository. All participants gave specific consent to use their tissue 
samples for research. The fat surrounding the tissue was removed before cutting 
the tissue into small pieces. The tissue was then treated with 10 mg collagenase 
A in DMEM (10% FBS, 2 mM glutamine, 1% penicillin/streptomycin, 1% fungizone) 
overnight, after which the fibroblasts were the only surviving cells. The following 
day, fibroblasts were isolated using a cell strainer and plated on a cell culture dish 
coated with 35 mg/ml collagen I. The isolated fibroblasts were either expanded 
and frozen down or used for subsequent immortalisation. Fibroblasts become 
senescent after several passages, so in order to continue using them for 
experiments, the pCAFs and pNFs were immortalised using an hTERT lentiviral 
construct (pIRES-hygro-hTERT) kindly provided by Dr. Fernando Calvo. HEK293T 
cells were used to generate the hTERT lentivirus. 2x106 HEK293T cells were plated 
in a 10 cm dish. The next day, the HEK293T were transfected with 10 µg of pIRES-
hygro-hTERT as well as 4 µg VSVG and 7.5 µg psPAX as packaging plasmids by 
calcium phosphate transfection. The following morning the medium was replaced 
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with DMEM with 1 mM sodium butyrate. After 24h, the medium containing the 
virus was collected and 4 µg/ml polybrene was added. The virus was filtered 
through a 0.45 µm membrane to remove HEK293T cells and transferred onto the 
primary fibroblasts. This step was repeated the following day. After 48h, the 
immortalised fibroblasts were selected with 100 µg/ml hygromycin. 
 
2.2.1.3 Cell culture 
iCAFs, iNFs, pCAFs, pNFs, MCF7 and HEK293T cells were cultured in DMEM 
supplemented with 10% FBS, 2 mM glutamine, and 1% penicillin/streptomycin. 
MCF10DCIS.com cells were cultured in F12 medium supplemented with 5% horse 
serum, 2 mM glutamine, 1% penicillin/streptomycin and 0.1% fungizone. For SILAC 
experiments, cells were cultured in DMEM supplemented with 10% FBS, 2 mM 
glutamine, 1% penicillin/streptomycin and either 84 mg/l 13C615N4 L-arginine and 
175 mg/l 13C615N2 L-lysine or 84 mg/l 12C614N4 L-arginine and 175 mg/l 12C614N2 L-
lysine for ‘heavy’ and ‘light’ labelled cells respectively. All cells were cultured at 
37°C, 5% CO2, 21% O2 and harvested with trypsin (0.025% in PE). 
 
2.2.2 Cell based assays 
 
2.2.2.1 EdU proliferation assay (Immunofluorescence) 
EdU (5-ethynyl-2’-deoxyuridine) is an analogue of thymidine which is incorporated 
into newly synthesised DNA strands during S-phase. EDU incorporation can be 
detected using a fluorophore conjugated to an azide which is covalently cross-
linked to EdU via a Click-iT reaction. It can therefore be used as a readout for the 
rate of cell proliferation. 5x105 cells were seeded on 13 mm coverslips. After 24h, 
EdU was added at a concentration of 1 mM and incubated for 2h at 37°C. Cells 
were fixed in 4% PFA for 15min, washed twice in PBS and simultaneously blocked 
and permeabilised with 1% BSA and 0.5% Triton-X100 in PBS. The Click-iT reaction 
was performed using Alexa-fluor 647 azide according to the manufacturers’ 
protocol and the cells were counterstained with DAPI. Images were taken using a 
Zeiss 710 confocal microscope, and the percentage of cells that had incorporated 
EdU was calculated using an Image J macro. 
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2.2.2.2 EdU proliferation assay (Flow Cytometry) 
EdU was added to medium at a concentration of 1 mM and incubated with the 
cells for 2h at 37°C. Cells were harvested and fixed in 4% PFA for 15 min, washed 
twice in PBS and simultaneously blocked and permeabilised with 1% BSA and 0.5% 
Triton-X100 in PBS. The Click-iT reaction was performed using Alexa-fluor 647 
azide according to the manufacturers’ protocol. The cells were washed x3 in PBS 
and resuspended in PBS with 1% BSA before analysis by flow cytometry using an 
Attune NxT (RL1 channel). The percentage of cells that had incorporated EdU was 
calculated using FloJo software. 
 
2.2.2.3 PDH activity assay 
Pyruvate dehydrogenase (PDH) activity was measured using the Pyruvate 
dehydrogenase enzyme activity microplate assay kit (abcam). The kit contains 96 
wells coated with an antibody which captures the intact pyruvate dehydrogenase 
complex. PDH activity is then measured by following the reduction of NAD+ to 
NADH, which is a by-product of the conversion of pyruvate to acetyl-coA by PDH. 
This reduction is coupled to a reporter dye which produces a yellow reaction 
product, the concentration of which can be detected by measuring the absorbance 
at OD450. 5x15 cm dishes of CAFs and NFs at 80-90% confluency were harvested 
for each reaction and the assay was carried out following the manufacturers’ 
protocol. OD450 absorbance was measured over 30 mins to determine the rate of 
reaction. 
 
2.2.2.4 Seahorse assay 
5x104 cells were seeded in each well of the Seahorse xf24 cell culture plates and 
cultured for 48h. 30 mins before the assay the medium was replaced with the 
Seahorse base medium supplemented with 1% FBS, 2 mM glutamine and 1% 
penicillin/streptomycin and the cell culture plate was placed in a CO2 free 
incubator at 37°C. The Seahorse xf24 assay plate was prepared according to the 
manufacturers’ protocol. Using the Seahorse xf24, the oxygen concentration in 
the wells was measured 3 times over 12 minutes at basal levels, then following 
stepwise addition of 1 µM oligomycin, 1 µM CCCP and 1 µM of both Antimycin A 
and rotenone. Oligomycin inhibits ATP synthase by blocking the proton channel 
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(F0 subunit) thus reducing oxygen consumption. CCCP uncouples the electron 
transport chain from ATP synthesis by making the inner mitochondrial membrane 
permeable to protons, forcing the cells to consume oxygen at their maximum 
capacity. Finally Antimycin A and Rotenone inhibit cytochrome C and Complex I in 
the electron transport chain respectively to reduce oxygen consumption to almost 
nothing. The oxygen consumption was normalised to the protein content of the 
wells using SRB (Sulphurhodamine B). The cells were fixed in 10% TCA 
(Trichloroacetic acid) at 4°C overnight. The wells were washed with water, dried 
at RT and incubated with 0.04% SRB in 1% (v/v) acetic acid for 1 hr at RT. The 
wells were washed in 1% acetic acid and dried at RT. 200 µl of Tris-HCl pH 10.5 
was added to each well and incubated at RT for 30 min to resolubilise the dye. 
The OD for each well was measured at 510 nm and the cell number for each well 
was calculated by comparing the results to a standard curve of 20,000-100,000 
cells 
 
2.2.2.5 Bioanalyzer assay 
8x104 fibroblasts were seeded in each well of 6 well plates. A control plate was 
included with media but no cells. Every 24h for 96h, 1 ml of media was taken from 
3 wells for each biological replicate, centrifuged at 16000xg for 5 min and the 
supernatant was stored at -80°C. The cells from the wells were harvested and 
counted and the cell number was used to make a growth curve for each replicate. 
After all samples had been collected, 200 µl of each sample was analysed using 
the YSI 2950 Biochemistry Analyzer. The concentration of glucose, lactate, 
glutamine and glutamate was measured for each sample. The data was 
subsequently normalised to the metabolite concentrations from the control plate 
and to the number of cells in each well. The rate of metabolite exchange between 
the cells and the media was calculated with the following equation: 
𝑀𝑒𝑑𝑖𝑎 𝑓𝑟𝑜𝑚 𝑐𝑒𝑙𝑙𝑠 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑚𝑒𝑑𝑖𝑎
𝑎𝑟𝑒𝑎 𝑢𝑛𝑑𝑒𝑟 𝑔𝑟𝑜𝑤𝑡ℎ 𝑐𝑢𝑟𝑣𝑒
 
 
2.2.2.6 Flow cytometry analysis of mitochondrial probes 
Cells were incubated for 30 min at 37°C with 100 nM MitoTracker Red CMXRos or 
100 nM TMRE in FBS free DMEM. Cells were harvested and fixed in 4% PFA for 15 
mins, washed twice in PBS and analysed by flow cytometry with the Attune NxT 
(YL1 or BL2 channel). The staining intensity was calculated using FloJo software. 
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2.2.3 Transient transfection and lentiviral infection 
 
2.2.3.1 Fibroblast transfection 
For transient expression or siRNA knockdown, 2x106 fibroblasts were harvested 
and used in each transfection. Cells were transfected with a Nucleofector device 
(Lonza) according to the manufacturer's protocol using the program T-20 and the 
Amaxa kit R. Cells were transfected with 1-3 nM non-targeting siRNA as a control 
or with siRNAs targeting PDK2 and PYCR1, or with 5µg pGCA-PDK2N255A or pGCA-
PDK2WT plasmids (kindly provided by Dr. Angus McQuibban, Shi et al. 2017). Cells 
were used for experiments 48-72h after transfection. 
 
2.2.3.3 Stable expression of shRNA in fibroblasts 
HEK293T cells were used to generate lentivirus expressing shRNA constructs. 2x106 
HEK293T cells were plated in a 10 cm dish. The next day, the HEK293T were 
transfected by calcium phosphate with 10 µg of DNA as well as 4 µg VSVG and 7.5 
µg psPAX as packaging plasmids. The following morning the medium was replaced 
with DMEM with 1 mM sodium butyrate. After 24h, the medium containing the 
virus was collected with the addition of 4 µg/ml polybrene, filtered through a 0.45 
µm membrane and transferred onto the fibroblasts. This step was repeated the 
following day. After 48h, the fibroblasts were selected with 1 µg/ml puromycin. 
Untreated fibroblasts were also placed under puromycin selection to ensure that 
all uninfected fibroblasts were killed. 
 
2.2.3.4 ECM production 
Cells were seeded at confluence and cultured for 3-7 days. Cells were lysed by 
incubating with extraction buffer (20mM NH4OH, 0.5% Triton X-100 in PBS) until 
no intact cells were visible but the ECM remained on the dish. The ECM was washed 
in PBS with Ca2+ and Mg2+, then residual DNA was digested with 10 µg/ml RNAse 
free recombinant DNAse I for 30 mins at 37°C. ECM was either stored at 4°C in 
PBS with Ca2+ and Mg2+ and used to plate cells on, or collected and lysed with 2% 
SDS buffer for western blot analysis. 
84 
 
2.2.5 Western blotting analysis 
 
2.2.5.1 Protein quantification 
Unless otherwise stated, cells were lysed in 2% SDS buffer, boiled at 95°C for five 
minutes, sonicated with a metal probe and centrifuged at 16000xg for 10 mins. 
The supernatant was quantified by Bradford assay. Up to 2 µl of each sample was 
added to 1 ml Optiblot Bradford reagent in triplicate, mixed and left to react for 
5 mins at RT. The absorbance at 595 nm was quantified with a spectrophotometer 
(Biophotometer plus, Eppendorf) and the absolute protein quantification was 
determined by comparison with a standard curve generated using 1-5 mg/ml BSA 
and an equal amount of SDS buffer. 
 
2.2.5.2 SDS Page and Western blotting 
Loading buffer containing 1M DTT was added to equal quantities of each sample 
and the samples were boiled for 5 mins at 95°C. Proteins were then separated on 
a 4-12% NuPage Bis-Tris polyacrylamide gel in MES or MOPS running buffer. 
Proteins were transferred onto methanol activated PVDF or nitrocellulose 
membrane at 100V for 60 mins in transfer buffer. The membrane was blocked in 
3% BSA or milk in TBST for 1 hr at RT, then incubated with the primary antibody 
diluted in the blocking solution overnight at 4°C. Excess antibody was removed 
with 3 x 10 min washes in TBST, followed by incubation with horseradish 
peroxidase conjugated secondary antibodies diluted 1:5000 in TBST for 45 mins at 
RT. Excess secondary antibody was removed with 3 x 10 min washes in TBST, and 
the western blots were imaged using chemiluminescence with a MyECL imager 
(Thermo Fisher Scientific). Image analysis was performed using Image Studio Lite 
software (LICOR). Western blots were stripped using 150 mM NaCl, 50 mM Glycine, 
1% NP-40, pH2 in PBS for 1 hr at RT. Stripping buffer was removed with 5 x 10 min 
washes in TBST, followed by re-blocking the membrane and probing with further 
primary antibodies. 
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2.2.6 Immunofluorescence 
 
2.2.6.1 2D cell cultures 
Cells were cultured on 13 mm coverslips and fixed in 4% PFA for 15 mins. The 
coverslips were washed x3 in PBS and simultaneously permeabilised and blocked 
for 1 hr at RT with 1% BSA in PBST. Incubation with the primary antibody diluted 
in blocking solution was performed for 1 hr at RT. Excess antibody was removed 
with 3 x 10 min washes in PBS and coverslips were then incubated with Alexa Fluor 
conjugated secondary antibodies diluted 1:500 in blocking solution for 1 hr at RT. 
Coverslips were counterstained with DAPI, washed with 3 x 10 min washes in PBS 
and mounted on glass slides in DAKO fluorescence mounting medium. Images were 
acquired using a Zeiss 710 confocal microscope. 
 
2.2.6.2 Xenograft tumour sections 
Tumours from xenografts containing shCtl or shPYCR1 pCAFs (Chapter 2.2.15) were 
sliced into 400 µm sections using a vibratome. The sections were blocked and 
permeabilised using blocking buffer (0.3% Triton-X, 0.05% Azide, 1% BSA, and 10% 
donkey serum in PBS) for 24h at RT. The primary antibody was diluted in blocking 
and incubated with the sections for 72h at RT, followed by an overnight wash in 
blocking buffer. The secondary antibody and DAPI were diluted in blocking buffer 
and incubated with the sections for 48h at RT. The sections were washed twice 
for 12h with blocking buffer, followed by a 1h wash in PBS. The sections were 
cleared with Ce3D solution for approximately 2h or until transparent (Li et al., 
2017) and mounted in Ce3D solution. Images were taken using a Zeiss 880 
multiphoton microscope with single harmonic generation imaging to detect 
collagen. 
 
2.2.7 Image analysis 
 
Quantification of collagen area and density or cell number in immunofluorescent 
images or tumour sections was carried out using ImageJ software. Quantification 
of cell number was achieved by splitting the image into red, green and blue 
channels, then keeping the blue channel which contained the DAPI stain. The 
number of nuclei were counted using the ‘Particle analysis’ function. To quantify 
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collagen overlapping with CAFs, the image was split into red, green and blue 
channels, with the red channel containing the collagen stain and the green 
channel for the CAFs. The area of CAFs was selected based on an appropriate 
threshold. In the case of the images acquired using the xenograft tumour sections, 
the selection was expanded by 0.05 inches to ensure that all collagen produced 
by the CAFs was included. The selection area was then applied to the red channel 
and the density of collagen staining within the selection or the percentage of the 
selection that was positive for collagen was calculated. For the analysis of 
collagen produced by non-CAF cells and therefore not overlapping with the CAFs, 
the selection of the CAF area was inverted and then applied to the red channel 
and analysed as described above. 
 
2.2.8 Bacterial transformation and plasmid generation 
 
Competent E. coli bacteria (DH5α or BL21-DE3) were thawed on ice and incubated 
with 2 µl plasmid for 30 mins on ice. The bacteria were then incubated for 1 min 
at 42°C before immediately being placed on ice for 2 mins. The transformed 
bacteria were then incubated in 1 ml LB broth for 1 hr at 37°C before being spread 
on an agar plate containing ampicillin or kanamycin and incubated overnight at 
37°C. One colony was subsequently picked and expanded in LB broth containing 
ampicillin or kanamycin for 24h at 37°C and 250 rpm. Bacteria were pelleted at 
4000xg for 20 min and the pellet was frozen. The plasmid was subsequently 
isolated from the pellet using a Qiagen maxiprep kit. 
 
2.2.9 CNA35-mCherry purification 
 
pET28a-mCherry-CNA35 was a gift from Maarten-Merx (Aper et al., 2014). The 
CNA35-mCherry plasmid was transformed into E.Coli BL21-DE3.  A single colony 
was expanded in LB broth containing 30 µg/µl kanamycin until the optical density 
at 600 nm reached circa 0.6 in 4 x 1 L flasks. CNA35-mCherry expression was 
induced by addition of 0.5 mM Isopropyl β-D-1-thioglasctopyranoside (IPTG). 
Expression was induced for 20 h at 25°C and 250 rpm. Bacteria were pelleted by 
centrifugation for 15 min at 10000xg and 4°C. The pellet was resuspended in 
Buffer 1 (20mM Tris-HCl pH 7.9, 0.5M NaCl) and the bacteria were lysed using a 
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High Pressure Homogeniser. The suspension was then centrifuged for 35 min at 
20000xg at 4°C and the supernatant containing the solubilised protein was purified 
by Ni2+-affinity chromatography since the protein has an N-terminal 6 x His-tag. A 
5 ml His-trap HP column (GE Healthcare) was used for purification in conjunction 
with an Akta flow system. The protein solution was loaded onto the column and 
CNA35-mCherry was eluted using an increasing imidazole gradient created by 
mixing Buffer 1 with an increasing proportion of Buffer 2 (20mM Tris-HCl pH 7.9, 
0.5M NaCl, 500 mM imidazole). The fractions containing the protein were easily 
identifiable as they were purple, and these were concentrated to 5 mL using 
Amicon Ultra-4 Centrifugal Filter Units. The protein was further purified using size 
exclusion chromatography. The protein containing fractions were concentrated to 
5 mL again and the concentration was determined by Bradford assay. 1 µl was 
added in triplicate to 1 ml Bradford reagent and allowed to react for 5 min at RT. 
The absorbance at 595 nm was measured using a spectrophotometer and absolute 
protein quantification was determined by comparison with a standard curve 
generated using 1-5 mg/ml BSA. Aliquots of the protein were snap frozen in liquid 
nitrogen and stored at -80. 
 
2.2.10 RNA extraction and RT-PCR 
 
2.2.10.1 RNA extraction 
RNA was extracted from cells grown to 80% confluence in 6 well plates. Cells were 
lysed in RLT buffer (Qiagen) and the cell lysate was either frozen immediately at 
-80°C or used immediately for RNA extraction. RNA was extracted using the Qiagen 
RNEasy mini kit according to the manufacturers protocol, eluted from the RNEasy 
spin column with 30 µl RNAse free H2O and 1 µl was used for quantification with a 
nanodrop. 
 
2.2.10.2 cDNA synthesis 
1 µg RNA was used for DNA synthesis. RNA was mixed with iScript reverse 
transcriptase and reverse transcription-reaction mix (BioRad) and RNAse free 
water was added to bring the total volume for each reaction to 20 µl. cDNA was 
generated using the following programme: 5 min at 25°C, 30 min at 42°C, 5 min 
at 85°C. 
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2.2.10.3 RT-PCR 
cDNA was diluted 1:5 for RT-PCR. 10 µl iTAQ Universal SYBR Green supermix 
(BioRad) was mixed with 2 µl cDNA and 400 nM forward and reverse primers diluted 
in 8 µl nuclease free H2O for each reaction. Each sample was analysed in triplicate, 
and, in addition to the target(s) of interest, primers for at least two reference 
genes were included for normalisation of each sample. Non-template controls 
were also run alongside each experiment. The RT-PCR reaction was carried out on 
a Quant Studio 3 RT-PCR machine (Thermo Scientific) using their Standard 
programme. 
 
2.2.11 MS-Metabolomics analysis 
 
2.2.11.1 Sample preparation for intracellular metabolomics 
2x105 fibroblasts were seeded in each well of 6 well plates. For each biological 
replicate 3 separate wells were used in each condition. For tracing experiments, 
cells were cultured in DMEM 10% FBS supplemented with either 25 mM U-13C6 
Glucose, 2 mM U-13C5 Glutamine, 1 mM U-13C3 Pyruvate or 100 µM U-13C16 
Palmitate. After 48h of culture, the cells were washed x3 in ice cold PBS to remove 
the media, then 400 µl ice cold extraction buffer (50% methanol, 30% acetonitrile, 
20% water) was added to each well and incubated at 4°C for 5 min. The extracted 
metabolites were collected and centrifuged at 16000xg for 5 min at 4°C. 200 µl 
from each sample was transferred to an LC-MS vial and stored at -80°C until 
analysis by LC-MS. 
 
2.2.11.2 Q-Exactive acquisition 
LC-MS was carried out using a previously described method (Mackay et al., 2015). 
A Q-Exactive Orbitrap mass spectrometer (Thermo Scientific) was used in 
combination with a Thermo Ultimate 3000 HPLC system. The HPLC system was set 
up with a Zic-pHILIC 5 µm polymer column, 150 x 2.1 mm (SeQuant, Merck) and a 
ZIC-pHILIC guard column, 20 x 2.1 mm (SeQuant, Merck). A volume of 5 µl of cell 
extract was injected and the metabolites were separated over a 15 min mobile 
phase gradient from an initial ACN content of 80% ACN with 20% ammonium 
bicarbonate (pH 9.2) decreasing to 20% ACN. The flow rate was 200 µL/min and 
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the column temperature was 45°C. The metabolites were detected over a period 
of 25 min using the Q-Exactive mass spectrometer across a mass range of 75-1000 
m/z and at a resolution of 35,000 (at 200 m/z). Electrospray ionisation and 
polarity switching enabled both positive and negative ions to be detected in the 
same run. Lock masses were used and the mass accuracy for each metabolite was 
less than 5 ppm. To detect acetyl-coA, a single ion monitoring (SIM) method was 
employed. The Q-Exactive mass spectrometer was used to monitor the three 
masses for acetyl-coA labelled M0, M1 or M2 (810, 811 and 812 m/z) with an 
isolation window of 1 m/z for each isotope. The resolution was 70,000 and the ion 
trap fill time was 100 ms. The automatic gain control (AGC) target value was 5e4. 
Only positive ions were detected as single polarity was used rather than polarity 
switching. Thermo Xcalibur software was used for data acquisition. 
 
 
2.2.11.3 Analysis of metabolomics data 
Data analysis was carried out using TraceFinder 4.0 software to determine the 
peak area of each metabolite of interest. The spectra were queried against a 
curated compound database created from analysis of commercial standards of 
each metabolite run previously on this LC-MS system and pHILIC column. 
Metabolites were identified based on the exact mass of the singly charged ion and 
the retention time on the column. Predicted retention times were manually 
adjusted based on those of a standard metabolite mix which was run on the LC-
MS system alongside the samples. The relative total metabolite levels and 13-C 
labelling patterns were determined based on the peak area for the accurate mass 
of each isotopologue for each metabolite. The peak areas were normalised to total 
protein content for each sample. Proteins were collected from each cell culture 
well after the metabolite extraction and quantified by Bradford assay. 
 
2.2.12 Sample preparation for MS-proteomics 
 
2.2.12.1 In solution digestion 
Proteins were denatured in urea buffer. The lysate was diluted 1:2 in 25 mM Tris-
HCl pH 8.5. For every 50 µg of protein, 1 µg of LysC was added and the mixture 
was incubated for 3h at RT. LysC partially digests the protein at the C terminus of 
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lysine residues, which enables more efficient trypsin digestion. The lysate was 
then further diluted 1:2 in 25 mM Tris-HCl pH 8.5 to give a final dilution of 1:4 
lysate:buffer, and 1 µg trypsin was added for every 50 µg of protein. The proteins 
were left to digest overnight at RT. The digestion reaction was then terminated 
by acidifying the sample with TFA (trifluoroacetic acid) to a final concentration of 
1%.  
 
2.2.12.2 In gel digestion 
Each sample was denatured in SDS buffer and run on a 4-12% SDS page gel to 
separate the proteins. The gel was stained with Coomassie blue for 1 hr and 
washed x3 in HPLC water. Each lane of the gel was cut into identical bands and 
each band was further chopped into small pieces and placed in a 1.5 ml Eppendorf 
tube. The Coomassie stain was removed with 3 x 20 min washes of a 1:1 mixture 
of 50 mM ABC and absolute ACN. The gel was then dehydrated in ACN for 10 min, 
and this step was repeated until the gel pieces were hard and white.  The gel was 
then dried in a Speed-Vac for 5 min. The gel was rehydrated in 10 mM DTT and 
incubated for 1 hr at 56°C to reduce cysteines. The reduced cysteines were then 
alkylated in 55 mM IAA at RT for 45 min in the dark. The gel pieces were washed 
in 50 mM ABC for 20 min and dehydrated with ACN for 10 min. The wash and 
dehydration steps were repeated. The gel was then dried in a Speed-Vac for 5 
mins. The proteins in the gel were digested with 625 ng trypsin for each sample. 
The trypsin was diluted in 50 µl of 50 mM ABC and allowed to rehydrate the gel 
pieces for 15 min. Then, a further 70 µl of 50 mM ABC was added, or enough to 
cover the gel pieces. The samples were incubated overnight at 37°C. The following 
day, the peptides were extracted from the gel pieces by alternating 10 min 
incubations of the extraction buffer (3% TFA, 30% ACN in water) with ACN to 
dehydrate the samples. The supernatant from each incubation step was kept and 
transferred to a new tube. After two rounds of extraction and dehydration, the 
supernatant was reduced in the Speed-Vac to a volume of approximately 100 µl. 
Samples were then desalted by StageTip before MS analysis. 
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2.2.12.2 StageTip desalting 
StageTips were prepared by loading 1 x C18 membrane for every 5 µg protein into 
a 200 µl pipette tip. The StageTip was activated for protein binding by adding 50 
µl methanol and centrifugation for 1.5 min at 600xg by which point all the 
methanol had passed through the membranes. Subsequently, 50 µl buffer B was 
passed through the membranes by centrifugation at 600xg, followed by 50 µl 
buffer A*. The digested peptides were then loaded onto the membranes and 
centrifuged at 200xg for 5 min. The bound peptides were washed with 50 µl buffer 
A at 600xg and eluted with 2 x 20 µl buffer B. The eluted peptides were stored at 
-80°C until MS-proteomic analysis, at which point the ACN was evaporated using 
a speed vacuum until ~3 µl remained and an equal volume of buffer A* was added. 
 
2.2.12.2 SILAC labelling 
SILAC (Stable isotype labelling of amino acids in cell culture) labelled cells were 
generated by culturing the cells in SILAC media (DMEM supplemented with light or 
heavy arginine and lysine) for 3 passages or until the cells were at least 95% 
labelled. The percentage of SILAC labelled proteins was determined by MS-
proteomics. Cells were lysed in urea buffer. The lysate was sonicated on ice with 
a metal probe and centrifuged at 16000xg for 10 mins. The supernatant was 
digested by in solution digestion followed by StageTip desalting and MS analysis. 
Incorporation of SILAC labels was determined using the peptides.txt output file 
from MaxQuant software analysis with R software. The incorporation of Arg10 and 
Lys8 were calculated separately with the equation 
𝐼𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑖𝑜𝑛 = 1 − (
1
𝑟𝑎𝑡𝑖𝑜 𝐻: 𝐿
) ∗ 100 
Once the incorporation was ≥ 95%, the cells were used for further MS-proteomic 
experiments. 
 
2.2.12.3 Acetylome enrichment 
SILAC labelled iCAFs and iNFs were grown to 80% confluence in 10 x 15 cm dishes 
for each cell line. The cells were lysed on ice in RIPA buffer supplemented with 
10 mM nicotinamide and 1 µM Trichostatin A to inhibit deacetylases. 1/10th of the 
volume of 5M NaCl was added to improve recovery of chromatin bound proteins 
and the lysates were incubated for 15 min on ice. The lysates were sonicated with 
a metal probe and centrifuged at 4800 x g. 4 volumes of ice cold acetone were 
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added and the lysates were incubated overnight at -20°C to precipitate proteins. 
The precipitate was pelleted at 4800 x g for 20 min at 4°C and washed with ice 
cold acetone. The pellets were resuspended in urea buffer and the protein 
concentration was determined by Bradford assay. Equal amounts of heavy and 
light labelled lysate were mixed and the samples were digested by in solution 
digestion. The samples were desalted by C18 SepPak column. The SepPak was 
activated by allowing 5 ml ACN to run through via gravitational flow and 
equilibrated with 2 x 5 ml 0.1% TFA. The sample was then loaded and allowed to 
flow through the column. The peptides were washed with 0.1% TFA and then with 
water. Peptides were eluted stepwise with an increasing gradient of ACN in 0.1% 
TFA (10, 15. 20, 25, 30, 40, 60% ACN). The eluates were pooled and evaporated 
by speed vacuum to a volume of approximately 1 ml. The sample was then mixed 
with 10 x IAP buffer to make a 1 x IAP buffer solution. The sample was brought to 
pH 7. 50 µl slurry containing agarose beads conjugated to anti-Acetyllysine 
antibody were centrifuged at 2000 x g for 30 sec and the supernatant was 
removed. The beads were washed x4 in PBS and resuspended in 40 µl PBS. The 
peptides were added to the beads and incubated on a rotation wheel overnight at 
4°C. The following day, the beads were centrifuged at 2000 x g for 1 min at 4°C. 
The beads were washed x4 with IAP buffer and x3 with water. The acetylated 
peptides were eluted with 50 µl 0.1% TFA and incubated at RT for 10 min before 
centrifugation at 2000 x g. The elution step was repeated twice and the combined 
supernatant was desalted by StageTip before MS analysis. 
 
2.2.13 Mass spectrometer set up 
 
2.2.13.1 Nano liquid chromatography 
All samples were further fractionated to separate the peptides by reverse-phase 
chromatography at high resolution. After StageTip desalting, the peptides were 
resuspended in buffer A* and injected into an EASY-nLC system coupled online to 
a mass spectrometer (Thermo Fisher Scientific). The peptides were separated on 
a 20 cm fused silica emitter column (New Objective) packed in-house with reverse-
phase Reprosil Pur Basic 1.9 µm (Dr. Maisch GmbH). The peptides were eluted 
with a flow rate of 300 nl/min over a 60 min linear gradient from 5% to 30% of 
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buffer B. The eluted peptides were ionised and injected into the mass 
spectrometer by electrospray ionisation. 
 
2.2.13.2 Q-Exactive HF acquisition 
The full MS scan was acquired with a mass range of 375-1500 m/z, a resolution of 
60,000 and an AGC of 3e6. The top 15 most intense peaks from the full MS scan 
were isolated for fragmentation and MS/MS analysis with an AGC target of 5e4 ions 
at a resolution of 15,000. Singly charged ions were excluded, and those ions that 
were selected for MS/MS analysis were subsequently added to a list of excluded 
ions to prevent the same ion from being fragmented multiple times. MS data were 
acquired using XCalibur software (Thermo Fisher Scientific). 
 
2.2.13.3 Orbitrap Fusion Lumos acquisition 
The full MS scan was acquired with a mass range of 350-1550 m/z, a resolution of 
60,000 and an AGC of approximately 5 x 105. The top 15-20 most intense peaks 
from the full MS scan were isolated for fragmentation and MS/MS analysis with an 
AGC target of 50-100,000 ions at a resolution of 15,000. The included charge range 
was 2-7 and those ions that were selected for MS/MS analysis were subsequently 
added to a list of excluded ions to prevent the same ion from being fragmented 
multiple times. MS data were acquired using XCalibur software (Thermo Fisher 
Scientific) 
 
2.2.14 Proteomic data analysis 
 
2.2.14.1 Data processing with MaxQuant 
The raw MS data files were processed for peptide and protein identification and 
quantification using MaxQuant software coupled to the Andromeda search engine 
(Cox and Mann, 2008, Cox et al., 2011). MaxQuant versions 1.6.0.7 or 1.6.3.3 were 
used. The data was queried against the human UniProt database 
(www.uniprot.org) to identify the presence of peptides and proteins based on 
their MS and MS/MS spectra. The following settings were used across all 
experiments: Acetyl (N-term) and Oxidation (M) were set as variable modifications 
and Carbomidomethyl (C) as a fixed modification and the digestion mode was 
Trypsin (P). Up to 2 missed cleavages were allowed. An initial mass deviation of 
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4-5 ppm for the parent mass and 20 ppm for the fragment ion was allowed. 
Matching between runs was enabled when fractions with similar chromatography 
were compared.  The false discovery rate was set to 1% for identification of 
peptides and proteins, and only unique peptides, i.e. peptides that are not found 
in any other protein, were used for quantification. For the acetylome experiment 
(2.2.11.3), I added Acetyl (K) as an additional variable modification. 
 
For SILAC experiments, MaxQuant can accurately quantify the relevant abundance 
of protein between samples based on the intensities of identified SILAC pairs. The 
additional MaxQuant settings for SILAC experiments were as follows: The 
multiplicity of the experiment was set to 2, with the light labels set as Arg0 and 
Lys0 and heavy labels Arg10 and Lys8. 
 
In the absence of isotopic labels, MaxQuant can still quantify differential peptide 
and protein amounts between samples using Label Free Quantification (LFQ) (Cox 
et al., 2014). Briefly, the normalisation of the fractions is delayed until all the 
peptide ion intensities across the fractions are summed and the normalisation 
factor for each fraction is then calculated in order to produce the least amount 
of variation between samples, based on the assumption that the majority of the 
proteome does not change between two conditions. For label free experiments, 
the LFQ setting was enabled in MaxQuant. 
 
MaxQuant software generates a set of output tables. For further analysis, I used 
the proteingroups.txt file and, if relevant, the Acetyl (K)Sites.txt file for further 
analysis with Perseus software (Tyanova et al., 2016). 
 
2.2.14.2 Perseus data analysis 
Perseus versions 1.5.5.3, 1.6.0.7 or 1.6.2.2 were used to carry out statistical 
analysis of the proteomic data. For all experiments, analysis of the 
proteingroups.txt file was as follows: For SILAC experiments, the SILAC ratios H/L 
were uploaded as main columns and for LFQ experiments the normalised LFQ 
intensities were uploaded as main columns. The data was then filtered by 
removing potential contaminants, such as keratins and trypsin derived peptides. 
Reverse peptides, which are identified by querying them against a decoy database 
(Elias and Gygi, 2010) were also removed. Finally peptides only identified by site, 
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meaning only the modified version of the peptide was identified, were also 
removed. Only proteins identified in at least two biological replicates were 
considered for analysis. For SILAC experiments, the SILAC ratio for the ‘Reverse’ 
experiment was inverted to make the comparison between Forward and Reverse 
labelled experiments consistent. SILAC ratios were then transformed by log2 and 
the intensities and LFQ intensities were transformed by log10. The distribution of 
the SILAC data was assessed using a histogram, and if the data did not follow a 
normal distribution centred on zero, the median ratio was subtracted from all the 
ratios for each sample. Proteins that were significantly different between 
conditions were identified by performing a two sample t-test (p ≤ 0.05) for the 
label free experiments.  
 
For the acetylome experiment, the Acetyl (K)Sites.txt file was analysed as follows: 
The data was filtered for contaminants and reverse peptides as described 
previously. Only peptides with a score differential > 0.5 and a localisation 
probability of > 0.75 were kept for the analysis. The site table was expanded to 
separate peptides with the same sequence but different numbers of acetylated 
sites. All acetylated peptides with a SILAC ratio in at least one biological replicate 
were used for the analysis to extract the maximum amount of data from the 
experiment. The acetylation sites were annotated with the following information 
about modification sites derived from the PhosphoSitePlus database 
(www.phosphositeplus.org): linear motifs, known sites, regulatory sites and 
sequence features. The SILAC ratios were transformed by log2 and the intensities 
by log10, and the Reverse ratios inverted. The data was then normalised to the 
total proteome by subtracting the SILAC ratio for each protein from the 
proteingroups.txt analysis from the SILAC ratio for each acetylated peptide. If the 
unmodified protein was not identified in the total proteome, a SILAC ratio of 0 
was imputed so as not to lose information about modifications. Significantly 
regulated peptides were identified using a one sample t-test, with an S0 ≤ 0.1 and 
a Benjamini-Hochberg false discovery rate (FDR) ≤ 0.05. The proteins were further 
annotated with information from the Gene Ontology Cellular Compartment 
(GOCC), Gene Ontology Biological Function (GOBF), Gene Ontology Molecular 
Function (GOMF), Kyoto encyclopaedia of genes (KEGG) and Protein families 
(Pfam) databases. A one dimension category enrichment analysis was then carried 
out to identify which categories from these databases were enriched for 
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acetylated peptides in the different conditions (Cox and Mann, 2012). The 
enrichment factor was calculated using the Fisher exact test with a Benjamini-
Hochberg FDR ≤ 0.02: 
 
𝐸𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 𝑓𝑎𝑐𝑡𝑜𝑟 =
𝑖𝑛𝑡𝑒𝑟𝑠𝑒𝑐𝑡𝑖𝑜𝑛 𝑠𝑖𝑧𝑒 𝑥 𝑡𝑜𝑡𝑎𝑙 𝑠𝑖𝑧𝑒
𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑜𝑛 𝑠𝑖𝑧𝑒 𝑥 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑦 𝑠𝑖𝑧𝑒
 
 
An enrichment factor of > 1 denotes an enriched category and < 1 a depleted 
category. 
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2.2.15 Xenografts of MCF10DCIS.com cells and CAFs 
 
MCFDCIS.com breast cancer cells were combined with either the shCtl or shPYCR1 
pCAF cell lines in a 1:3 ratio and resuspended in 50% growth factor reduced 
matrigel and 50% PBS. 200 µl of the matrigel mixture containing 0.5 x 106 
MCF10DCIS.com cells and 1.5 x 106 CAFs was injected subcutaneously into the 
mammary fat pad of 12 Balb-C nude mice for each condition. The tumours were 
measured by calliper every 2-3 days. After 2 weeks, six mice from each condition 
with the largest tumours as measured by the calliper were culled and the tumours 
were collected. The tumours were weighed and cut in half. One half was fixed in 
4% PFA overnight and transferred to 70% ethanol before being embedded in 
paraffin blocks for immunohistochemical analysis. The other half was fixed in 4% 
PFA for 1 hr and subsequently sliced into 400 µm sections which were used for 
single harmonic generation imaging to detect collagen. The remaining mice were 
allowed to reach endpoint as determined by the tumours reaching a length of 15 
mm or the presence of ulceration. Each mice was culled at endpoint and the 
tumours were collected. The injection, monitoring and tumour collection were 
carried out by Sandeep Dhayade from the Beatson Institute. 
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Chapter 3  Pyruvate dehydrogenase activity is 
upregulated in mammary CAFs 
 
3.1 Characterisation of CAFs and NFs 
 
In this study I used paired CAFs and NFs derived in two different ways. The first 
are the iCAFs and iNFs which were kindly provided by Professor Akiro Orimo 
(Chapter 2.2.1.1). The iCAFs and iNFs have been characterised by the Orimo group 
and the iCAFs were shown to have an activated, myofibroblastic phenotype in 
comparison to the iNFs (Kojima et al., 2010), and this phenotype is maintained in 
culture in an autocrine manner through TGF-β and SDF-1 signalling. The iCAFs and 
iNFs have also been well characterised by our group (Hernandez-Fernaud et al., 
2017) (Kugeratski et al., 2019) and the iCAFs have been demonstrated to be more 
pro-invasive, pro-angiogenic and pro-tumourigenic than the iNFs, all of which are 
important characteristics of the CAF phenotype. 
 
The second type of CAFs and NFs are the pCAFs/pNFs which are derived from 
human breast cancer patients and which I immortalised (Chapter 2.2.1.2). I 
immortalised 3 matched pairs of CAFs and NFs where both cell types came from 
the same patient (pCAFs/NFs 1-3), and one unmatched CAF and NF cell line (pCAF 
4, pNF 5). All of the fibroblast lines expressed the mesenchymal cell marker 
vimentin as shown by immunofluorescence (Figure 3-1). Furthermore, our group 
has checked by flow cytometry analysis that the patient derived fibroblasts are 
uncontaminated with endothelial, immune or epithelial cells. In order to verify 
the activation of all the CAF cell lines I measured the levels of αSMA expression, 
which is the most commonly used marker of the activated myofibroblast 
phenotype, by western blot. Overall CAFs expressed more αSMA than NFs, 
although pNF 5 had relatively high αSMA levels (Figure 3-2). I regularly monitored 
αSMA levels in both the iCAFs/iNFs and pCAFs/pNFs during this study in order to 
be sure that they were maintaining their respective CAF and NF phenotypes. In 
this way I could carry out my experiments both using the iCAFs/iNFs, which have 
been extensively characterised, and the pCAFs/pNFs, which have been less well 
characterised and are likely to be more heterogeneous since we do not know what 
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cells the CAFs originate from, but are patient derived and therefore more 
clinically relevant. 
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Representative images of the pCAFs post-immortalisation stained for vimentin (green), 
phalloidin (red) to visualise the actin cytoskeleton and DAPI (blue). Images were 
acquired using the Zeiss 710 at 20x magnification. Representative images of n ≥ 3 
replicates 
 
 
Figure 3-1 Patient derived CAFs express the fibroblast marker vimentin 
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Representative western blots of n ≥ 3 biological replicates of αSMA levels in all the pairs of 
fibroblasts. Vinculin or β-tubulin was used as a loading control. Positions of molecular weight 
markers are shown.  
 
 
 
 
Figure 3-2 CAFs express more αSMA than NFs 
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3.2 Predicting kinase activity in iCAFs and iNFs 
 
Many key signalling pathways in cells are driven by changes in phosphorylation due 
to altered kinase activity. In particular, kinase dysregulation is a common feature 
of cancer cells. To further probe into how CAFs maintain their activated 
phenotype, we collaborated with Dr. Julio Saez-Rodriguez and Enio Gjerga from 
RWTH Aachen University (Germany) to elucidate changes in kinase activity from 
the phosphoproteomes of the iCAFs and iNFs. The MS-phosphoproteomic data was 
previously acquired and analysed by Juan Ramon Hernandez-Fernaud from our 
group. Samples from SILAC labelled iCAFs and iNFs were enriched for 
phosphorylated peptides and analysed by MS-proteomics. The experiment was 
performed with both forward and reverse labelled cells (i.e. heavy CAFs with light 
NFs and light CAFs with heavy NFs) to give two total experiments. The Saez-
Rodriguez group then used the differences between iCAFs and iNFs in the log2 
SILAC ratios of phosphosites known to be targeted by specific kinases to predict 
which kinases were more or less active in the iCAFs. From this modelling, only five 
kinases were predicted to have significantly different activity between iCAFs and 
iNFs: MAPK1, MAPK3, AKT3, CDK2 and PDK2 (Figure 3-3). Of these, I decided to 
focus on PDK2 (Pyruvate dehydrogenase kinase), the activity of which was 
downregulated in the iCAFs, because it was predicted to have the greatest 
difference in activity between iCAFs and iNFs. Furthermore, it has only one main 
target: Pyruvate dehydrogenase (PDH), although it has recently been shown to 
also phosphorylate PARL (Shi and McQuibban, 2017). The pyruvate dehydrogenase 
complex is made up of three subunits, of which the PDH subunit catalyses the rate 
limiting step of pyruvate decarboxylation and is therefore subject to the most 
regulation at the post-translational level. The PDC is a key metabolic enzyme 
because it converts pyruvate to acetyl-coA in the mitochondria, thus connecting 
the two major metabolic pathways of glycolysis and the TCA cycle. Acetyl-coA 
produced by the PDC can also be used for a variety of other metabolic pathways 
including cholesterol and fatty acid synthesis, as well as for protein acetylation, 
making it a versatile and central metabolite. Therefore changes in PDH activity 
could have a profound impact on the CAF phenotype. PDH was also the most highly 
regulated protein at the phosphorylation level in the phosphoproteomics data; 
three out of its four phosphorylation sites on the A1 subunit were highly 
downregulated in the iCAFs, including S293 which is the site that PDK2 has the 
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highest affinity for (Figure 3-4). Phosphorylation of any of these three sites is 
known to inhibit PDH activity by blocking binding of pyruvate to the active site. 
Therefore, since PDH phosphorylation was less phosphorylated in the iCAFs I 
hypothesised that PDH activity was downregulated due to a decrease in PDK2 
activity. 
104 
 
 Plot showing the score for the predicted difference in kinase activity in iCAFs 
compared to iNFs based on phosphoproteomic data from the iCAFs and iNFs. Data from 
two experiments with both forward and reverse labelled fibroblasts was used for the 
modelling. Each dot represents a kinase used in the analysis. Kinases with a significant 
p-value are named. 
Figure 3-3 Visualisation of predicted kinase activity in iCAFs and iNFs 
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Scatter plot showing the log2 difference of phosphorylated proteins between iCAFs 
and iNFs in two independent SILAC experiments. For each experiment both forward 
and reverse labelled experiments were averaged. Each dot represents a 
phosphorylation site. The three identified phosphorylation sites on PDH are 
highlighted in blue 
Figure 3-4 Phosphoproteomic data of iCAFs and iNFs highlighting PDH phospho-sites 
106 
 
3.3 Pyruvate dehydrogenase is less phosphorylated in 
CAFs 
 
To verify the results of the phosphoproteomic data, I assessed the levels of PDH 
phosphorylation in CAFs and NFs by western blot. I chose the S293 phosphorylation 
site to study because this is the site with the highest affinity for PDK2. I compared 
PDH phosphorylation levels between the iCAFs and iNF as well as two pCAF and 
pNF pairs: pCAF2/pNF2 and pCAF3/pNF3. I selected these two pairs because both 
had a good regulation of αSMA between NFs and CAFs and because the pCAF2/NF2 
fibroblasts are from an ER positive patient whereas the pCAF3/pNF3 are from a 
triple negative patient and I wanted to demonstrate that the regulation of PDH 
phosphorylation is not specific to CAFs from one subtype of breast cancer. I then 
used these pCAF/pNF pairs in all subsequent experiments involving pCAFs and 
pNFs. In all the fibroblast pairs, PDH was significantly less phosphorylated in the 
CAFs as shown by western blot analysis (Figure 3-5). The total amount of PDH did 
not decrease, showing that PDH phosphorylation is being regulated rather than 
the protein expression. This supports the phosphoproteomic data from the iCAFs 
and iNFs and shows that PDH regulation is not specific to the iCAFs but also occurs 
in patient derived CAFs. 
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 Representative western blots and quantification of pPDHA1 levels in CAFs and NFs. Graphs show 
SEM and mean of 3 independent experiments. Quantification represents pPDHA1 intensity 
normalised to both total PDHA1 intensity and vinculin intensity. Molecular weight markers are 
indicated next to the blots. Significance was calculated using an unpaired student t-test with 
Welch’s correction: p≤0.05 *, p≤0.01 ** 
Figure 3-5 PDHA1 phosphorylation in CAFs and NFs 
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3.4 PDK2 regulates PDH phosphorylation 
 
3.4.1 PDK2 expression is downregulated in CAFs 
 
Although PDK2 was the only pyruvate dehydrogenase kinase predicted to be 
regulated in the iCAFs by the modelling of the phosphoproteomic data, there are 
in fact four pyruvate dehydrogenase kinases that can phosphorylate and inactivate 
PDH: PDK1, PDK2, PDK3 and PDK4. These are isoforms which share ~70% homology. 
Of these, PDK3 is predominantly found in heart and skeletal muscle tissue in 
humans and detected only in lung, brain, kidney and testes in mice, so I discounted 
PDK3 from being the main driver of changes in PDH phosphorylation in the 
mammary CAFs. PDK1 and PDK4 are also only expressed highly in heart and skeletal 
muscle, however, they are overexpressed in several cancers (Grassian et al., 2011) 
(Hsieh et al., 2008) (Kaplon et al., 2013) (Pate et al., 2014) and PDK1 is known to 
be upregulated in response to hypoxia (Kim et al., 2006a), which is a common 
feature of the tumour microenvironment. PDK2 however is ubiquitously expressed 
in all tissues. In addition there are two pyruvate dehydrogenase phosphatases: 
PDP1 and PDP2 which can regulate PDH phosphorylation and activity. There are 
few studies on the PDPs, although there is evidence suggesting they are regulated 
at the post translational level in some cancers (Fan et al., 2014) (Shan et al., 
2014). However, neither PDP has ever been investigated as a drug target in the 
context of cancer or any other disease, whereas PDKs can be targeted with several 
drugs including dichloroacetate (DCA) which has so far been shown to be well 
tolerated in Phase I clinical trials involving cancer patients (Dunbar et al., 2014) . 
I therefore wanted to assess whether PDK2 was indeed the main kinase or 
phosphatase responsible for the difference in PDH phosphorylation. I designed and 
tested primers for PDK1, PDK2 and PDK4. PDK4 could not be detected by qPCR, 
but PDK2 was significantly downregulated at the mRNA level in CAFs compared to 
NFs and PDK1 was significantly downregulated in the pCAF2s (Figure 3-6a). PDK2 
was much more highly expressed in the fibroblasts than PDK1, so I concluded that 
the regulation of PDK2 in CAFs would have a greater effect on PDH 
phosphorylation. Although PDK4 could not be detected at the mRNA level, the 
protein expression of PDK4 in lysates from iCAFs and iNFs could be detected by 
western blot, but there was no difference in expression between iCAFs and iNFs. 
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I also tried to detect PDP1 and PDP2 by western blot, however, PDP1 expression 
was not upregulated in the iCAFs and I could not detect PDP2 (Figure 3-6b). 
Furthermore, treatment of the iNFs with DCA, the PDK inhibitor, greatly reduced 
PDH phosphorylation as shown by western blot (Figure 3-7a). This suggests that a 
PDK is driving increased PDH phosphorylation in NFs rather than a PDP driving 
increased dephosphorylation of PDH in CAFs. 
 
To see if PDK2 was also downregulated in CAFs in a clinical context, the expression 
of the PDKs was measured in laser capture microdissected sections of normal or 
tumour associated stroma from triple negative breast cancer patients in 
collaboration with Dr. Morag Park. This data showed that both PDK2 and PDK4 are 
downregulated in tumour associated stroma, whereas PDK1 and PDK3 are not 
(Figure 3-8). Although PDK4 was also highly downregulated in the tumour-
associated stroma, since it was not highly expressed or regulated between my 
CAFs and NFs whereas PDK2 consistently was, I focussed on PDK2 in my future 
experiments. 
 
I therefore concluded from these experiments that PDK2 expression was 
downregulated in CAFs and that this was likely to be the cause of the observed 
decrease in PDH phosphorylation 
 
3.4.2 PDK2 expression regulates PDH phosphorylation 
 
To confirm that PDK2 was controlling PDH phosphorylation in CAFs, I modulated 
the expression of PDK2 in the iCAFs and iNFs and quantified the level of PDH 
phosphorylation by western blot (Figure 3-7b). The iNFs were transfected with an 
siRNA pool against PDK2 to transiently knock down PDK2. The efficiency of the 
knock down was verified by RT-qPCR and showed that 48h after transfection there 
was a reduction in phosphorylated PDH in siPDK2 transfected iNFs compared to 
the siCTL. Conversely, the iCAFs were transfected with a plasmid to transiently 
overexpress either wild-type PDK2 or PDK2 with the mutation N255A which 
abrogates its kinase activity (Shi and McQuibban, 2017). Expression of PDK2WT was 
sufficient to increase PDH phosphorylation in comparison to PDK2N255A 48h after 
transfection. Therefore PDK2 is indeed a major regulator of PDH phosphorylation 
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in fibroblasts, and I am able to control PDH phosphorylation in both CAFs and NFs 
by overexpression or siRNA knock down of PDK2. 
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a: mRNA expression of PDK1 and PDK2 in CAFs and NFs as measured by RT-qPCR. The 
mean and SEM of at least 3 independent experiments are shown. PDK1 and PDK2 
expression was normalised to GAPDH expression for each cell line. n ≥ 3 biological 
replicates. Significance was calculated using an unpaired student t-test test with 
Welch’s correction: p≤0.05 *, p≤0.01 **, p≤0.001 *** 
b: Western blots showing the levels of PDK4 and PDP1 in the iCAFs and iNFS. Molecular 
weight markers are shown next to the blots. Representative images of n ≥ 3 biological 
replicates 
 
 
a 
b 
Figure 3-6 PDK expression in CAFs and NFs 
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a: Western blot showing the levels of phospho-PDHA1 in iNFs after 24h of treatment with 5 mM 
DCA or DMSO control. Molecular weight markers are shown next to the blots. b: Western blot 
showing the levels of phospho-PDHA1 in iCAFs transfected for 48h with PDK2N255A or PDKWT and 
iNFs transfected for 48h with siCTL or siPDK2. c. Western blot showing phospho-PDHA1 levels 
are not altered in CAFs transfected for 48h with the inactive PDK2N255A compared to an empty 
vector control. d. PDK2 expression measured by RT-qPCR in iNFs transfected for 48h with siCTL 
or siPDK2. PDK2 mRNA levels were normalised to TBP2. Graph shows mean and SEM of 3 
biological replicates. Significance was calculated using an unpaired student t-test with Welch’s 
correction: p≤0.05 * 
All Western blots are representative images of n ≥ 3 biological replicates 
 
 
a 
b c 
Figure 3-7 PDK2 regulated PDH phosphorylation 
d 
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Expression of PDK1,2,3 and 4 mRNA in microdissected sections of normal and tumour 
associated stroma from triple negative breast cancer patients. Each dot represents 1 
patient. Data was provided by Morag Park (McGill University). Error bars show mean 
and SEM. Significance was calculated using an unpaired student t-test: p≤0.05 *, 
p≤0.01 **, p≤0.001 *** 
 
 
Figure 3-8 PDK expression in normal and tumour-associated stroma 
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3.5 PDH is more active in CAFs 
 
3.5.1 The PDH complex is more active in CAFs in an in vitro assay 
 
It is well known that phosphorylation of PDH decreases its activity. Therefore the 
decrease in phosphorylated PDH in CAFs should mean that PDH is more active. To 
confirm that PDH is in fact more active in CAFs, I used an enzymatic assay to 
measure PDH activity in CAFs and NFs. The assay can be used to measure the rate 
of NADH production by immunocaptured PDH from cell lysates using a reporter 
dye which gives a yellow reaction product. The rate of NADH production was 
significantly higher in all CAF cell lines compared to their paired NFs, showing that 
PDH was indeed more active in CAFs than NFs (Figure 3-9). 
 
3.5.2 CAFs produce more acetyl-coA in a PDH phosphorylation-dependent 
manner 
 
The role of PDH is to convert pyruvate to acetyl-coA; in order to show that the 
decrease in PDH phosphorylation increased its activity in the CAFs I used MS-
metabolomics to quantify the amount of intracellular acetyl-coA in CAFs and NFs. 
The total amount of acetyl-coA in the CAFs was significantly higher than in NFs 
across all three pairs of fibroblasts, suggesting that CAFs do produce more acetyl-
coA (Figure 3-10a). However, acetyl-coA can be derived from several pathways. 
In addition to PDH, acetyl-coA can be produced from beta-oxidation of fatty acids, 
or from TCA cycle metabolites via citrate. I therefore performed a metabolomics 
tracing experiment to find out what proportion of acetyl-coA in CAFs was actually 
produced by PDH. The fibroblasts were labelled for 48h with media containing 
either 13C6-glucose or 13C3-pyruvate to trace acetyl-coA through PDH, 13C5-
glutamine for acetyl-coA produced via the TCA cycle or 13C16-palmitate for acetyl-
coA coming from fatty acids (Figure 3-10b). The intracellular metabolites were 
then harvested and analysed using LC-MS, and the percentage of heavy labelled 
metabolites incorporated into acetyl-coA was determined. This experiment 
showed that about 70% of acetyl-coA in the CAFs is derived from glucose and 
pyruvate combined, meaning that PDH is the main source of acetyl-coA in CAFs. 
To investigate whether PDH phosphorylation levels were responsible for the 
difference in acetyl-coA production between CAFs and NFs, I transfected the iNFs 
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with siPDK2 or siCTL and the iCAFs with PDK2WT or PDK2N255A to increase PDH 
phosphorylation in iNFs and decrease it in the CAFs, respectively. The intracellular 
metabolites were extracted from the fibroblasts 48h after transfection and the 
relative total amount of acetyl-coA was quantified (Figure 3-10c). Increasing PDH 
phosphorylation decreased intracellular acetyl-coA and vice versa. Therefore PDH 
activity is increased in CAFs as shown by the increase in acetyl-coA production, 
and this is dependent on the level of PDH phosphorylation, which is controlled by 
PDK2 expression. 
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Rate of pyruvate to acetyl-coA conversion by immunocaptured PDH. Rate of reaction 
was measured as the change in absorbance at OD405 nm and normalised to the rate 
of reaction in the NFs. Graphs show the mean and SEM of at least 3 independent 
experiments. Significance was calculated using an unpaired student t-test test with 
Welch’s correction: p≤0.05 *, p≤0.01 ** 
 
 
Figure 3-9 PDH complex activity in CAF and NFs 
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a: Total intracellular acetyl-coA in NFs and CAFs measured by LC-MS and normalised 
to protein content. b: Fraction of acetyl-coA labelled by glucose, glutamine, pyruvate 
and palmitate in iCAFs. Acetyl-coA was measured by LC-MS and normalised to protein 
content. c: Total intracellular acetyl-coA in iCAFs transfected for 48h with PDK2N255A 
or PDKWT and iNFs transfected for 48h with siCTL or siPDK2. Acetyl-coA was measured 
by LC-MS and normalised to protein content. 
Graphs show the mean and SEM of at least 3 independent experiments. Significance 
was calculated using an unpaired student t-test test with Welch’s correction:         
p≤0.05 *, p≤0.01 **, p≤0.001 *** 
 
 
a 
b 
c 
Figure 3-10 PDH activity regulates acetyl-coA in fibroblasts 
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3.6 Investigation of PDK2 regulation in CAFs 
 
I have shown that the decrease in PDH phosphorylation in CAFs is regulated by 
PDK2 expression, however, it is unknown what pathway in the CAFs leads to 
decreased PDK2 expression. I reasoned that there must be some aspect of the 
activated CAF phenotype that was linked to PDK2 expression. Upregulated TGF-β 
signalling is a hallmark of activated CAFs, so initially I investigated the impact of 
TGF-β on PDH phosphorylation. I treated the iNFs with recombinant human TGF-
β1 for 48h. This caused an increase in the levels of phospho-Smad2, a readout of 
activated TGF-β signalling, showing that the treatment was effective (Figure 3-
11). However, it did not decrease phospho-PDH, in fact, it slightly increased 
phospho-PDH levels. It is also well known that CAF activation is stimulated by 
factors produced by cancer cells. Therefore I also cultured the iNFs with 
conditioned media from MDA-MB-231 cells, which are a highly aggressive and 
invasive triple negative breast cancer cell line, for 48h (Figure 3-11). However, 
this also failed to reduce PDH phosphorylation in the iNFs. 
 
It has been previously shown that PI3K/Akt signalling stimulates decreased PDH 
phosphorylation on S293 by PDKs in head and neck cancer (Cerniglia et al., 2015). 
From the phosphoproteomic data from the iCAFs and iNFs there was evidence to 
suggest that Akt signalling is upregulated in iCAFs and other works have shown 
that PI3K-Akt signalling is active in CAFs (Sun et al., 2019). I therefore treated the 
CAFs with the Akt inhibitor MK2066 to investigate the effect of Akt signalling on 
PDH activity in the CAFs. The Akt inhibitor effectively reduced phospho-Akt, i.e. 
active Akt, levels after 24h of treatment, and correspondingly increased phospho-
PDHA1 levels in both the iCAFs and pCAF3s, although not in the pCAF2s (Fig. 3-
12). As PI3K/Akt signalling is stimulated by integrin signalling in response to 
extracellular matrix (ECM) adhesion and CAFs produce a very different ECM to NFs, 
both in terms of amount of protein and of composition, I investigated whether CAF 
and NF ECM produced a different response in regard to PDH phosphorylation. Both 
CAFs and NFs were seeded at confluence and allowed to produce ECM for 7 days. 
Then, the ECM was decellularised, and CAFs or NFs were seeded on the fibroblast-
derived ECM and cultured for 48h. Each pair of CAFs and NFs was seeded on ECM 
derived from the same pair. By western blot, CAF ECM significantly decreased 
phospho-PDH levels in NFs relative to NF ECM or plastic (Fig. 3-13). I also analysed 
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the expression of PDK2 in response to iCAF and iNF derived ECM by RT-PCR and 
again found that PDK2 expression decreased more in response to being cultured 
on iCAF derived ECM than iNF ECM or plastic (Fig. 3-14). I therefore concluded 
that there is a component of CAF derived ECM that stimulates a pathway leading 
to decreased PDK2 expression and thereby decreased PDH phosphorylation, 
probably via integrin mediated Akt signalling. 
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Western blot showing phospho-Smad, phospho-PDHA1 and total PDHA1 levels in iNFs 
after 48h treatment with either recombinant TGFβ or conditioned media from 
MBAMB231 cancer cells. β-tubulin was used as a loading control. Molecular weight 
markers are shown next to the blots. Representative image of n ≥ 3 biological 
replicates 
 
 
Figure 3-11 TGFB and cancer cell conditioned media do not activate PDH 
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Western blot showing phospho-Akt and phospho-PDHA1 levels in CAF cell lines after 
24h treatment with MK2206. Vinculin was used as a loading control. Molecular weight 
markers are shown next to the blots. Representative image of n ≥ 2 biological 
replicates 
 
 
Figure 3-12 Akt inhibitor increases PDH phosphorylation 
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Representative Western blot and quantification of pPDHA1 levels in CAFs and NFs 
cultured on plastic or on CAF or NF-derived ECM for 48h. The pPDHA1 intensity was 
normalised to total PDHA1 intensity and loading control intensity. Molecular weight 
markers are shown next to the blots.  
Graphs show mean and SEM of 3 independent experiments. Significance was calculated 
using a one-way ANOVA with Tukey’s multiple comparisons test p≤0.05 *, p≤0.01 **, 
p≤0.001 *** 
 
 
Figure 3-13 CAF ECM decreases PDH phosphorylation 
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RT-qPCR quantification of PDK2 expression on CAFs and NFs cultured on plastic or CAF 
or NF-derived ECM for 48h. PDK2 expression was normalised to 18S expression Graphs 
show mean and SEM of 3 independent experiments. Significance was calculated using 
a one-way ANOVA p≤0.05 *, p≤0.01 **, p≤0.001 *** 
 
 
Figure 3-14 CAF ECM decreases PDK2 expression 
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3.7 Conclusions 
 
The key finding of this chapter is that pyruvate dehydrogenase, a central 
metabolic enzyme which produces the versatile metabolite acetyl-coA, is more 
active in CAFs. The most common way that PDH activity is regulated in cells is by 
inhibitory phosphorylation, and this is decreased in CAFs compared to NFs. This 
decrease in phosphorylation was predicted to be regulated by PDK2 based on 
phosphoproteomic data from the iCAFs and iNFs and I then confirmed this 
prediction by showing that PDK2 is downregulated in the three CAF cell lines I am 
using, as well as in microdissected sections of tumour associated stroma from 
patients, and that PDK2 expression regulates PDH phosphorylation in the 
fibroblasts. Although there are other enzymes that modify PDH phosphorylation, 
the fact that PDH phosphorylation is drastically reduced by the PDK inhibitor DCA 
in NFs points towards the kinases rather than the phosphatases being responsible 
for regulating PDH phosphorylation in the fibroblasts. Furthermore, PDK2 is the 
only PDK that was consistently regulated both in my fibroblast cell lines and in 
stroma from patient samples, and was overall more highly expressed than the 
other PDKs. Finally, I could significantly alter PDH phosphorylation simply by 
modulating PDK2 expression in the fibroblasts, again pointing towards PDK2 as the 
major regulator of PDH phosphorylation in CAFs and NFs. Interestingly, a study 
found that PDH levels were increased in lung fibroblasts when co-cultured with 
tumour cells, although there was no difference in phosphorylation, showing that 
upregulated PDH activity could be a general mechanism across different types of 
CAFs and not specific to breast cancer stroma. Furthermore, increased levels of 
PDH in fibroblasts stimulated tumour cell migration, demonstrating that increased 
PDH activity has a functional effect in the tumour microenvironment (Koukourakis 
et al., 2017). 
 
There have been few studies investigating pathways that regulate PDK2 expression 
(Cerniglia et al., 2015, Contractor and Harris, 2012). I began to investigate 
possible upstream pathways regulating PDK2 expression and showed that CAF 
derived ECM decreases PDK2 expression. Integrin receptors mediate cellular 
responses to the ECM, suggesting that this is an integrin regulated pathway. 
Integrin signalling has been shown to play an important role in the CAF phenotype; 
integrins αvβ3, α3 and β6 have all been shown to stimulate CAF activation (Jang 
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and Beningo, 2019). Integrins activate signalling pathways mainly through 
recruiting kinases to the membrane where they are activated. One such kinase is 
PI3K which activates Akt signalling. This was a good candidate for PDK2 regulation 
as we know Akt signalling is upregulated in the iCAFs and it has previously been 
shown to impact PDH phosphorylation. An Akt inhibitor effectively increased PDH 
phosphorylation in only two out of my three CAF cell lines however, so there may 
be different regulatory mechanisms happening. I did not pursue investigation into 
the upstream factors controlling PDK2 expression further, preferring instead to 
concentrate on the impact that increased PDH activity has on the CAF phenotype, 
which will be discussed in the following chapters. 
 
The output of increased PDH activity is an increase in acetyl-coA production, 
which I have demonstrated occurs in my CAF cell lines and that this is regulated 
by PDK2 dependent PDH phosphorylation. The next question was therefore what 
this increase in acetyl-coA levels is used for in the CAFs. PDH is primarily a 
mitochondrial protein, although it has been observed in the nucleus (Sutendra et 
al., 2014). The metabolic impact of PDH activity has been widely studied in 
tumour cells, although not in the tumour microenvironment. PDH has been called 
the ‘mitochondrial gatekeeper’ as it connects glycolysis to mitochondrial 
metabolism and many studies on PDH activity have shown that altering PDH 
phosphorylation and activity pushes cancer cells towards either glycolytic or 
oxidative metabolism, and that this impacts on tumour progression (McFate et al., 
2008, Kaplon et al., 2013, Saunier et al., 2017, Yonashiro et al., 2018). However, 
acetyl-coA can be exported from the mitochondria into the cytoplasm via citrate, 
and it has been shown that PDH activity affects cytoplasmic lipid synthesis 
(Rajagopalan et al., 2015). Acetyl-coA is also a substrate for protein acetylation, 
and PDH activity has also been shown to affect protein acetylation (Sutendra et 
al., 2014, Lozoya et al., 2019). An increase in acetyl-coA could therefore modulate 
a wide variety of pathways contributing to aspects of the activated CAF phenotype 
either through altered metabolism or through protein acetylation.  
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Chapter 4  PDH activity regulates histone 
acetylation in CAFs 
 
4.1 PDH is localised in the mitochondria 
 
In this chapter, I investigated how the acetyl-coA produced by PDH is used by the 
CAFs, since acetyl-coA is a highly versatile metabolite and can be used for a wide 
variety of metabolic and acetylation pathways (Pietrocola et al., 2015). PDH is 
typically known as a mitochondrial enzyme, however, studies have shown that 
PDH can relocalise to the nucleus and produce acetyl-coA there to promote 
histone acetylation (Sutendra et al., 2014, Shi et al., 2017). The localisation of 
PDH could impact on how the acetyl-coA it produces is used, although acetyl-coA 
can be shuttled between the cytosol and mitochondria or nucleus via citrate or 
acetyl-carnitine. Therefore, there is no barrier to acetyl-coA being produced in 
one compartment and being used in another. Even so, as a starting point to 
investigating the function of acetyl-coA in CAFs, I first determined the localisation 
of PDH. iCAFs and iNFs were labelled in culture with MitoTracker, which stains 
mitochondria. The cells were then fixed and probed by immunofluorescence with 
an antibody against PDHA1, which is the regulatory subunit of the PDH complex 
(Fig. 4-1a). The PDHA1 staining overlapped entirely with the mitochondrial 
staining and there was no detectable PDHA1 in the nucleus. To further verify these 
results, I fractionated lysate from iCAFs into nuclear, mitochondrial and cytosolic 
fractions using a cell fractionation kit. The efficacy of the fractionation was 
assessed by western blot of each fraction using an antibody cocktail for nuclear, 
mitochondrial, cytosol and plasma membrane markers: histone 3, ATP5A, GAPDH 
and Na+/K+ ATPase respectively. The localisation of PDHA1 in each fraction was 
determined by western blot and this showed that the PDHA1 band was only visible 
in the mitochondrial fraction (Fig 4-1b). Therefore, I have conclusively shown that 
PDH is localised in the mitochondria in the fibroblasts. 
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a: Representative image of CAFs stained for PDHA1 (green), MitoTracker Red (red) and 
DAPI (blue). Images were acquired at 40x magnification. Representative image of n ≥ 3 
biological replicates b: Western blot of mitochondria, cytosol and nuclear fractions from 
iCAF lysate showing expression of PDHA1 (top) and mitochondrial, plasma membrane, 
cytosol and nuclear markers (bottom). Molecular weight markers are shown beside the 
blots. Representative image of n = 2 biological replicates 
a 
b 
Figure 4-1 PDH is mitochondrial in CAFs 
128 
 
4.2 There is no difference in glycolysis or oxidative 
phosphorylation between CAFs and NFs 
 
4.2.1 There are no differences in uptake or secretion of major metabolites 
between CAF and NFs 
 
The majority of pathways that use acetyl-coA are metabolic pathways. Therefore 
when investigating the role of increased PDH activity in CAFs, the first step was 
to discover if there were any metabolic differences between CAFs and NFs. In 
order to obtain a basic overview of CAF and NF metabolism and to find out if there 
were major differences between them, I used the YSI 2900 biochemistry analyser 
to calculate the rate of uptake or secretion of four key metabolites: glucose, 
lactate, glutamine and glutamate. These metabolites account for most of the 
metabolic uptake and secretion by cells and are the main carbon sources for the 
two major metabolic pathways of glycolysis and the TCA cycle. 
I took samples of media from CAFs and NFs after 48h of culture and used the 
biochemistry analyser to measure the concentration of glucose, lactate, glutamine 
and glutamate in the media. The concentration of each metabolite was normalised 
to cell number and the rate of uptake or secretion per hour was calculated relative 
to media that had not been cultured with cells (Fig. 4-2). There were no consistent 
differences between the CAFs and NFs, which was surprising given that several 
studies have shown that mammary CAFs are more glycolytic than NFs (Guido et 
al., 2012, Pavlides et al., 2009, Yu et al., 2017) so I would have expected 
differences in glucose uptake and lactate secretion. I did however normalise for 
the increase in cell number over 48h, which would remove any differences in 
glycolysis due to differences in proliferation rate.  
 
The results of the above experiment were taken from cells under standard cell 
culture conditions, in media with a plentiful supply of metabolites. However in 
the tumour microenvironment cells can be under different stresses, including 
hypoxia and nutrient deprivation. To investigate whether stressing the fibroblasts 
would elucidate metabolic differences and possible vulnerabilities in the CAFs, I 
repeated the previous experiment with the CAFs and NFs, however the cells were 
either cultured in hypoxic conditions with 1% oxygen (Fig 4-3) or with ‘low glucose’ 
media (Fig 4-4), which contains 1 g/l glucose instead of 5 g/l and is more similar 
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to the glucose concentration in a tumour. Again, I took media after 48h of culture 
and measured the concentration of glucose, lactate, glutamine and glutamate 
using the biochemistry analyzer. Although the rate of glucose uptake and lactate 
secretion increased under hypoxia and decreased under low glucose conditions, 
there were still no consistent differences between CAFs and NFs. However, there 
were differences in individual metabolites between CAFs and NFs from the same 
pair, highlighting the heterogeneity of the patient derived CAFs compared to the 
iCAFs. For example, the pCAF2 line takes up a high amount of glutamine and 
secretes a high amount of glutamate under low glucose conditions. 
 
However, these experiments show that there are no metabolic differences 
between the mammary CAFs and NFs at the basic level of conversion of glucose to 
lactate and the glutamine/glutamate cycle. In order to discover whether the 
increased PDH activity in CAFs had any metabolic effects, it was necessary to gain 
a more in depth understanding of the metabolism of the CAFs and NFs. 
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Graphs showing the exchange rate between fibroblasts and media of glucose, lactate, 
glutamine and glutamate. Bars show the mean and SEM of three independent 
experiments. Significance between CAFs and NFs of the same pair was calculated using a 
students t-test with Welch’s correction 
Figure 4-2 Metabolic flux of CAFs and NFs in normoxia/high glucose conditions 
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Graphs showing the exchange rate between fibroblasts and media of glucose, lactate, 
glutamine and glutamate. Cells were cultured in 1% O2 for the duration of the 
experiment. Bars show the mean and SEM of three independent experiments. Significance 
between CAFs and NFs of the same pair was calculated using a students t-test with 
Welch’s correction: *p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-3 Metabolic flux of CAFs and NFs in hypoxia 
132 
 
 
Graphs showing the exchange rate between fibroblasts and media of glucose, lactate, 
glutamine and glutamate. Cells were cultured in media containing 1 g/l glucose for the 
duration of the experiment. Bars show the mean and SEM of three independent 
experiments. Significance between CAFs and NFs of the same pair was calculated using a 
students t-test with Welch’s correction: *p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-4 Metabolic flux of CAFs and NFs cultured in low glucose media 
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4.2.2 MS-metabolomic tracing experiments show few differences between 
CAFs and NFs 
 
The most obvious route for acetyl-coA produced in the mitochondria is to enter 
the TCA cycle. Indeed, the majority of studies on increased PDH activity show that 
it is used to fuel and promote oxidative metabolism in cells. In addition to fuelling 
oxidative phosphorylation, TCA cycle metabolites have many other roles including 
as precursors for amino acid and nucleotide synthesis and as signalling molecules. 
In order to obtain a more in depth overview of the metabolism of CAFs and NFs, I 
performed metabolomic tracing experiments with the iCAFs and iNFs as well as 
the pCAFs and pNFs. I cultured the fibroblasts with media containing 13C6-glucose 
for 48h before extracting the metabolites and analysing heavy glucose 
incorporation and relative levels of metabolites by LC-MS. 
 
Although in individual CAF and NF pairs there were significant differences in some 
metabolites, overall there were few consistently regulated metabolites between 
CAFs and NFs. N-acetyl-aspartate levels were higher in CAFs than in NFs in 2 out 
of 3 pairs, and incorporated heavy glucose at M+2, which could come from acetyl-
coA since the acetyl group has two carbons (Fig. 4-8). Additionally, intracellular 
proline and asparagine levels were consistently higher in CAFs than in NFs (Fig. 4-
7). I found that glycolytic metabolites were highly labelled, showing that the cells 
effectively took up the labelled glucose (Fig. 4-5), and that glucose labelled about 
25% of intracellular citrate. There was an increase in labelled citrate in CAFs 
compared to NFs. However, there was minimal labelling in the other TCA cycle 
metabolites (Fig 4-6), and in amino acids derived from them (Fig 4-7). This strongly 
suggested that acetyl-coA produced by PDH is converted to citrate, but is then 
exported out of the mitochondria where it can be converted back to acetyl-coA 
by ATP-citrate lyase (ACLY). Interestingly, a high proportion of heavy glucose was 
incorporated into acetylcarnitine in CAFs (Fig. 4-8). Acetylcarnitine is another 
pathway that can be utilised to export acetyl-coA out of the mitochondria. 
Mitochondrial carnitine O-acetyltransferase (CRAT) catalyses the reversible 
transfer of the acetyl group of acetyl-coA onto carnitine, which is shuttled out of 
the mitochondria and can again be converted back to acetyl-coA and carnitine in 
the cytosol. This has been shown to act as means of maintaining a steady state of 
oxidative phosphorylation by removing excess acetyl-coA from the mitochondria 
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(Davies et al., 2016). Taken together, the metabolomics tracing data suggests that 
acetyl-coA produced by PDH has a role outside of the mitochondria and is not used 
to fuel the TCA cycle.  
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 Graphs show the total intracellular glycolytic metabolites with the proportion of labelled 
carbons incorporated into each metabolite after 48h of labelling with 13C-glucose. NFs 
and CAFs were compared for each pair of fibroblasts. For each isotope, the peak area was 
normalised to the protein content of the cells from which the metabolites were 
harvested. Error bars show the mean and SEM for each isotope from 3 independent 
experiments. Significance was calculated using a student’s t-test with Welch’s correction: 
*p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-5 13C-Glucose labelling of glycolytic metabolites 
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 Graphs show the total intracellular TCA cycle metabolites with the proportion of labelled 
carbons incorporated into each metabolite after 48h of labelling with 13C-glucose. NFs 
and CAFs were compared for each pair of fibroblasts. For each isotope, the peak area was 
normalised to the protein content of the cells from which the metabolites were 
harvested. Error bars show the mean and SEM for each isotope from 3 independent 
experiments. Significance was calculated using a student’s t-test with Welch’s correction: 
*p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-6 13C-Glucose labelling of TCA cycle metabolites 
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   Figure 4-7 13C-Glucose labelling of non-essential amino acids 
Graphs show the total intracellular non-essential amino acids with the proportion of 
labelled carbons incorporated into each metabolite after 48h of labelling with 13C-
glucose. NFs and CAFs were compared for each pair of fibroblasts. For each isotope, the 
peak area was normalised to the protein content of the cells from which the metabolites 
were harvested. Error bars show the mean and SEM for each isotope from 3 independent 
experiments. Significance was calculated using a student’s t-test with Welch’s correction: 
*p≤0.05, ** p≤0.01, *** p≤0.001 
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Graphs show the total intracellular acetylated metabolites with the proportion of labelled 
carbons incorporated into each metabolite after 48h of labelling with 13C-glucose. NFs 
and CAFs were compared for each pair of fibroblasts. For each isotope, the peak area was 
normalised to the protein content of the cells from which the metabolites were 
harvested. Error bars show the mean and SEM for each isotope from 3 independent 
experiments. Significance was calculated using a student’s t-test with Welch’s correction: 
*p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-8 13C-Glucose labelling of acetylated metabolites 
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Graphs show the NADH:NAD+ ratio calculated based on the total intracellular metabolite. 
NFs and CAFs were compared for each pair of fibroblasts. The peak area was normalised 
to the protein content of the cells from which the metabolites were harvested. Error bars 
show the mean and SEM for each isotope from 3 independent experiments. Significance 
was calculated using a student’s t-test with Welch’s correction: *p≤0.05, ** p≤0.01, *** 
p≤0.001 
Figure 4-9 NADH:NAD+ ratio in CAFs and NFs 
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4.2.3 Glutamine is the main source of TCA cycle metabolites in CAFs and NFs 
 
To further verify that acetyl-coA derived from PDH was not an important source 
of TCA cycle metabolites, I performed additional metabolomics tracing 
experiments with the iCAFs and iNFs. The fibroblasts were labelled for 48h with 
either 13C6-glucose, 13C5-glutamine or 13C16-palmitate. Glutamine can enter the 
TCA cycle via conversion to glutamate (glutaminolysis) and palmitate can enter 
the TCA cycle through conversion to acetyl-coA (fatty acid oxidation). I then 
extracted the intracellular metabolites and analysed the incorporation of heavy 
carbon by MS-metabolomics (Fig. 4-10, Fig. 4-11). Once again, there were no 
differences in the total proportion of heavy carbon incorporation into glycolysis or 
TCA cycle metabolites between CAFs and NFs. However, it was clear from this 
experiment that the majority of TCA cycle metabolites are derived from glutamine 
and not from glucose or palmitate. Glutamine labelled around 70% of TCA cycle 
metabolites, whereas glucose and palmitate gave around 5-10% label 
incorporation, with the exception of citrate as shown in the previous experiment. 
This experiment further supported my previous metabolomics data in showing that 
increased PDH activity does not increase oxidative phosphorylation in CAFs. 
141 
 
 Graphs show the proportion of labelled carbons incorporated into each metabolite after 
48h of labelling with 13C-glucose, glutamine or palmitate in the iNFs and iCAFs. For each 
isotope, the peak area was normalised to the protein content of the cells from which the 
metabolites were harvested. Error bars show the mean and SEM for each isotope from 3 
independent experiments. Significance was calculated using a student’s t-test with 
Welch’s correction: *p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-10 13C labelling of glycolytic metabolites 
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 Graphs show the proportion of labelled carbons incorporated into each metabolite after 
48h of labelling with 13C-glucose, glutamine or palmitate in the iNFs and iCAFs. For each 
isotope, the peak area was normalised to the protein content of the cells from which the 
metabolites were harvested. Error bars show the mean and SEM for each isotope from 3 
independent experiments. Significance was calculated using a student’s t-test with 
Welch’s correction: *p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-11 13C labelling of TCA cycle metabolites 
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4.2.4 CAFs have decreased mitochondrial functionality and are more 
autophagic than NFs 
 
To further investigate whether there are mitochondrial differences between CAFs 
and NFs, I stained the cells with MitoTracker or TMRE. MitoTracker labels 
mitochondria, thus giving a readout of the total mitochondrial content of the cells. 
TMRE, however, labels mitochondria in a membrane potential dependent manner, 
and therefore only labels functional mitochondria. After labelling the fibroblasts 
with the mitochondrial dyes in culture, the cells were harvested and fixed, and 
the intensity of the staining was quantified using flow cytometry. I could not 
detect significant differences in the total amount of mitochondria using 
MitoTracker staining between iCAFs/iNFs or pCAF3s/pNF3s, although pCAF2s had 
a significantly decreased mitochondrial content (Fig. 4-11a). However, both the 
iCAFs and the pCAF2s had a significantly lower amount of TMRE labelling after 
normalisation to the total mitochondrial content, indicating that their 
mitochondria are less functional (Fig. 4-12b).  
 
It has previously been reported that CAFs are more autophagic than NFs due to 
increased accumulation of reactive oxygen species (ROS), and it has been shown 
that the degradation products of autophagic CAFs provide tumour cells with key 
nutrients and building blocks for their faster rate of biosynthesis and metabolic 
turnover (Capparelli et al., 2012, Pavlides et al., 2012, Pavlides et al., 2010a). 
Mitochondrial dysfunction is a key aspect of autophagy, as dysfunctional 
mitochondria which cannot carry out oxidative phosphorylation accumulate ROS 
due to their dissipated membrane potential and thus stimulate autophagy (Ding 
and Yin, 2012). To assess whether the CAFs were more autophagic than NFs, I 
quantified the expression of LCBII after treatment of the iCAFs and iNFs with 
bafilomycin and chloroquine. LC3BII is the lapidated form of LC3B that recognises 
ubiquitinylated proteins and is recruited to autophagosomes as part of the 
autophagy process. In order for degradation to occur, autophagosomes must fuse 
with lysosomes and both bafilomycin and chloroquine inhibit this step, causing 
accumulation of autophagosomes and thereby LC3BII. Therefore the more LC3BII 
that is present after bafilomycin or chloroquine treatment, the higher the rate of 
autophagic flux is in the cells. The iCAFs accumulated more LC3BII after the drug 
treatment, indicating that in accordance with the literature they do have higher 
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levels of autophagy than the iNFs (Fig. 4-13). In this case, it is interesting that in 
spite of having a decrease in mitochondrial functionality and increased autophagic 
flux, the iCAFs still maintain the same quantity of mitochondria as the iNFs, as 
shown by MitoTracker Red (Fig. 4-12a). Normally, dysfunctional mitochondria are 
separated from the healthy network and degraded through a specific form of 
autophagy called mitophagy. This suggests that either the CAFs are synthesising 
new mitochondria to maintain the same amount as the NFs, or that mitophagy is 
impaired in some way. Interestingly, it has recently been shown that a second 
target of PDK2 is PARL (presenilin-associated rhomboid-like) (Shi and McQuibban, 
2017), which is a key player in one of the canonical mitophagy pathways. The 
authors showed that in response to mitochondrial depolarisation, PDK2 
phosphorylates PARL and prevents it from cleaving PINK-1 (PTEN-induced putative 
kinase 1). PINK-1 therefore accumulates at the outer mitochondrial membrane 
and recruits an E3 ubiquitin ligase to stimulate mitophagy. It is therefore possible 
that the lack of PDK2 in CAFs also reduces the efficacy of this mitophagy pathway, 
leading to accumulation of dysfunctional mitochondria. However, although PDK2 
expression may be involved in the observed differences in autophagy and 
mitochondrial dysfunction in between CAFs and NFs, it is unlikely that the 
increased PDH activity in CAFs would affect this pathway. Additionally, the 
pCAF3s/pNF3s did not show any differences either in mitochondrial content or 
TMRE labelling, so the differences are not consistent between different fibroblast 
pairs. Therefore I did not pursue this line of research any further, although it 
would be interesting to do so in the future. 
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a: Intensity of MitoTracker staining as measured by flow cytometry. Intensity was 
normalised to NF data for each pair of fibroblasts. b: Intensity of TMRE staining as 
measured by flow cytometry. Intensity was normalised to total mitochondrial content as 
determined by the MitoTracker staining, and to the NF data for each pair.  
Significance was calculated using a student’s t-test with Welch’s correction: *p≤0.05, ** 
p≤0.01, *** p≤0.001 
a 
b 
Figure 4-12 Mitochondrial content of CAFs and NFs 
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Western blot showing accumulation of LC3B-II (lower band) after 4h treatment with 
bafilomycin (Baf) or chloroquine (CQ) in iCAFs and iNFs. Vinculin was used as a loading 
control. Molecular weight markers are shown next to the blots 
Figure 4-13 LCB-II accumulation in iCAFs and iNFs 
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4.2.5 PDH activity does not affect mitochondrial functionality 
 
To further analyse mitochondrial metabolism in CAFs and NFs, I used the Seahorse 
XF24 Flux analyser. This measures oxygen consumption by cells and thus provides 
a readout for the rate of oxidative phosphorylation. I grew CAFs and NFs for 24h 
in Seahorse 24 well culture plates before carrying out the analysis with the 
Seahorse. Initially the basal oxygen consumption rate was measured, before 
adding oligomycin to block ATP synthesis and thereby reduce oxygen consumption, 
followed by CCCP to uncouple the electron transport chain from ATP synthase, 
forcing the cells to consume oxygen at their maximum capacity. Finally, antimycin 
A and rotenone were added to inhibit the electron transport chain and block 
oxygen consumption entirely. I could detect no difference between CAFs and NFs 
in basal oxygen consumption rate, although the iCAFs did have a lower 
mitochondrial capacity than the iNFs which is consistent with the TMRE staining 
showing that CAFs have a decrease in mitochondrial functionality (Fig 4-13a). The 
oxygen consumption rate of the pCAFs and pNFs was extremely low and I could 
detect no differences between CAFs and NFs (Fig 4-14a). To verify that the 
fibroblasts truly had a low level of oxygen consumption, I compared the rates with 
that of the MCF7 breast cancer cell line, which is known to have a high level of 
mitochondrial respiration (Rodriguez-Enriquez et al., 2010). All the fibroblast cell 
lines had a lower oxygen consumption rate compared to the MCF7 breast cancer 
cell line (Fig 4-14b). This experiment further supports the metabolomics data 
showing no differences in mitochondrial metabolism under normal conditions 
between CAFs and NFs and supports my hypothesis that PDH produced acetyl-coA 
is not used to increase flux through the TCA cycle in CAFs, especially since the 
fibroblasts have a low oxygen consumption rate. 
 
To finally show that PDH activity does not impact mitochondrial function, I 
transfected the iNFs with siPDK2 or siCtl to reduce PDH phosphorylation and 
increase its activity, then, 48h after transfection, I used the Seahorse to measure 
oxygen consumption. I could detect no differences between siCtl and siPDK2 
transfected iNFs in oxygen consumption either at the basal level or in 
mitochondrial capacity (Fig 4-13c). Therefore it seems that although CAFs do have 
a decrease in mitochondrial functionality compared to NFs, this does not affect 
their basal level of oxidative phosphorylation, which is relatively low. 
148 
 
Furthermore, PDH activity has no effect on oxidative metabolism and the evidence 
from the metabolomics tracing data strongly suggests that the majority of acetyl-
coA produced by PDH is exported out of the mitochondria and used elsewhere. 
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 a: OCR as measured by the Seahorse in all CAF and NF cell lines. Time points at which drugs 
were added are shown with dotted lines. OCR was normalised to cell number. b: OCR in 
CAF and NF cell lines in comparison with that of MCF7 cancer cell line. OCR was normalised 
to cell number. c: OCR of iNFs 24h after transfection with siCtl or siPDK2 and knockdown 
efficiency as measured by RT-qPCR. OCR was normalised to cell number. PDK2 mRNA was 
normalised to GAPDH. 
Mean and SEM of 3 independent experiments are shown. Significance was calculated using 
a student’s t-test: *p≤0.05, ** p≤0.01, *** p≤0.001 
 
 
a 
b 
c 
Figure 4-14 Oxygen consumption rate (OCR) of CAFs and NFs 
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4.3 ATP-citrate lyase is active in CAFs 
 
Acetyl-coA cannot traverse the mitochondrial membrane by itself. The most 
common way for acetyl-coA to leave the mitochondria is via conversion to citrate, 
which crosses the mitochondrial membrane via the transporter SLC25A1. Once 
outside the mitochondria, citrate can be converted back to acetyl-coA by ACLY, 
which is present both in the cytosol and the nucleus. ACLY is active when 
phosphorylated on S455 (Potapova et al., 2000). Interestingly, phosphorylation of 
this site is known to be stimulated by PI3K/Akt signalling, which I found to be a 
possible upstream pathway regulating PDK2 expression in the previous chapter. 
This means increased PI3K/Akt signalling in CAFs could doubly enhance acetyl-coA 
production by both activating PDH and ACLY. I therefore assessed the activation 
status of ACLY by western blot of lysates from all the CAF and NF cell lines using 
an antibody against phospho-ACLY (Fig. 4-15). ACLY was more phosphorylated in 
the iCAFs and pCAF2s that in their respective NFs, but phosphorylation was 
decreased between pCAF3 and pNF3. However, this experiment showed that ACLY 
is more active in two out of the three CAF cell lines I am using, and that activated 
ACLY is present in all the cell lines, meaning that acetyl-coA exported out of the 
mitochondria as citrate can be converted back to acetyl-coA in the cytosol and 
nucleus. 
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Western blot showing levels of phosphorylated and total ACLY in CAFs and NFs. Vinculin 
and β-tubulin were used as a loading control, and pACLY levels were further normalised 
to total ACLY levels. Molecular weight markers are shown next to the blots. pACLY 
quantification is shown under the blots. Representative images of n ≥ 2 biological 
replicates are shown 
Figure 4-15 p-ACLY levels in NFs and CAFs 
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4.4 PDH derived acetyl-coA is not used to fuel increased 
lipid synthesis 
 
Once outside the mitochondria, acetyl-coA can be used to fuel a variety of 
metabolic pathways, including synthesis of sterols and fatty acids. There was some 
evidence from previously acquired proteomic data of the iCAFs and iNFs that 
several proteins in the cholesterol synthesis pathway were upregulated in iCAFs, 
so initially I investigated the possibility of increased cholesterol synthesis in CAFs. 
I labelled the iCAFs and iNFs for 48h with media containing both 13C6-glucose and 
13C5-glutamine to maximise the amount of labelled carbon being incorporated into 
cholesterol. Then, in collaboration with Grace McGregor from Dr. Jurre 
Kamphorst’s group, the lipids were extracted from the fibroblasts and the heavy 
carbon incorporation was detected by GC-MS. We were unable to see any label 
incorporation in either the iCAFs or the iNFS, and furthermore there was no 
increase in the total amount of cholesterol in the iCAFs (Fig. 4-16a). In fact, there 
was slightly more cholesterol in the iNFs. This experiment therefore ruled out the 
possibility of acetyl-coA fuelling increased cholesterol synthesis in the CAFs. 
 
The next question to be addressed was whether the extra acetyl-coA in the CAFs 
was being used for fatty acid synthesis. Once again, I labelled the iCAFs and iNFs 
for 48h with media containing either 13C6-glucose or 13C6-glucose and 13C5-
glutamine and in collaboration with Grace McGregor extracted the lipids and 
determined the label incorporation into palmitate, oleate and stearate, using GC-
MS. There was an extremely low rate of incorporation of both glucose and 
glutamine into the fatty acids, and, as with the cholesterol, there was no 
detectable incorporation or increase in the total amount of metabolite in the 
iCAFs (Fig. 4-16b). In fact, I saw a slight decrease in the percentage of the fatty 
acids labelled in the iCAFs compared to the iNFs. Therefore it does not seem that 
the increase in acetyl-coA produced by PDH in CAFs is used to fuel increased lipid 
synthesis. 
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a: Total intracellular cholesterol in iNFs and iCAFs. b: Fraction of intracellular fatty acids 
labelled with either 13C-glucose or 13C-glucose+13C-glutamine after 48h of labelling in 
iNFs and iCAFs. 
Significance was calculated using a student’s t-test with Welch’s correction: *p≤0.05, ** 
p≤0.01, *** p≤0.001 
 
 
a 
b 
Figure 4-16 Lipid metabolism in iNFs and iCAFs 
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4.5 Histones are more acetylated in iCAFs 
 
Acetyl-coA is the substrate for acetylation of lysine residues on proteins. In the 
mitochondria, where the concentration of acetyl-coA is abnormally high and the 
environment is alkaline, proteins can be autoacetylated dependent on the amount 
of acetyl-coA present (Weinert et al., 2014). Outside the mitochondria, higher 
levels of acetyl-coA can stimulate acetyltransferase enzymes to increase protein 
acetylation (Choudhary et al., 2014). Acetylation is a common translational 
modification, and it is increasingly recognised that acetylation has significant 
impacts on protein functionality. Therefore changes in protein acetylation could 
have wide ranging effects on the CAF phenotype.  
 
To investigate whether there were differences in protein acetylation between 
CAFs and NFs, I used MS-proteomics to study the acetylomes of SILAC labelled 
iCAFs and iNFs. Because such a small fraction of the total proteome is modified, 
the samples had to be enriched for acetylated peptides. After digesting the lysates 
from the fibroblasts, agarose beads conjugated to an antibody against acetylated 
lysine residues were used to bind the acetylated peptides. After eluting the 
acetylated peptides, the samples were analysed by mass spectrometry using a Q-
Exactive HF. MaxQuant software (Cox and Mann, 2008) was used to identify the 
peptides discovered by the mass spectrometry with the addition of Acetyl(K) as a 
variable modification, and Perseus software (Tyanova et al., 2016)to carry out 
statistical analysis on the data. Data from three independent experiments, two of 
which was carried out by a visiting student, Claudia Boldrini,  was analysed in 
which for each experiment both forward and reverse labelled fibroblasts (i.e. 
heavy CAFs with light NFs and light CAFs with heavy NFs) were analysed, giving a 
total of four experiments. The log2 SILAC ratios of the acetylated peptides were 
normalised to the log2 SILAC ratios of the total protein in order to normalise for 
differences in protein levels between iCAFs and iNFs. Acetylation sites that were 
identified in at least two experiments were considered for the analysis. From a 
one-sample t-test analysis of the data, there were no significant differences in 
acetylation between iCAFs and iNFs. However, there was a trend towards histones 
being more acetylated in the iCAFs (Fig. 4-17). The identified proteins were 
further annotated with the gene ontology pathways for biological process, cellular 
compartment and molecular function. A one dimension enrichment analysis (Cox 
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and Mann, 2012)of the acetylation sites revealed that many of the categories with 
significantly upregulated acetylation in CAFs were related to histones, histone 
modifications and the nucleus, further supporting the increase in histone 
acetylation in the iCAFs (Fig. 4-18). 
  
Post translational modification of histones, and particularly on histone tails, is a 
major epigenetic factor determining which genes are transcribed into mRNA. 
Although modification of different sites can impact transcription differently, in 
general, histone acetylation is a marker of increased transcriptional activation. 
This is thought to be because acetylation of lysine residues neutralises the positive 
charge on lysine, which normally binds strongly to the negatively charged DNA 
(Margueron et al., 2005). Thus acetylation frees DNA from being so tightly bound 
to histones and allows the transcriptional machinery to be recruited. An increase 
in histone acetylation in CAFs could therefore have an extremely important role 
in activating transcription of genes required to maintain the activated CAF 
phenotype.  
 
To see if any of the upregulated histone acetylation sites were known to be 
involved in regulating transcription, I annotated the dataset using the PhosphoSite 
Plus database (https://www.phosphosite.org/homeAction.action), which is a 
repository for information on post translational modifications and how they affect 
protein function. According to this annotation, there were only a few acetylation 
sites identified in my data which have a known and verified functional impact on 
a protein (Fig. 4-19). Of these, the only upregulated histone acetylation site was 
H3K27ac. Acetylated H3K27 is a well characterised marker of activated 
transcription, and has been shown to be present at ‘super enhancer’ regions on 
chromatin (Raisner et al., 2018, Sen et al., 2019). I therefore chose to further 
investigate the regulation of H3K27 acetylation in relation to PDH activity in CAFs. 
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   Figure 4-17 iCAF vs iNF acetylome 
Volcano plot of a one-sample t-test showing regulation of acetylated peptides in iCAFs 
compared to iNFs. The x axis indicates the log2 SILAC ratio CAF/NF. Each point represents 
one acetylated peptide. Points above the dotted line have a p value < 0.05. Histone 
acetylation sites are coloured as follows: Histone 2, Histone 3, Histone 4. Results from 3 
independent SILAC experiments with both forward and reverse labelling were used in the 
analysis 
 
More acetylated in iCAF More acetylated in iNF 
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 Acetylated proteins were annotated using the gene ontology database and a 1D-
enrichment analysis was performed using the annotations. Plot shows significantly 
enriched and depleted annotations (FDR < 2%) in the dataset. Annotations relating to 
histones and histone modifications are highlighted in pink. 
Enriched in iCAF 
Figure 4-18 One-dimension enrichment analysis of acetylome data 
158 
 
 
Graph shows the log2 CAF/NF SILAC ratios for acetylated peptides with a known 
regulatory function identified in the acetylomes of iCAFs and iNFs. Error bars indicate the 
mean and SEM. 
Figure 4-19 Regulatory acetylated sites 
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4.6 H3K27 acetylation is regulated by PDH dependent 
acetyl-coA production 
 
4.6.1 H3K27 is more acetylated in CAFs than NFs 
 
In order to verify the results of the MS-acetylome data of the iCAFs and iNFs, I 
confirmed the upregulation of H3K27 acetylation by Western blot using lysates 
from all the CAF and NF cell lines. All the CAFs had increased H3K27ac levels 
compared to their respective NFs (Fig 4-20). 
 
4.6.2 H3K27 acetylation is regulated by acetyl-coA availability 
 
Histone acetylation is known to be regulated by the amount of acetyl-coA 
available in the cytosol and nucleus. ACLY is the main route of export of acetyl-
coA from the mitochondria via citrate, and ACLY expression has been shown to 
influence histone acetylation (Wellen et al., 2009). I had previously shown that 
ACLY is active in CAFs and that CAFs incorporate a higher proportion of glucose 
into citrate, therefore I investigated the role of ACLY activity in histone 
acetylation. To show that export of acetyl-coA from the mitochondria was 
necessary for H3K27 acetylation in the CAFs, I used an inhibitor against ACLY to 
prevent exported citrate from being converted back to acetyl-coA outside the 
mitochondria: BMS303141 (Li et al., 2007). To determine the effectiveness of the 
drug I used MS-metabolomics to demonstrate that BMS303141 caused an 
accumulation of citrate in CAFs. The iCAFs were treated with 10 or 50 µM 
BMS303141 in media with 13C6-glucose for 48h. The intracellular metabolites were 
then harvested and analysed by LC-MS. (Fig. 4-21a). The peak area was normalised 
to protein content of the fibroblasts for each samples. The metabolomics data 
clearly showed an accumulation of labelled citrate in the BMS303141 treated 
iCAFs, implying that the ACLY inhibitor was working because the acetyl-coA was 
being converted into citrate but was then unable to undergo conversion back to 
acetyl-coA. There was little effect with the 10 µM dose but a significant effect 
with the 50 µM dose so I used 50 µM BMS303131 in the following experiments. 
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To investigate the effect of ACLY inhibition of H3K27 acetylation, I treated CAFs 
with 50 µM BMS303141 with or without 2 mM sodium acetate. Acetate can be used 
by cells as a source of nucleocytosolic acetyl-coA, because it is converted to 
acetyl-coA by ACSS (Acyl-CoA synthetase short-chain family member) enzymes. By 
giving the fibroblasts an exogenous supply of acetate I expected to rescue the 
effect of ACLY inhibition because the cells would still be able to synthesise acetyl-
coA outside the mitochondria and use it for histone acetylation. After 48h of 
treatment, the CAFs were lysed and the levels of H3K27ac were determined by 
western blot (Fig. 4-21b). BMS303141 did indeed decrease the levels of H3K27ac, 
and this was rescued by additionally giving the CAFs sodium acetate. This 
experiment shows that H3K27 acetylation in the CAFs depends on the 
concentration of acetyl-coA outside the mitochondria. 
 
4.6.3 PDH activity regulates H3K27 acetylation 
 
I have shown that H3K27 acetylation is upregulated in CAFs, and is regulated by 
the presence of acetyl-coA outside the mitochondria. However, the impact of PDH 
activity on H3K27 acetylation was still unknown. To connect PDH activity to H3K27 
acetylation, I modulated PDK2 expression in the CAFs and NFs to regulate PDH 
phosphorylation and activity. The iCAFs were transfected with the enzymatically 
inactive PDK2N255A or PDK2WT. In contrast, the iNFs were transfected with siCTL or 
siPDK2 to decrease PDH phosphorylation, then after 48h the fibroblasts were lysed 
and the levels of H3K27ac were analysed by western blot (Fig 4-22). PDK2WT 
overexpression effectively reduced H3K27 acetylation compared to PDK2N255A 
overexpression, and siPDK2 transfection increased H3K27 acetylation compared to 
siCtl. I also created shCtl and shPDK2 cell lines using the pNF2 cells by lentiviral 
transduction. The level of PDK2 knockdown was determined by RT-qPCR, and the 
shRNA which gave the most efficient knockdown was used for the experiments. By 
western blot analysis of shCtl and shPDK2 cell lysates, shPDK2 both decreased PDH 
phosphorylation and increased H3K27 acetylation, in concordance with the siRNA 
knockdown of PDK2 (Fig. 4-23). Although the shPDK2 knockdown was not as 
effective as the siRNA knockdown, the level at which it altered PDH 
phosphorylation and H3K27 acetylation was similar, suggesting that a small change 
in PDK2 expression in the fibroblasts is sufficient to alter histone acetylation 
patterns. 
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In order to rescue the PDK2WT phenotype, the iCAFs were treated with 2 mM 
sodium acetate, providing a cytosolic supply of the acetyl-coA precursor which 
could be used to maintain H3K27 acetylation. 48h after transfection with or 
without acetate treatment, the iCAFs were lysed and the levels of H3K27ac were 
analysed by western blot (Fig 4-24a). PDK2WT overexpression effectively reduced 
H3K27 acetylation compared to PDK2N255A overexpression, and this was rescued by 
the acetate treatment. 
 
Conversely, to reverse the siPDK2 phenotype, the iNFs were treated with 25 µM 
c646, which is an EP300 inhibitor. EP300 is a histone acetyltransferase (HAT) 
known to target H3K27 and has been shown to induce H3K27 acetylation at 
enhancer regions (Raisner et al., 2018). After 48h with or without c646 treatment, 
the iNFs were lysed and the levels of H3K27ac were analysed by western blot (Fig 
4-24b). The inhibitor c646 reduced PDH activity-induced H3K27 acetylation, as 
predicted. Therefore acetyl-coA produced by PDH is required for the increase in 
histone acetylation in CAFs, and modulates H3K27 acetylation. Furthermore I 
could rescue the effects of modulating PDH activity in the fibroblasts on histone 
acetylation with either acetate or pharmacological inhibition of c646, which 
provided me with a good experimental system to further investigate the 
phenotypic effects of increased PDH activity in the CAFs. 
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Representative western blots from n ≥ 2 independent experiments showing that all CAF cell lines have increased 
histone acetylation at H3K27 compared to their paired NFs. Vinculin and β-tubulin antibodies were used as a 
loading control. Molecular weight markers are shown next to the blots. 
Figure 4-20 H3K27 is more acetylated in CAFs 
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  Figure 4-21 H3K27 acetylation is regulated by ACLY inhibition 
a: Total citrate with 13C-glucose label incorporation in iCAFs after 48h treatment with 
DMSO control, 10 µM or 50 µM BMS303141. Graph shows the mean and SEM of 3 
experiments. b,c,d: Representative western blots and quantification of H3K27ac in iCAFs, 
pCAF2s and pCAF3s respectively treated with 50 µM BMS303141 +/- 2 mM acetate. β-
tubulin was used as a loading control. Molecular weight markers are shown next to the 
blots. Graphs show the mean and SEM of at least 4 independent experiments. Significance 
was calculated using one-way ANOVA with Dunnett’s multiple comparisons test: *p≤0.05, 
** p≤0.01, *** p≤0.001 
a 
b 
c 
d 
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Representative western blots and quantification of H3K27ac in iCAFs/iNFs and 
pCAF2s/pNF2s transfected with siCTL/siPDK2 or PDK2N255A/PKD2WT. Vinculin or GAPDH was 
used as a loading control. Molecular weight markers are shown next to the blots. Graphs 
show the mean and SEM of 3 independent experiments. Significance was calculated using 
one-way ANOVA with Dunnett’s multiple comparisons test: *p≤0.05, ** p≤0.01, *** p≤0.001 
Figure 4-22 H3K27 acetylation is regulated by PDK2 expression 
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Figure 4-23-shPDK2 increases H3K27 acetylation 
a. qPCR for PDK2 expression in shCtl and shPDK2 pNFs. PDK2 mRNA was normalised to 18S 
mRNA. Graph shows the mean and SEM of 3 independent experiments. Significance was 
calculated using one-way ANOVA with Dunnett’s multiple comparisons test: *p≤0.05, ** 
p≤0.01, *** p≤0.001. b. Western blots of pPDHA1 and H3K27ac in shCtl/shPDK2 pNFs. 
Quantification of H3K7ac is shown under the blots. GAPDH was used as a loading control. 
Molecular weight markers are shown next to the blots. Representative image of 2 
independent experiments shown. 
a b 
1.35 2.86 
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Representative western blots and quantification of H3K27ac in a. iCAFs/iNFs and b. 
pCAF2s/pNF2s transfected with siCTL/siPDK2 or PDK2N255A/PKD2WT and treated with 2 mM 
acetate or 25 µM c646. Vinculin or β-tubulin was used as a loading control. Molecular 
weight markers are shown next to the blots. Graphs show the mean and SEM of 4 
independent experiments. Significance was calculated using one-way ANOVA with 
Dunnett’s multiple comparisons test: *p≤0.05, ** p≤0.01, *** p≤0.001 
a b 
Figure 4-24 H3K27 acetylation is regulated by PDK2 expression 
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4.7 Discussion 
 
In this chapter I set out to discover what the purpose of the increase in 
intracellular acetyl-coA produced by PDH in CAFs was. Because the majority of 
pathways involving acetyl-coA are related to metabolism, I first investigated 
metabolic differences between CAFs and NFs. I was expecting there to be 
differences in mitochondrial metabolism because I had demonstrated that PDH 
was localised in the mitochondria, and because PDH had been shown in previous 
studies to be a key metabolic enzyme controlling entry of glycolysis-derived 
metabolites to the TCA cycle to support its activity (Kaplon et al., 2013, McFate 
et al., 2008, Michelakis et al., 2008, Randle, 1986). For this reason, it has been 
named the ‘mitochondrial gatekeeper’ (Saunier et al., 2016). Initial experiments 
showed that there were no differences between CAFs and NFs in the uptake and 
secretion of four major metabolites: glucose, lactate, glutamine and glutamate. 
These are the main metabolic sources controlling flux through glycolysis and the 
TCA cycle. Further metabolic analysis of the CAFs and NFs using MS-metabolomics 
revealed that there were very few consistent metabolic differences between CAFs 
and NFs. This was surprising as there are many studies showing that CAFs are 
reprogrammed metabolically to produce metabolites which fuel tumour cell 
growth and invasion. However, these studies also highlight the high level of 
heterogeneity in CAFs. This is consistent with the literature since studies from 
different tumour types and tissues have discovered different metabolic pathways 
contributing to the pro-tumourigenic phenotype of the CAFs and their cross talk 
with the cancer cells. For example, Yang et al. have demonstrated that glutamine 
and glutamate production is a key metabolic cross talk pathway between ovarian 
CAFs and cancer cells (Yang et al., 2016), whereas studies in pancreatic cancer 
have shown that alanine secretion by pancreatic stellate cells, which are the cells 
that CAFs originate from in the pancreas, is a vital pathway to produce fuel for 
the cancer cells under nutrient deprived conditions (Sousa et al., 2016, Serrao et 
al., 2016). Conversely, my mammary CAFs showed increased total levels of proline 
and asparagine compared to their paired NFs as well as increased production of 
N-acetylaspartate, none of which have been previously been reported to be 
upregulated in CAFs.  Both asparagine and N-acetylaspartate are products of 
aspartate metabolism, levels of which were also upregulated in the pCAF cell 
lines. Since the production of aspartate involves conversion of glutamate to α-KG, 
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aspartate production could be increased in order to maintain α-KG levels, which 
were also higher in the CAFs. Since neither asparagine nor N-acetylaspartate can, 
so far as we know, be used for further metabolic reactions, these metabolites 
could then be a means of storing the excess aspartate without affecting other 
metabolic pathways.  
 
However, two themes of CAF metabolism which have been reported in CAFs from 
several tissues, including breast, is that CAFs are more glycolytic and autophagic 
(Bonuccelli et al., 2010, Guido et al., 2012, Whitaker-Menezes et al., 2011b, 
Pavlides et al., 2012, Zhang et al., 2015). None of my extensive metabolic profiling 
of the CAFs and NFs suggested that the CAFs were more glycolytic than the NFs. 
As many of the experiments showing that mammary CAFs upregulate glycolysis 
were done using co-cultures of CAFs and cancer cells (Martinez-Outschoorn et al., 
2010a, Whitaker-Menezes et al., 2011b, Martinez-Outschoorn et al., 2010b, 
Martinez-Outschoorn et al., 2011b), one possibility is that I would need to co-
culture my CAFs with cancer cells to see an upregulation in glycolysis. 
Furthermore, other studies have shown that there is variation in whether 
mammary CAFs are predominantly glycolytic or oxidative depending on the tumour 
they are derived from, so it is possible that I derived CAFs from tumours where 
glycolysis was not upregulated in the stroma (Choi et al., 2013). All of my CAFs 
and NFs however appear to be highly glycolytic cells as there is little incorporation 
of glucose into the TCA cycle metabolites from the metabolomics data and the 
oxygen consumption rate was lower than that of cancer cells, suggesting that 
fibroblasts in general rely more on glycolysis than oxidative phosphorylation.  
 
While I was investigating mitochondrial differences between the mammary CAF 
and NF cell lines I did however discover that there were differences in 
mitochondrial functionality between CAFs and NFs. CAFs had decreased levels of 
functional mitochondria, decreased mitochondrial capacity and increased 
autophagic flux compared to NFs. As mentioned previously, several studies have 
shown that CAFs are more autophagic and that the products of autophagic break 
down are used to fuel tumour cells. For example, Lisanti et al. showed that in co-
culture with breast cancer cells, fibroblasts experienced increased oxidative 
stress and upregulated autophagy and mitophagy via caveolin-1 downregulation 
(Martinez-Outschoorn et al., 2010a), providing tumour cells with metabolites such 
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as lactate and ketones. It is interesting to note that in data generated in our lab 
from proteomic analyses on the iCAFs and iNFs and on the pCAFs and pNFs, 
caveolin-1 is indeed downregulated in CAFs compared to NFs, suggesting that a 
similar autophagic pathway could be active in the CAFs used for my studies, 
although I do not see a corresponding increase in lactate secretion. Dysfunctional 
mitochondria can be degraded through mitophagy. However, the total levels of 
mitochondria were consistent between the iCAFs and iNFs, suggesting the 
dysfunctional mitochondria are not being degraded. This has a possible link to the 
downregulation of PDK2 in CAFs, as PDK2 has been shown to phosphorylate PARL 
to stimulate mitophagy. When PDK2 was knocked down in the iNFs, I did not 
observe the decrease in mitochondrial capacity that I had seen in the iCAFs, 
however this was a transient knockdown for only 48h and it would be interesting 
to investigate whether stable knockdown of PDK2 in NFs would decrease 
mitochondrial capacity in the long term, as this would suggest that it was involved 
in a mitophagy related pathway. 
 
Despite there being some differences in mitochondrial functionality between CAFs 
and NFs, I could not find any evidence that the increase in acetyl-coA produced 
by CAFs was used to increase flux through the TCA cycle. The majority of TCA 
cycle metabolites were derived from glutamine as shown by metabolic tracing 
experiments, and apart from citrate there was minimal label incorporation from 
heavy glucose into TCA cycle metabolites. Furthermore, there was no difference 
in OXPHOS under basal conditions between CAFs and NFs as shown by the Seahorse 
analysis, and altering PDH activity by knocking down PDK2 in NFs had no effect on 
oxygen consumption. Therefore I can conclude that PDH activity does not affect 
the TCA cycle in the fibroblasts. It is unclear why glucose is incorporated into 
citrate in both CAFs and NFs, but then makes a minimal contribution to other TCA 
cycle metabolites. One possibility is that the fibroblasts have an low isocitrate 
dehydrogenase activity, which would mean that α-ketoglutarate is synthesised 
mainly from glutamine and is converted through the TCA cycle to citrate, where 
it is blocked from re-entering the TCA cycle. This could explain why the fibroblasts 
also have a generally low oxygen consumption rate. Proliferating fibroblasts have 
previously been shown to have low IDH activity (Lemons et al., 2010). 
Mitochondrial IDH can be inhibited by acetylation (Zou et al., 2017), however the 
regulatory site was not identified in my analysis of the acetylomes of the iCAFs 
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and iNFs. IDH3 downregulation has been reported previously in CAFs as a means 
to maintain CAF activation through TGF-β and HIF-1α signalling (Zhang et al., 
2015), however, this does not account for the decrease in citrate conversion to α-
KG that I also see in the NFs. Therefore, if mitochondrial IDH is downregulated in 
fibroblasts, the mechanism is yet to be elucidated. It would be interesting to 
compare the relative activities of citrate synthase and IDH between the fibroblasts 
and a cell line such as the MCF7 cells which are known to have a functioning TCA 
cycle. 
 
Since I did see an increase in intracellular citrate labelled by glucose in the CAFs 
and also significant label incorporation into acetyl-carnitine, both of which are 
means of exporting acetyl-coA out of the mitochondria, I hypothesised that the 
acetyl-coA produced by PDH had a cytosolic role. Acetylcarnitine can cycle in and 
out of the mitochondria, and although it has mostly been studied as a means of 
transferring acetyl-coA groups derived from beta-oxidation of fatty acids into the 
mitochondria, it has also been shown to be a means of removing excess acetyl-
coA from the mitochondria in order to maintain a steady rate of TCA cycle 
metabolism. Citrate on the other hand is well known to be the main route of 
acetyl-coA export from the mitochondria. I demonstrated that ACLY was 
phosphorylated and therefore active in all the CAF cell lines and furthermore was 
more phosphorylated than the respective NFs in two out of three pairs. Inhibiting 
ACLY pharmacologically in the iCAFs caused significant accumulation of glucose-
labelled citrate, which must be derived from acetyl-coA, demonstrating that 
citrate is an important route of acetyl-coA export from the mitochondria. 
 
I therefore investigated the roles of acetyl-coA outside the mitochondria. 
Metabolically, acetyl-coA is used for lipid synthesis in the cytosol. However, by 
carrying out further metabolic tracing experiments in the iCAFs and iNFs it was 
clear that fatty acid and cholesterol synthesis in the fibroblasts is minimal and 
there is no difference in the rate of synthesis between CAFs and NFs. This is 
perhaps unsurprising given that the fibroblasts I am using are all derived from 
mammary tissue, which has a particularly high fat content. Therefore it is unlikely 
that in a breast tumour these CAFs would need to increase lipid synthesis since 
they are probably able to take up everything they need from their 
microenvironment. The increase in acetyl-coA produced by PDH in CAFs does not 
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seem to be contributing to any metabolic pathways in the CAFs; neither for 
oxidative phosphorylation in the mitochondria nor for lipid synthesis in the 
cytosol. 
 
The other major use for acetyl-coA is for protein acetylation. Protein acetylation 
was first studied in the context of histones, where it generally activates gene 
transcription by altering chromatin folding to open up DNA for transcription 
machinery binding and acting as a marker for recruitment of bromodomain 
containing transcription factors, acetyltransferases, and chromatin remodelling 
factors. Acetyl-coA availability and concentration has been shown to be a rate 
limiting factor for histone acetylation (Cai et al., 2011, Galdieri and Vancura, 
2012). For example, acetyl-coA production by ACLY, which as I previously 
discussed is activated in my CAF cell lines, has been shown to be required to link 
growth factor signalling to regulation of gene expression by histone acetylation 
(Wellen et al., 2009). However, acetylation has more recently been shown to also 
be an important post translational modification outside of the nucleus. 63% of 
mitochondrial proteins contain acetylation sites, and it has been shown that 
increased concentrations of acetyl-coA in mitochondria causes increased 
acetylation of proteins (Weinert et al., 2014). Moreover, acetylation can regulate 
the activity of mitochondrial metabolic enzymes such as succinate dehydrogenase 
(Cimen et al., 2010). Cytosolic proteins have also been shown to be regulated by 
acetylation; for example, acetylation of cytoskeletal proteins such as actin can 
increase fibre stability (Kim et al., 2006b). I therefore wanted to analyse the 
entire acetylome of the iCAFs and iNFs and not just histones. 
 
The most accurate method of quantifying global changes in post translational 
modifications in an unbiased manner is through mass spectrometry (Witze et al., 
2007). Using an IP enrichment for acetylated peptides to enable quantification of 
acetylation sites I analysed the acetylomes of SILAC labelled iCAFs and iNFs. This 
revealed a general upregulation of histone acetylation in the iCAFs. There was no 
overall increase of acetylation of mitochondrial proteins in the iCAFs, further 
supporting my previous data showing that acetyl-coA produced by PDH does not 
affect the mitochondria and that acetyl-coA is preferentially exported out of the 
mitochondria in CAFs via ACLY. Other nuclear proteins also showed an increase in 
acetylation in CAFs, including nucleoporins, splicing factors, transcription factors 
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including BRD8 and the histone acetyl-transferase CREBBP. Of interest, 
cytoskeletal proteins and ECM proteins including actin, filamin, fibronectin, 
collagen and myosin 9 showed a trend towards being less acetylated in CAFs. This 
could indicate increased cytoskeletal turnover since acetylation of cytoskeletal 
proteins has been shown to increase fibre stability. Glycolytic enzymes such as 
ALDOA, ENO1 and G6PD also showed decreased acetylation in CAFs. Acetylation 
of glycolytic enzymes has previously been shown to be inhibitory (Liu and Shyh-
Chang, 2017, Nakayasu et al., 2017), which would suggest that the enzymes are 
more active in CAFs, however, as discussed previously I was unable to discover 
any significant increase in glycolysis in CAFs. That being said, there is a slight 
increase in total intracellular glyceraldehyde-3-phosphate and 
phosphoenolpyruvate, which are produced by ALDOA and ENO1 respectively. G6PD 
catalyses the first step in the pentose phosphate pathway, however, I did not 
investigate the production of pentose phosphate metabolites in my experiments 
so whether the acetylation of this enzyme has a functional output is unknown. 
 
Acetylation is not so well characterised as post translational modifications such as 
phosphorylation; however, there a were few acetylation sites identified in my 
dataset which have a characterised regulatory function. Of these, the only site 
upregulated in CAFs was H3K27, which is a hallmark of activated transcription and 
is found at enhancer regions in chromatin. I demonstrated that H3K27 acetylation 
is indeed upregulated in all my CAF cell lines compared to their respective NF 
partners. Acetylation of H3K27 was also dependent on PDH activity in fibroblasts, 
as regulated by PDK2-mediated phosphorylation, and was further dependent on 
export of PDH produced acetyl-coA out of the mitochondria via citrate and ACLY. 
H3K27 is a known target of the HAT EP300, and other sites known to be acetylated 
by EP300, such as H3K18 and H3K23 were also among the most highly acetylated 
in the iCAFs. This suggests that EP300 activity is required for the increased histone 
acetylation CAFs, and my data showed that indeed EP300 inhibition reversed the 
increase in H3K27ac mediated by PDK2 knockdown in fibroblasts.  
 
Therefore in this chapter I have shown that the increase in acetyl-coA produced 
by PDH in CAFs does not contribute towards metabolic pathways in CAFs but is 
instead channelled into increasing histone acetylation, and in particular 
acetylation of the transcriptional activator H3K27. In CAFs, then, PDH is not a 
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metabolic regulator but an epigenetic regulator, which is an understudied role of 
PDH. This could have major implications for how CAFs epigenetically regulate their 
pro-tumourigenic phenotype and therefore in the following chapter I set out to 
investigate the phenotypic effects of PDH induced histone acetylation on the CAFs. 
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Chapter 5  H3K27 acetylation regulates collagen 
production in CAFs 
 
5.1 MS-proteomic analysis of c646 treated CAFs 
 
Since histone acetylation is generally associated with transcriptional activation, I 
predicted that modulating histone acetylation levels would affect the proteome 
of the fibroblasts. As discussed in the previous chapter, the EP300 inhibitor c646 
is known to target H3K27 acetylation and treatment of the iNFs with c646 was 
sufficient to reverse the effects of PDK2 knockdown on H3K27ac levels. Although 
other EP300 target sites were also regulated in the iCAF and iNF acetylomes, I 
focussed on H3K27ac as a readout for EP300 activity and histone acetylation since 
this site is the most highly associated with increased transcriptional activity. I 
therefore carried out a proteomic analysis of the iCAFs treated with c646 or DMSO 
control for 72 hours. The efficacy of EP300 on H3K27ac levels was assessed by 
western blot, which showed that c646 successfully reduced H3K27 acetylation in 
the iCAFs (Fig. 5-1). Lysates from three independent experiments of iCAFs 
cultured for 96h with or without c646 treatment were digested and the peptides 
were analysed using a Q-Exactive HF mass spectrometer. The relative amounts of 
each protein between samples was determined by label free quantification (LFQ) 
(Cox et al., 2014). In total, 5480 proteins were identified, and those that were 
quantified in at least two replicates were included in the analysis. A two tailed t-
test analysis revealed that c646 treatment drastically altered the proteome of the 
iCAFs, in fact, 489 proteins were significantly regulated by c646 which is almost a 
tenth of the proteins identified. I then considered proteins that were 
downregulated by c646 treatment as potential candidates for genes regulated, 
directly or indirectly, by histone acetylation. Strikingly, extracellular matrix (ECM) 
proteins, especially collagens and fibronectin, were highly downregulated in the 
c646 treated CAFs (Fig 5-2). Collagen and ECM production is an extremely 
important aspect of the activated CAF phenotype, as CAFs are the main source of 
collagen in the tumour microenvironment. Upregulated collagen production by 
CAFs has been shown to be an important factor contributing to increased tumour 
growth, progression and metastases. In support of this, proteomic data of SDS 
soluble ECM derived from the iCAFs previously acquired in our lab showed that 
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collagens and fibronectin make up the majority of CAF-derived ECM, with 
collagens alone constituting 40% of the total ECM (Fig. 5-2). I therefore further 
investigated the regulation of collagen expression in CAFs by histone acetylation. 
176 
 
 
  
Representative Western blot and quantification of H3K27ac levels in iCAFs treated 
for 48h with 25 µM c646 or DMSO control. GAPDH was used as a loading control.  
Molecular weight markers are shown next to the blots. Graph shows mean and SEM 
of 5 biological replicates.   
Significance was calculated using an unpaired student t-test with Welch’s 
correction: *p≤0.05 
 
Figure 5-1 c646 reduces H3K27 acetylation 
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Volcano plot showing the results of a two-sample t-test comparing the proteomes 
of control and c646 treated iCAFs. Three independent experiments were included 
in the analysis.  Each dot represents a protein. Proteins above the black line were 
classed as significantly regulated (cut-off values: p=0.05, S0=0.1). All collagens 
identified in both proteomes are highlighted in red. 
Figure 5-2 c646 downregulates collagen proteins 
178 
 
 
Plot showing all the proteins identified by MS-proteomics in the iCAF ECM and their 
average abundance, ranked from most abundant to least abundant. Collagens VI, I 
and XII are highlighted as being among the 10 most abundant ECM proteins. 
Figure 5-3 Collagens are highly abundant in iCAF ECM 
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5.2 c646 regulates collagen expression in CAFs 
 
To corroborate the results of the MS-proteomic data from iCAFs treated with c646, 
I assessed the effects of c646 treatment on collagen expression at the mRNA and 
protein level. From the MS-proteome of the iCAF ECM, two of the most abundant 
collagens were collagen VI and collagen I, expression of both of which are known 
to be increased in breast cancer (Kauppila et al., 1998, Chen et al., 2013) and 
both of which were downregulated in the proteomes of c646 treated CAFs. 
Collagen VI is a mediator between the interstitial matrix and basement membrane 
and has been shown to stimulate tumour growth, angiogenesis and inflammation 
(Nissen et al., 2019, Chen et al., 2013). Collagen I is the classic structural collagen, 
with no imperfections in the Gly-X-Y repeats, and has been shown to promote 
tumour proliferation and metastasis in many tumour types including breast (Nissen 
et al., 2019). I therefore focussed on the expression of these two collagens in the 
following experiments. mRNA was extracted from CAFs treated with c646 or DMSO 
control for 72h and the expression of COL1A1 and COL6A1 was measured by RT-
PCR. Both mRNAs were downregulated in both c646 treated iCAFs and pCAF3s (Fig. 
5-4). This showed that c646 controls collagen expression at the transcriptional 
level, and strongly points to a role for histone acetylation and particularly H3K27 
acetylation in regulating Collagen I and Collagen VI expression. 
 
To show that collagen in the CAF ECM is regulated by EP300 activity, I determined 
the levels of Collagen VI in ECM from CAFs by western blot analysis. CAFs were 
seeded at confluence and treated with c646 or DMSO control for 1 week. 
Subsequently, the CAFs were lysed and removed, leaving the cell-free ECM 
attached to the dish. The ECM was harvested and the proteins denatured and 
analysed by western blot (Fig. 5-5). Collagen VI was significantly depleted in ECM 
from c646 treated CAFs, showing that not only does c646 treatment reduces 
collagen mRNA expression within the CAFs, but it also affects its abundance in the 
ECM. 
 
To further demonstrate that EP300 regulates collagen production by CAFs, I used 
fluorescent microscopy to visualise collagen in the ECM. I used a pan-collagen 
binding fluorescent protein: CNA35-mCherry. This protein has the advantage of 
binding all collagen proteins, rather than using an antibody against a specific 
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collagen, and also binds collagen in live cell cultures or in in vivo tissues (Aper et 
al., 2014).  The iCAFs were seeded at confluence on glass coverslips and allowed 
to produce ECM for 72h, with or without 25 µM c646 treatment. CNA35-mCherry 
was then added to the media at a concentration of 1 µM for two hours, following 
which the coverslips were fixed in 4% PFA, counterstained with DAPI and imaged 
(Fig. 5-6). The images clearly showed that collagen was reduced in the c646 
treated samples, again showing that inhibition of histone acetylation reduces ECM 
production in the CAFs. 
 
In order to show that this effect also occurs in CAFs when in the presence of cancer 
cells, I seeded the pCAF2s in a 1:1 ratio with Cellaria-Wood cancer cells at 
confluence on glass coverslips. The Cellaria-Wood cell line is a primary breast 
cancer cell line, derived from an ER+ infiltrating ductal and lobular carcinoma. 
After 96h of co-culture with or without c646 treatment, CNA35-mCherry was 
added to the media at a concentration of 1 µM for two hours, following which the 
coverslips were fixed, counterstained with DAPI and imaged (Fig. 5-7a). The 
pCAF2s are GFP positive, so I classed nuclei within the green area as fibroblasts, 
and nuclei outside the green area as cancer cells. The collagen staining overlapped 
almost solely with the fibroblasts, confirming that they are the main source of 
collagen (Fig.  5-7b). In the c646 treated cultures, there was a dramatic decrease 
in collagen staining, confirming that the c646 treatment is also effective when 
CAFs are in the presence of cancer cells (Fig. 5-7c). Interestingly, in the control 
cultures the Cellaria-Wood cells formed large clusters around which the fibroblasts 
formed a network, whereas in the c646 treated cultures the Cellaria-Wood cells 
formed much smaller clusters, suggesting that c646 affects interactions between 
the cells, or that interactions with the CAF-derived ECM is required for the cancer 
cells to form clusters. 
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a: COL1A1 mRNA levels in iCAFs (blue) and pCAF3s (green) with or without 25 µM 
c646 treatment. b: COL6A1 mRNA levels in iCAFs (blue) and pCAF3s (green) with or 
without 25 µM c646 treatment. The mRNA levels were measured by RT-qPCR and 
collagen mRNA was normalised to TBP2 levels. Graphs show mean and SEM of at 
least 3 independent experiments. Significance was calculated using an unpaired 
student t-test with Welch’s correction: *p≤0.05 
a 
b 
Figure 5-4 c646 reduces collagen expression at the mRNA level 
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Representative western blots and quantification of Collagen VI levels in ECM 
derived from iCAFs or pCAF2s after treatment with 25 µM c646 or DMSO control. 
Graphs show mean and SEM of 3 independent experiments. Significance was 
calculated using an unpaired student t-test with Welch’s correction: *p≤0.05 
* 
Figure 5-5 c646 reduces collagen levels in the ECM 
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Representative images and quantification of collagen stained with CNA35-mCherry 
after treatment with 25 µM c646 or DMSO control. Images were acquired using a 
Zeiss 710 at 20x magnification and the staining density was calculated using ImageJ 
software and normalised to cell number. Graph shows mean and SEM of 6 
independent experiments. Significance was calculated using an unpaired student t-
test with Welch’s correction: ***p≤0.001 
Figure 5-6 c646 reduces collagen production by CAFs 
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a: Representative images of pCAF2 (GFP positive) and Cellaria-Wood cancer cells in  
1:1 co-culture after 96h treatment with 25 µM c646 or DMSO control. Collagen was 
stained with CNA35-mCherry. Images were acquired as 5x5 tilescan using a Zeiss 
710 at 10x magnification. b: Graph showing mean density of collagen staining 
overlapping with CAF or Cellaria cells in the DMSO control treated cultures. c: Mean 
density of total collagen staining in the control vs c646 treated cultures. d: Mean 
area of Cellaria-Wood clusters in the control vs c646 treated cultures 
The staining density and cluster size was calculated using ImageJ software. Graphs 
show mean and SEM of 3 experiments. Significance was calculated using an 
unpaired student t-test with Welch’s correction: **p≤0.01 
a 
b c d 
Figure 5-7 c646 reduces collagen production in CAF/Cellaria-Wood co-cultures 
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5.3 Acetyl-coA availability regulates collagen production 
in CAFs 
 
5.3.1 ACLY inhibition reduces collagen production in CAFs 
 
I have shown that c646 treatment, which inhibits EP300 and thereby reduces 
H3K27 acetylation, decreases collagen production by CAFs. However, although I 
demonstrated that histone acetylation regulates collagen production, this is not 
necessarily dependent on acetyl-coA. Therefore, in order to further prove that 
acetyl-coA availability regulated collagen production by the CAFs, the iCAFs were 
cultured at confluence for seven days and were treated for the duration of the 
experiment with DMSO or BMS303141, the ACLY inhibitor which, as I showed in the 
previous chapter, regulates H3K27 acetylation. The ACLY inhibition was rescued 
by additionally treating the CAFs with 2 mM acetate to provide them with a source 
of nucleocytosolic acetyl-coA. The CAFs were then lysed and removed, leaving the 
ECM intact, and the cell-free ECM was harvested, denatured and analysed by 
Western blot. The level of collagen VI in the CAF-derived ECM was significantly 
reduced by BMS303141 treatment, and was subsequently rescued by the additional 
acetate treatment, thus showing that collagen production in CAFs requires a 
cytosolic and nuclear pool of acetyl-coA (Fig. 5-8). 
 
Again, to further demonstrate that inhibition of ACLY to block acetyl-coA export 
from the mitochondria reduces collagen production in CAFs, the iCAFs were 
cultured at confluence with Cellaria-Wood cancer cells with or without BMS303141 
treatment for 96 h, following which the collagen in the ECM was labelled with 
CNA35-mCherry and imaged. This clearly showed that ACLY inhibition also reduced 
collagen deposition by CAFs in the ECM when in the presence of cancer cells (Fig 
5-9). Interestingly, BMS303141 also reduced the size of the clusters of Cellaria-
Wood cells, as I saw previously with the EP300 inhibitor. This again suggests that 
blocking histone acetylation also affects some interactions between the cells, 
which could be related to the decreased ECM production or to an entirely different 
pathway that is regulated by acetyl-coA dependent histone acetylation. 
 
Finally, in order to show that ACLY inhibition affected collagen production at the 
gene expression level, mRNA was extracted from CAFs treated with BMS303141 
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with or without acetate rescue for 72h. The expression of COL1A1 and COL6A1 
mRNA was determined by RT-qPCR. This showed that ACLY inhibition reduced 
expression of the collagens compared to the DMSO treated control, and that this 
could be rescued by exogenous acetate treatment (Fig. 5-10). Therefore the 
nucleocytosolic pool of acetyl-coA in the fibroblasts regulates collagen production 
at the transcriptional level, further supporting my hypothesis that collagen 
production in CAFs is epigenetically regulated by increased histone acetylation in 
an acetyl-coA dependent manner.  
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Representative western blot and quantification of Collagen VI levels in ECM derived 
from iCAFs after treatment with 50 µM BMS303141 +/- 2 mM acetate or DMSO 
control for 72h. Graphs show mean and SEM of 3 independent experiments. 
Significance was calculated using a one way ANOVA with Dunnett’s multiple 
comparisons test: *p≤0.05 
 
 
Figure 5-8 BMS303141 reduces collagen in CAF-derived ECM 
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a: Representative images and quantification of pCAF2 (GFP positive) and Cellaria-
Wood cancer cells in 1:1 co-culture after 96h treatment with 50 µM BMS303141 or 
DMSO control. Collagen was stained with CNA35-mCherry. Images were acquired as 
5x5 tilescans using a Zeiss 710 at 10x magnification. b: Graph shows mean density 
of total collagen staining in the control vs BMS303141 treated cultures. The staining 
density was calculated using ImageJ software. c: Graph shows the mean area of 
Cellaria-Wood clusters in the control vs BMS303141 treated cultures.  
The staining density and cluster size was calculated using ImageJ software. Graphs 
show mean and SEM of 3 experiments. Significance was calculated using an 
unpaired student t-test with Welch’s correction: **p≤0.01 
a 
b c 
Figure 5-9 BMS303141 reduces collagen production in CAF/Cellaria-Wood co-
cultures 
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COL1A1 and COL6A1 mRNA levels in iCAFs after 48h of BMS303141 +/- 2 mM acetate 
or DMSO control treatment.  
The mRNA levels were measured by RT-qPCR and collagen mRNA was normalised to 
TBP2 levels. Graphs show mean and SEM of at 5 independent experiments. 
Significance was calculated using a one way ANOVA with Dunnett’s multiple 
comparisons test: **p≤0.01 
Figure 5-10 BMS303141 reduces collagen expression at the mRNA level 
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5.3.2 Acetate increases collagen production in NFs 
 
I had shown that reducing the cytosolic and nuclear pool of acetyl-coA decreased 
collagen production and deposition in CAFs, therefore I also attempted to increase 
the nucleocytosolic pool of acetyl-coA in NFs in order to activate collagen 
production. The NFs were treated with exogenous acetate to stimulate acetyl-coA 
production. After 72h of acetate treatment, the NFs were lysed for either western 
blot or RT-qPCR analysis. Western blot analysis confirmed that, as in the CAFs, 
acetate treatment increased H3K27 acetylation (Fig. 5-11). The mRNA was also 
extracted from NF lysates and the expression of COL1A1 and COL6A1 mRNA was 
determined by RT-qPCR (Fig. 5-12b). Acetate treatment significantly increased 
expression of both collagens at the mRNA level, suggesting that increased levels 
of acetyl-CoA are sufficient to epigenetically increase transcription of collagen 
genes. 
 
To show that acetate increases collagen deposition in the ECM in NFs, NFs were 
cultured at confluence with acetate treatment for seven days and then lysed and 
removed, leaving the ECM behind. The cell-free ECM was then harvested and 
analysed by Western blot (Fig 5-12a). This showed that Collagen VI levels in NF-
derived ECM were upregulated upon acetate treatment, thus connecting the 
increase in transcription of collagen genes with an increase in production and 
secretion of the protein. 
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Representative western blot and quantification of H3K27ac levels in iNFs after 
treatment with 2 mM acetate or DMSO control for 48h. Graphs show mean and SEM 
of 4 independent experiments. Significance was calculated using a paired student 
t-test: *p≤0.05 
 
 
Figure 5-11 Acetate increases H3K27 acetylation in NFs 
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a 
b 
a: Representative western blot and quantification of collagen VI levels in ECM 
derived from iNFs after treatment with 2 mM acetate or DMSO control for 48h. 
Graph shows mean and SEM of 4 independent experiments. b: Levels of COL1A1 and 
COL6A1 mRNA in iNFs after treatment with 2 mM acetate or DMSO control for 48h. 
mRNA levels were measured by RT-qPCR and normalised to TBP2 mRNA. Graphs 
show mean and SEM of 3 independent experiments. Significance was calculated 
using an unpaired student t-test with Welch’s correction t: *p≤0.05, **p≤0.01 
 
 
Figure 5-12 Acetate increases collagen expression in NFs 
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5.4 PDH activity regulates collagen production in 
fibroblasts 
 
I showed in the previous chapter that PDH activity regulates H3K27 acetylation in 
the fibroblasts, and in this chapter that pharmacological inhibition of histone 
acetylation either via EP300 or ACLY regulates collagen production in the CAFs. 
Therefore, I hypothesised that modulating PDH activity in the fibroblasts would 
also regulate collagen production and deposition in the ECM. In order to control 
PDH activity, I modulated the expression of PDK2 to control PDH phosphorylation, 
either by transfection of NFs with siCtl or siPDK2, or by transfection of CAFs with 
the enzymatically inactive PDK2N255A or PDK2WT. The transfected fibroblasts were 
seeded at confluence for 72h to produce ECM, and the ECM was then 
decellularised. The cell-free ECM was harvested, denatured and analysed by 
Western blot. As predicted, PDK2 knockdown to decrease PDH phosphorylation in 
NFs increased collagen VI deposition in the ECM, whereas PDK2 overexpression in 
CAFs decreased collagen VI in the ECM (Fig. 5-13). 
 
In order to assess the effect of PDK2 expression on collagen expression at the 
mRNA level, the fibroblasts were transfected as described above, with the 
addition of EP300 inhibition in the NFs and acetate treatment of the CAFs to 
reverse the effects of modulating PDK2 expression on H3K27 acetylation. The 
mRNA was extracted from the fibroblasts 48h after transfection with or without 
treatment, and the levels of COL1A1 and COL6A1 were assessed by RT-qPCR. In 
the NFs, siPDK2 increased collagen expression and this was reduced by c646 
treatment (Fig. 5-14a). Conversely, collagen mRNA levels were decreased by PDK2 
overexpression in CAFs and this was rescued with exogenous acetate (Fig 5-14b). 
Therefore PDH phosphorylation, as regulated by PDK2 expression, controls acetyl-
coA production to epigenetically regulate collagen production by CAFs. 
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a: Representative western blot and quantification of collagen VI levels in ECM 
derived from iNFs 48h after transfection with siCtl or siPDK2. b: Representative 
western blot and quantification of collagen VI levels in ECM derived from iCAFs 48h 
after transfection with PDK2-N255A or PDK2-WT. Graphs show mean and SEM of 6 
independent experiments. Significance was calculated using an unpaired student t-
test with Welch’s correction: *p≤0.05 
 
 
a b 
Figure 5-13 PDK2 expression regulates collagen production in fibroblasts 
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a: Levels of PDK2, COL1A1 and COL6A1 mRNA in iNFs 48h after transfection with 
siCtl or siPDK2 +/- 25 µM c646. The mRNA levels were measured by RT-qPCR and 
normalised to TBP2 mRNA. b: Levels of COL1A1 and COL6A1 mRNA in iCAFs 48h 
after transfection with PDK2-N255A or PDK2-WT +/- 2 mM acetate. mRNA levels 
were measured by RT-qPCR and normalised to TBP2 mRNA. Graphs show mean and 
SEM of 6 independent experiments. Significance was calculated using a one way 
ANOVA with Dunnett’s multiple comparisons test: *p≤0.05 
 
 
a 
b 
Figure 5-14 PDK2 expression regulates collagen mRNA in fibroblasts 
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5.5 Discussion 
 
The key finding of this chapter is that collagen production in CAFs is epigenetically 
regulated by histone acetylation, as measured by H3K27 acetylation, and that this 
in turn is regulated by the increase in acetyl-coA produced by upregulated PDH 
activity in CAFs. My proteomic analysis of proteins regulated by EP300 inhibition 
highlighted collagens as a key group of proteins whose expression correlated with 
EP300 activity, and I then demonstrated that EP300 activity does indeed regulate 
collagen expression both at the mRNA and protein level. This strongly suggests 
that collagen production is being controlled at the epigenetic level. I then 
connected collagen expression at the mRNA and protein level to acetyl-coA 
availability by pharmacologically controlling the pool of acetyl-coA in the cytosol 
and nucleus, further demonstrating that collagen expression in CAFs and NFs is 
dependent on acetyl-coA mediated histone acetylation. Finally, I showed that the 
increase in collagen expression and production in CAFs is dependent on PDH 
activity, thus linking for the first time metabolic regulation of acetyl-coA 
production to an epigenetic regulation of the CAF phenotype. 
 
The proteomic analysis of c646 treated CAFs clearly showed that collagens were 
a major group of proteins that were significantly downregulated by EP300 
inhibition, suggesting that they are under epigenetic control by histone 
acetylation. Other extracellular matrix proteins such as fibronectin, emilin and 
laminin were also downregulated, suggesting that there is a general 
downregulation of ECM production by c646. Another group of proteins that was 
downregulated by c646 was proteins related to cell adhesion and integrin 
signalling, including ITGB5, ITGAV, ITGA6, CDH6, CDH11 and IGTA11. Interestingly, 
ITGA11 is known to be a receptor for collagen and CDH11 has been implicated in 
regulating collagen synthesis (Row et al., 2016) (Fig. 5-15). It is possible that 
regulation of these two groups of proteins is connected, as if ECM production is 
decreased it makes sense to also decrease expression of proteins that bind to and 
respond to ECM proteins. A third group of proteins to be downregulated by EP300 
inhibition was proteins involved in collagen assembly (Fig. 5-16). This included 
PLOD1 and PLOD3, which are lysyl hydroxylases that convert lysine residues in 
collagen to hydroxylysine, enabling crosslinking of collagen fibres in the ECM. An 
increase in cross-linked collagen in the ECM of tumours leads to increased stiffness 
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of the tumour microenvironment, which has been shown to promote angiogenesis 
and metastasis. The prolyl hydroxylases P4HA2, P3H3 and P3H1 were also 
downregulated. Proline hydroxylation is a key part of collagen production and is 
critical for the correct folding and assembly of collagen. About half of all proline 
residues in collagen are modified to hydroxyproline. Indeed, proline is a vital 
amino acid for collagen production since one of the defining features of collagens 
is a tightly packed triple helix consisting of repeats of the Gly-X-Y motif. X and Y 
are most commonly proline or hydroxyproline, meaning that about 25% of collagen 
is comprised of proline or hydroxyproline residues. Interestingly the translation 
factor EIF5A, which is required for translation of polyproline sequences (Gutierrez 
et al., 2013, Doerfel et al., 2013) was also downregulated by c646 treatment. 
Additionally, the enzymes PYCR1 and OAT, which are involved in proline synthesis 
were downregulated by c646, with PYCR1 being one of the most highly 
downregulated proteins (Fig. 5-16). This suggested that proline production itself 
could be a limiting factor in collagen synthesis by CAFs, and I investigated this 
possibility further in the following chapter. Taken together, these proteomic data 
from the c646 treated fibroblasts show that collagen production is a major 
pathway regulated by histone acetylation in CAFs, since not only the collagen 
proteins but also proteins involved in collagen production and modification to 
promote its stability and structural assembly in the ECM were similarly regulated. 
 
Increased collagen and ECM production is one of the key aspects of the CAF 
phenotype. In fact, increased collagen production is a general feature of activated 
fibroblasts not only in the tumour microenvironment but also in fibrosis and in 
wound healing. In the context of cancer, the presence of collagen in the ECM 
drives tumour progression through a plethora of different pathways. It provides a 
substrate for integrin binding and downstream signalling to promote cell growth, 
acts as a reservoir for angiogenic factors, drives EMT and promotes focal adhesion 
assembly to drive cell migration. The finding that histone modification, and 
particularly H3K27 modification, is a driver of collagen production in fibroblasts is 
not a novel discovery. In fibroblasts in both cancer and other fibrotic diseases, 
collagen production has been shown to be epigenetically regulated. For example, 
BET inhibitors, which bind to BRD proteins and prevent them from binding to 
acetylated enhancer regions and activating transcription, have been shown to 
inhibit collagen production in pancreatic stellate cells. The BET inhibitors both 
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attenuated pancreatic fibrosis and decreased pancreatic tumour growth in a 
mouse model of pancreatic ductal adenocarcinoma (Kumar et al., 2017). H3K27 
trimethylation, the opposing modification to H3K27 acetylation, which decreases 
transcriptional activation, was shown to decrease collagen expression and 
fibroblast activation in sclerotic fibrosis (Kramer et al., 2013). Upregulated TGFβ 
signalling, which is one of the hallmarks of fibroblast activation, has been shown 
to alter histone methylation at the promoters of ECM related genes, including 
collagens, in fibroblasts (Sun et al., 2010). However, my work is the first study to 
link fibroblast metabolism with epigenetic regulation of aspects of the CAF 
phenotype, and particularly with collagen production. Most previous studies on 
CAF metabolism have focussed on how CAFs upregulated production and secretion 
of metabolites which can be taken up and used as fuel by the cancer cells. My 
results show that CAF metabolic rewiring is important for the CAFs themselves to 
maintain key aspects of their activated phenotype at the epigenetic level. 
 
Pharmacologically, targeting tumours at the epigenetic level has long been 
investigated as a line of treatment. Aberrant hypomethylation can drive the 
expression of oncogenes, and the presence of specific histone modifications can 
be a predictor of patient outcome. For example H3K4me was found to predict the 
recurrence of prostate cancer (Ellinger et al., 2010). DNA-methyltransferase 
inhibitors such as azacitadine and decitabine are effective in the treatment of 
some leukaemias. Azcitadine combined with histone deacetylase (HDAC) inhibition 
has also been shown to combat non-small cell lung cancer. My data show that 
epigenetic alterations are also an important feature of the tumour 
microenvironment, and should be taken into account when considering epigenetic 
therapies. In particular, HDAC inhibitors would also promote increased histone 
acetylation in the CAFs which, as I have shown, might increase collagen production 
which could then lessen the anti-tumour effects of the drug, either by hindering 
drug delivery or by its positive effects on tumour growth and metastasis. 
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Volcano plot showing the results of a two-tailed t-test comparing the proteomes of 
control and c646 treated iCAFs. Three independent experiments were included in 
the analysis.  Each dot represents a protein. Proteins above the black line were 
classed as significant (cut-off values: p=0.05, S0=0.1). All ECM and ECM adhesion 
proteins which were significantly downregulated by c646 treatment are highlighted 
in red.  
Figure 5-15 c646 downregulates ECM proteins 
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Volcano plot showing the results of a two-sample t-test comparing the proteomes 
of control and c646 treated iCAFs. Three independent experiments were included 
in the analysis.  Each dot represents a protein. Proteins above the black line were 
classed as significant (cut-off values: p=0.05, S0=0.1). All proteins relating to 
proline synthesis or collagen modification which were significantly downregulated 
by c646 treatment are highlighted in red. 
Figure 5-16 c646 downregulates proteins involved in proline and collagen synthesis 
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Chapter 6 6 Upregulated proline synthesis in CAFs 
promotes collagen production 
 
6.1 c646 regulates PYCR1 expression 
 
As mentioned in chapter 4, one of the few metabolites that was consistently 
regulated between CAFs and NFs was proline, which was upregulated in CAFs. I 
have also discussed how two enzymes involved in proline synthesis were 
downregulated in the proteome of c646 treated iCAFs: OAT and PYCR1. In 
particular, PYCR1 is known to be the rate limiting enzyme for proline synthesis 
and was one of the most highly downregulated proteins upon inhibition of EP300 
with c646. I therefore hypothesised that in addition to regulating collagen 
expression, the epigenetic control induced by PDH activity in CAFs could also be 
upregulating proline synthesis by increasing PYCR1 expression. Furthermore, 
proline makes up a significant proportion of the amino acids in collagen. Collagens 
are the most abundant proteins in the CAF ECM and most of them are among the 
top 334 proteins that make up 95% of CAF derived ECM as determined by MS-
proteomic analysis of iCAF ECM (Fig. 5-3). Therefore collagens provide a significant 
proportion of the total amount of proline in the ECM. Therefore it is possible that 
in order to support the increase in collagen production, CAFs need to increase 
proline production. In this chapter I investigated the regulation of PYCR1 
expression by PDH-mediated histone acetylation and its impact on proline and 
collagen synthesis. 
 
Firstly, I verified the results of the proteomic data by demonstrating that p300 
inhibition by c646 did indeed reduce PYCR1 expression. Expression of PYCR1 in 
lysates from CAFs treated with 25 µM c646 for 48h was examined at both the mRNA 
and the protein level. RT-qPCR for PYCR1 showed that c646 decreased PYCR1 
expression at the mRNA level (Fig. 6-1a), and western blot analysis showed that 
PYCR1 was also downregulated by c646 at the protein level and could therefore 
be regulated by the increase in histone acetylation in CAFs (Fig. 6-1b). 
Furthermore, PYCR1 and OAT were both upregulated in tumour associated stroma 
compared to normal stroma in microdissected sections of TNBC and normal stroma 
analysed in collaboration with Dr. Morag Park from McGill University, suggesting 
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that stromal PYCR1 expression  and proline synthesis is also relevant in a clinical 
setting (Fig. 6-2). Conversely, PRODH, the enzyme that degrades proline, was not 
upregulated. 
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a: PYCR11 mRNA levels in iCAFs treated for 48h with 25 µM c646 or DMSO control. 
mRNA levels were measured by RT-qPCR and PYCR1 mRNA was normalised to TBP2 
levels. b: Representative Western blot and quantification of PYCR1 levels in iCAFs 
treated for 48h with 25 µM c646 or DMSO control.  
 
Graphs show mean and SEM of at least 3 independent experiments. Significance 
was calculated using an unpaired Student t-test with Welch’s correction: *p≤0.05 
a 
b 
Figure 6-1 c646 reduces PYCR1 expression 
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PYCR1 and OAT mRNA expression in microdissected sections of stroma from normal 
and tumour associated stroma from triple negative breast cancer patients. Data was 
provided by Dr. Morag Park (McGill University). Error bars show mean and SEM. 
Significance was calculated using an unpaired student t-test: p≤0.05 *, p≤0.01 **, 
p≤0.001 *** 
 
Figure 6-2 Proline synthesis enzymes are upregulated in tumour-associated 
stroma 
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6.2 PYCR1 expression is regulated by acetyl-coA 
 
In order to determine whether the increase in PYCR1 expression in CAFs is 
regulated by the extra-mitochondrial pool of acetyl-coA, the CAFs were treated 
with the ACLY inhibitor BMS303141 for 48h to prevent export of acetyl-coA out of 
the mitochondria, and given exogenous acetate to replenish the cytosolic and 
nuclear pool of acetyl-coA. PYCR1 mRNA was downregulated by BMS303141 
treatment, and the expression of PYCR1 was restored by the acetate treatment as 
measured by RT-qPCR in both the iCAFs and the pCAF2s (Fig. 6-3a). Similarly, in 
the iCAFs, PYCR1 protein levels were decreased with the BMS303131 treatment 
and rescued by acetate when analysed by Western blot (Fig. 6-3b). Therefore the 
increase in PYCR1 mRNA also translated into an increase in PYCR1 protein, 
suggesting that this could have functional implications regarding proline 
production. 
 
To further show that the extra-mitochondrial pool of acetyl-coA controls PYCR1 
expression, iNFs and pNF2s were treated with 2 mM acetate for 48h. Acetate 
treatment was sufficient to increase PYCR1 expression at the mRNA level as 
determined by RT-qPCR (Fig. 6-4). Taken together, these data show that PYCR1 
expression at the mRNA level in both CAFs and NFs is dependent on the 
nucleocytosolic pool of acetyl-coA and is therefore likely to be under epigenetic 
regulation by histone acetylation.  
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a. PYCR1 mRNA expression measured by RT-qPCR in iCAFs treated for 48h with 50 µM 
BMS30141 ± 2 mM acetate. PYCR1 mRNA was normalised to TBP2. b. PYCR1 mRNA 
expression measured by RT-qPCR in pCAF2s treated for 48h with 50 µM BMS30141 ± 
2mM acetate. PYCR1 mRNA was normalised to TBP2. c. Representative Western blot 
and quantification of PYCR1 levels in iCAFs treated for 48h with 50 µM BMS30141 ± 2 
mM acetate. β-tubulin was used as a loading control. Molecular weight markers are 
shown next to the blots. 
 
Error bars show mean and SEM of ≥3 biological replicates. Significance was calculated 
using a one way ANOVA with Dunnett’s multiple comparisons test: p≤0.05 *, p≤0.01 
**, p≤0.001 *** 
 
a 
c 
b 
Figure 6-3 PCYR1 expression is regulated by extra-mitochondrial acetyl-coA 
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Figure 6-4 PCYR1 expression is regulated by extra-mitochondrial acetyl-coA 
a. PYCR1 mRNA expression measured by RT-qPCR in iNFs treated for 48h with 2 mM 
acetate. PYCR1 mRNA was normalised to TBP2. b. PYCR1 mRNA expression measured 
by RT-qPCR in pCAF2s treated for 48h with 2 mM acetate. PYCR1 mRNA was 
normalised to TBP2. 
 
Error bars show mean and SEM of 3 biological replicates. Significance was calculated 
using a Students’ t-test with Welch’s correction: p≤0.05 *, p≤0.01 **, p≤0.001 *** 
 
a b 
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6.3 PYCR1 expression is regulated by PDH activity 
 
To investigate the effect of PDH activity on PYCR1 expression in fibroblasts, I again 
modulated PDK2 expression in order to control PDH phosphorylation and thereby 
its activity. PDK2 expression was altered either by transfection of NFs with siCtl 
or siPDK2, or by transfection of CAFs with PDK2N255A or PDK2WT. To further tie PDH 
activity-induced PYCR1 expression to histone acetylation, I treated the siPDK2 
transfected NFs with c646 to reduce histone acetylation. Conversely I treated the 
PDK2 overexpressing CAFs with 2 mM acetate to replenish the intracellular pool of 
acetyl-coA and increase histone acetylation. 48h after transfection, the 
fibroblasts were lysed and the expression of PYCR1 was assessed by RT-qPCR. PDK2 
knockdown in the NFs to increase PDH activity increased PYCR1 expression at the 
mRNA level, and this was successfully reversed by c646 treatment (Fig. 6-5a). In 
the reverse, overexpression of PDK2 in the CAFs decreased PYCR1 expression at 
the mRNA level but acetate treatment rescued PYCR1 expression (Fig. 6-5b). This 
verified that PDH activity is an upstream regulator of PYCR1 expression, and that 
the increase in acetyl-coA and histone acetylation produced by PDH in CAFs is 
required for the increase in PYCR1 expression. 
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a. PYCR1 mRNA expression measured by RT-qPCR in iNFs 48h after transfection with 
siCtl or siPDK2 ± 25 µM c646 treatment. PYCR1 mRNA was normalised to TBP2. b. 
PYCR1 mRNA expression measured by RT-qPCR in iCAFs 48h after transfection with 
PDK2N255A or PDK2WT ± 2 mM acetate treatment. PYCR1 mRNA was normalised to TBP2. 
 
Error bars show mean and SEM of 3 biological replicates. Significance was calculated 
using a one way ANOVA with Dunnett’s multiple comparisons test: p≤0.05 *, p≤0.01 
**, p≤0.001 *** 
 
a b 
Figure 6-5 PYCR1 expression is regulated by PDK2 levels 
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6.4 PYCR1 expression regulates proline production 
 
6.4.1 PYCR1 knockdown reduces intracellular proline 
 
Although I had shown that expression of PYCR1 was upregulated by PDH activity 
in CAF, I had not yet shown that PYCR1 expression affected the intracellular 
proline levels. As discussed in Chapter 4, CAFs have more total intracellular 
proline than NFs, and, using 13C-labelled metabolites, I showed that in the 
fibroblasts proline is mainly derived from glutamine via the TCA cycle. Therefore, 
using the pCAF2s, I created shCtl and shPCYR1 cell lines via lentiviral transduction 
with five different shPYCR1 constructs. The level of PYCR1 knockdown in lysates 
of the shPYCR1 cell lines was assessed both by RT-qPCR and by Western blot. Two 
out of the five shRNAs against PYCR1 successfully knocked down PYCR1 expression 
by around 70% at the mRNA level and 50% at the protein level compared to the 
shCtl CAFs: henceforth called shPYCR1-a and shPCYR1-b (Fig. 6-6a, b). I therefore 
used these two cell lines for future experiments. To determine whether the 
shPYCR1 cell lines reduced proline production, the intracellular metabolites from 
shCtl and shPYCR1 cells were harvested and analysed by LC-MS. The total amount 
of intracellular proline was calculated by normalising the peak area to the protein 
content of the cells. Both shPYCR1 cell lines produced significantly less proline 
than the shCtl cells, demonstrating that PYCR1 activity is required to maintain 
intracellular proline levels in CAFs (Fig. 6-6c).  
 
There is another pyrroline-5-carboxylate reductase: PYCR2, which shares 84% 
homology with PYCR1. PYCR2 was not among the proteins regulated by c646 in the 
proteomic data, but in order to demonstrate that it does not compensate for the 
reduction in PYCR1 expression, I also assessed the expression of PYCR2 mRNA in 
the shPYCR1 and shCtl CAFs by RT-qPCR (Fig. 6-7). PYCR2 was not upregulated in 
the shPYCR1 cells, in fact it was also downregulated, showing that it is not acting 
as a compensatory mechanism. 
 
 
To further demonstrate that PYCR1 expression controls proline production, the 
CAFs were transfected with either siCtl or siPYCR1. The efficacy of the siPYCR1 
knockdown was determined by RT-qPCR and significantly reduced PYCR1 mRNA 
211 
 
48h after transfection. The intracellular metabolites were then harvested and 
analysed by LC-MS. The total amount of intracellular proline was calculated by 
normalising the peak area to the protein content of the cells. siPYCR1 also 
significantly reduced proline production by the CAFs (Fig. 6-8).  
 
6.4.2 Acetyl-coA regulates proline production 
 
In order to link proline production to upregulation of PYCR1 expression by acetyl-
coA dependent histone acetylation, I treated the iCAFs with the ACLY inhibitor 
BMS303131 with or without 2 mM acetate for 48h, which I previously showed 
regulates both H3K27 acetylation and PYCR1 expression. The intracellular 
metabolites were then harvested and analysed by LC-MS. The total amount of 
intracellular proline was calculated by normalising the peak area to the total 
protein content of the cells. BMS303141 reduced the amount of proline in the cells 
and this was rescued by the acetate treatment, showing that the extra-
mitochondrial pool of acetyl-coA regulates proline production in CAFs (Fig. 6-9). 
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 a. PYCR1 mRNA expression measured by RT-qPCR in shCtl and shPYCR1 CAFs. PYCR1 
mRNA was normalised to TBP2. b. Western blot and quantification of PYCR1 levels in 
shCtl and shPYCR1 CAFs. β-tubulin was used as a loading control. Molecular weight 
markers are shown next to the blots. c. Total proline in shCtl and shPYCR1 cell lines 
measured by LC-MS and normalised to total proline content. 
 
Error bars show mean and SEM of 3 biological replicates. Significance was calculated 
using a one way ANOVA with Dunnett’s multiple comparisons test: p≤0.05 *, p≤0.01 
**, p≤0.001 *** 
 
a 
b 
c 
Figure 6-6 Proline synthesis is regulated by PYCR1 expression 
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PYCR2 mRNA expression measured by RT-qPCR in shCtl and shPYCR1 CAFs. PYCR2 
mRNA was normalised to TBP2.  
 
Error bars show mean and SEM of 3 biological replicates. Significance was calculated 
using a one way ANOVA with Dunnett’s multiple comparisons test: p≤0.05 *, p≤0.01 
**, p≤0.001 *** 
 
Figure 6-7 PYCR2 does not compensate for PYCR1 
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a. PYCR1 mRNA expression measured by RT-qPCR in iCAFs 48h after transfection with 
siCtl or siPYCR1. PYCR1 mRNA was normalised to TBP2. b. Total proline in iCAFs 48h 
after transfection with siCtl or siPYCR1 measured by LC-MS and normalised to total 
protein content. 
 
Error bars show mean and SEM of ≥3 biological replicates. Significance was calculated 
using a student’s t-test with Welch’s correction: p≤0.05 *, p≤0.01 **, p≤0.001 *** 
 
a b 
Figure 6-8 Proline synthesis is regulated by PYCR1 expression 
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Total proline in iCAFs treated for 48h with 50 µM BMS30141 ± 2mM acetate measured 
by LC-MS and normalised to total protein content. 
 
Error bars show mean and SEM of 4 biological replicates. Significance was calculated 
using a one way ANOVA with Dunnett’s multiple comparisons test: p≤0.05 *, p≤0.01 
**, p≤0.001 *** 
 
Figure 6-9 Proline synthesis is regulated by acetyl-coA levels 
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6.5 PYCR1 produces proline for collagen production 
 
As I had demonstrated that PYCR1 expression does indeed control proline synthesis 
in cells, I then sought to assess whether, as I had hypothesised, this had a 
significant impact on collagen production by the fibroblasts. I wanted to show 
specifically that proline produced by PYCR1 is incorporated into collagen. Since 
PCYR1 produces proline from glutamate, we hypothesised that by giving the CAFs 
heavy glutamine we would be able to detect the incorporation of heavy proline 
into collagen. I therefore seeded the shCtl and shPYCR1 CAFs at confluence and 
cultured them with medium containing either 12C-glutamine or 13C-glutamine for 
72h. I then decellularised the ECM and lysed it. I separated the ECM proteins on 
an SDS-page gel and cut each sample into 3 bands, which I then processed by in-
gel digestion for MS-proteomic analysis. Sergio Lilla in the Proteomics Facility then 
carried out the data acquisition and analysis using the MaxQuant computational 
platform to determine the incorporation of heavy proline residues into peptides 
from ECM proteins. As a proof of principle, we focussed on peptides from COL1A1 
for the analysis, because it is highly abundant in the samples. I then compared the 
LFQ intensities of heavy labelled COL1A1 peptides in shCtl and shPYCR1 ECMs. For 
this analysis, I only considered peptides in which just proline residues were 
labelled, since glutamine can be used to produce many amino acids. Furthermore 
I only considered peptides in which all the proline residues were labelled to avoid 
complications due to different combinations of sites being quantified. Four 
quantified peptides fit these criteria. The 13C-proline containing peptides had a 
high intensity in the 13C-labelled samples while they were not detected in the 
unlabelled control, demonstrating that proline produced from glutamate via 
PYCR1 is used to produce collagen (Fig. 6-10a). Furthermore all of the peptides 
showed a decreased intensity in the shPCYR1 samples compared to the shCtl 
samples, again showing that proline produced by PYCR1 is required for collagen 
production in CAFs (Fig. 6-10b). 
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 a: Comparison of LFQ intensities for the 
13C-proline labelled COL1A1 peptides between 
heavy labelled and unlabelled shCtl CAF-derived ECM. There is a significant 
incorporation of 13C-glutamine-derived proline into collagen in the labelled shCtl CAFs. 
b: Comparison of LFQ intensities of 13C-proline labelled COL1A1 peptides between shCtl 
and shPCYR1 CAF-derived ECM.  
Graphs show mean and SEM of 3 biological replicates. Significance was calculated using 
a Students t-test with Welch’s correction: p≤0.05 * p≤0.01 **, p≤0.001 *** 
 
a 
b 
Figure 6-10 PCYR1 produces proline for collagen synthesis 
218 
 
6.6 PYCR1 regulates collagen production 
 
I have shown that PYCR1 expression affects both proline synthesis and proline 
incorporation into collagen in CAFs; next, I wanted to investigate whether this 
affected the total amount of collagen produced by the fibroblasts. The shCtl, 
shPYCR1-a and shPYCR1-b CAFs were seeded at confluence and cultured for seven 
days to produce ECM. Additionally, the shPYCR1 were treated with 500 µM proline 
in order to rescue the effects of shPYCR1 loss on proline production. The ECM was 
then decellularised, and subsequently harvested and analysed by Western blot for 
collagen VI. shPYCR1 significantly reduced collagen VI in the ECM, and this could 
be rescued with the exogenous proline (Fig. 6-11). 
 
To confirm that PYCR1 levels regulated collagen accumulation in the ECM, I also 
transfected iCAFs with siCTL or siPYCR1 to acutely downregulate PYCR1, and the 
siPYCR1 transfected CAFs were further treated with 500 µM proline. 72h after 
transfection, the cells were removed and the ECM harvested and analysed by 
Western blot. As with the shRNAs against PYCR1, siPYCR1 decreased the amount 
of collagen VI in the ECM and this was rescued by treating the cells with proline 
(Fig. 6-12). 
 
To further demonstrate that collagen production by CAFs was dependent on 
proline levels produced by PYCR1, the shCtl and shPYCR1 CAFs were cultured at 
confluence on coverslips for seven days with or without proline treatment, 
following which the collagen in the ECM was stained with CNA35-mCherry. The 
cells were then fixed and counterstained with DAPI before being imaged (Fig. 6-
13). The intensity of the collagen staining was quantified using ImageJ software, 
and clearly demonstrated a decrease in the amount of collagen produced by the 
shPYCR1 cells, which was then rescued by the addition of extracellular proline. 
Therefore the production of collagen in CAFs is proline dependent, and relies on 
the expression of PYCR1. 
 
To finally link PDH activity to both proline production and collagen synthesis via 
PYCR1, the iNFs were transfected with siCtl, siPDK2 or both siPDK2 and siPYCR1. 
72h after transfection, the cells were removed, leaving the ECM intact and the 
ECM was harvested and analysed by Western blot. As demonstrated before, siPDK2 
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was sufficient to increase collagen VI levels in the NF derived ECM, however, the 
additional silencing of PYCR1 reduced the collagen VI levels back to those in the 
ECM from the siCtl cells (Fig. 6-14). This experiment showed that the proline 
produced by PYCR1 is required to support the increase in collagen production that 
is stimulated by the upregulated PDH activity following silencing of PDK2. 
Therefore collagen production in CAFs is regulated by a twofold metabolic 
pathway. First, upregulated PDH activity leads to an increase in acetyl-coA which 
is used to increase histone acetylation levels and in particular the transcription 
activation marker H3K27ac. This leads to an upregulation in transcription of 
collagen genes, but in order to provide sufficient amino acids for the translation 
of collagen mRNA an increase in proline synthesis is required. This is achieved by 
simultaneously upregulating PYCR1 expression via the increase in PDH-dependent 
histone acetylation. 
 
220 
 
 
Representative Western blot and quantification of collagen VI in ECM derived from 
shCtl CAFs compared to shPYCR1-a and shPYCR1-b CAFs ± 500 µM proline. Molecular 
weight markers are shown next to the blot. 
 
Error bars show mean and SEM of ≥3 biological replicates. Significance was calculated 
using a one way ANOVA with Dunnett’s multiple comparisons test: p≤0.05 *, p≤0.01 
**, p≤0.001 *** 
 
Figure 6-11 Collagen production is regulated by PCYR1 expression 
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Representative Western blot and quantification of collagen VI in ECM derived from 
CAFs 72 after transfection with siCtl or siPYCR1 ± 500 µM proline. Molecular weight 
markers are shown next to the blot. 
Error bars show mean and SEM of 4 biological replicates. Significance was calculated 
using a one way ANOVA with Dunnett’s multiple comparisons test: p≤0.05 * 
 
Figure 6-12 Collagen production is regulated by PYCR1 expression 
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Representative images and quantification of collagen produced over 5 days by shCtl 
and shPYCR1-b CAFs ± 500 µM proline. Collagen was stained with CNA35-mCherry 
and nuclei were stained with DAPI. Images were acquired using a Zeiss 710 at 20x 
magnification and the staining density was calculated using ImageJ software and 
normalised to cell number. Graph shows mean and SEM of 4 independent 
experiments. Significance was calculated using a one way ANOVA with Dunnett’s 
multiple comparisons test: *p≤0.05 
Figure 6-13 Collagen production is regulated by PYCR1 expression 
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Representative Western blot and quantification of collagen produced by iNFs 72h 
after transfection with siCtl, siPDK2 or siPDK2 and siPYCR1. Molecular weight 
markers are shown next to the blot. Graph shows mean and SEM of 4 independent 
experiments. Significance was calculated using a one way ANOVA with Dunnett’s 
multiple comparisons test: *p≤0.05 
Figure 6-14 PYCR1 is required for PDH activity-induced collagen production 
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6.7 in vivo co-transplantation of CAFs and 
MCF10DCIS.com cells 
 
In order to validate our findings in vivo I investigated the effect of PYCR1 
knockdown in CAFs on collagen production and tumour growth. MCF10DCIS.com 
cells were coinjected subcutaneously with either the shCtl or shPYCR1-b pCAF cell 
lines into Balb-C nude mice, with a ratio of CAFs to cancer cells at 3:1. Twelve 
mice were used for each condition. After two weeks, when the tumours started 
increasing size, half of the mice from each group were culled and the tumours 
were harvested. We took the tumours at such an early timepoint because, based 
on the experience of our group (Hernandez-Fernaud et al., 2017) the human CAFs 
are eventually overtaken by the murine stroma and we wanted to be sure that any 
effects on the tumours were due to the CAFs which we had transplanted. Even at 
the two week timepoint, there was already a significant reduction in tumour size 
in the mice that had been injected with the shPYCR1 CAFs (Fig. 6-15). I then fixed 
the tumours in 4% PFA and sliced them into 400 µm sections using a vibratome. 
The CAFs were GFP positive and were therefore easily detected using fluorescent 
microscopy. Z-stacks of the tissues were acquired using multi-photon microscopy 
with single harmonic generation imaging to visualise the collagen. Since collagen 
can be also produced by cancer cells, or by fibroblasts from the mice that had 
infiltrated the tumour, to assess whether shCtl and shPYCR1 CAFs deposited 
different amounts of collagen, I quantified only the collagen surrounding the GFP 
positive CAFs. There was significantly less collagen surrounding the shPYCR1 CAFs 
compared to the shCtl CAFs, which provides initial support to my hypothesis that 
PYCR1 knockdown also reduces collagen production in vivo (Fig. 6-16a). Although 
the amount of GFP positive fibroblasts remaining varied between tumours, there 
was no overall decrease in the area of GFP positive CAFs in the shPCYR1 tumours 
compared to the shCtl tumours, suggesting that the difference in collagen 
production is not due to an increase in cell death or decrease in proliferation 
caused by the PYCR1 knockdown (Fig. 6-16b). The remaining mice were allowed 
to reach endpoint before being culled, however there was no significant 
difference in the time take to reach endpoint between the tumours containing 
shCtl and shPYCR1 CAFs, probably because by this point the murine fibroblasts had 
completely taken over from the pCAFs. 
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Tumour weight of MCF10DCIS.com xenografts containing shCtl or shPYCR1 CAFs taken two 
weeks after injection. Graph shows mean and SEM of 6 tumours from one experiment. 
Significance was calculated using a Students t-test with Welch’s correction: p≤0.05 * 
Figure 6-15 Stromal PYCR1 promotes tumour growth 
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a 
a: Representative images and quantification of the proportion of the area of GFP positive CAFs 
that is also positive for collagen in sections of xenografts containing shCtl or shPYCR1 CAFs. b: 
Quantification of the average CAF area in the images used for a. 
Graphs show mean and SEM of at 3 biological replicates. Z-stacks of at least two areas from 
each tumour were acquired using a Zeiss 880 and each plane was analysed separately and the 
average taken.  
Significance was calculated using a Students t-test with Welch’s correction 
b 
Figure 6-16 PCYR1 promotes collagen production in vivo 
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6.8 Discussion 
 
In this chapter I investigated the link between proline synthesis and collagen 
production. Collagen is a significant proportion of the protein output of CAFs, and 
is a vital component of the ECM. Proline and hydroxyproline together constitute 
about 25% of the amino acids in collagen. Therefore when I found that firstly the 
amount of intracellular proline was higher in CAFs than in NFs and secondly that 
PYCR1, the rate limiting enzyme for proline synthesis was also upregulated in CAFs 
and was regulated by c646 suggesting that it was under the control of histone 
acetylation, I hypothesised that the upregulation of PYCR1 drives an increase in 
proline production that can be used to support the translation of collagen. 
Although some studies have correlated the proline synthetic pathway with ECM 
production in the genetic disorder cutis laxa (Skidmore et al., 2011, Liang et al., 
2019), until now there has not been an in depth investigation into whether proline 
production by PYCR1 affects collagen production. 
 
It is interesting to note that in the MS-proteomics experiment with c646 treated 
iCAFs, several genes related to proline were regulated, including OAT, which 
catalysed the first step in proline synthesis from ornithine, and EIF5A, which 
enables polyproline regions of mRNA to be translated. Therefore PYCR1 may not 
be the only enzyme relating to proline production or incorporation of proline into 
collagen to be under epigenetic control in CAFs. However, as PYCR1 is the rate 
limiting enzyme in proline synthesis, it is likely to play the most significant part 
in this process. 
 
I first demonstrated that PYCR1 is under control of the same pathway as collagen 
proteins in CAFs. This is the first time that acetyl-coA and proline production have 
been connected, and demonstrates the importance of acetyl-coA as a central 
metabolite in regulating diverse pathways. I verified using pharmacological 
inhibitors that EP300 activity does regulate PYCR1 expression in CAFs, and that 
PYCR1 expression is also regulated by the pool of extra-mitochondrial acetyl-coA. 
PYCR1 was regulated both at the mRNA and at the protein level, implying that 
there is an increase in PYCR1 transcription and therefore that PYCR1 expression 
may also be epigenetically regulated. Finally, I showed that PYCR1 expression is 
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also regulated by the activity of PDH, which again corroborates my previous results 
showing that PDH activity controls the levels of intracellular acetyl-coA and 
histone acetylation. I then demonstrated that PYCR1 expression does indeed 
control intracellular proline levels. Furthermore, intracellular proline was also 
regulated by the extra-mitochondrial pool of acetyl-coA. Therefore production of 
acetyl-coA regulates production of proline by regulating PYCR1 expression through 
increased histone acetylation. 
  
I then investigated whether the two pathways of proline synthesis and collagen 
production are connected, and indeed I demonstrated that collagen levels in 
fibroblast-derived ECM were regulated by PYCR1 expression. Collagen production 
was rescued by treating the cells with exogenous proline, showing that it is 
specifically proline availability that regulates collagen production. Furthermore, 
PYCR1 was required for PDH activity-induced collagen production, showing that 
PYCR1 is downstream from PDK2 and PDH activity in the process of collagen 
synthesis. Therefore, although PDH activity may cause increased transcription of 
collagen genes, the increased proline produced by PYCR1 is necessary to produce 
the collagen protein.  
 
The final question of this thesis was whether PYCR1 activity could limit collagen 
production in vivo and whether or not this would have an impact on tumour 
progression. Xenografts of the human breast cancer cell line MCF10DCIS.com and 
CAFs expressing shCtl or shPYCR1 showed that tumours with shPYCR1 CAFs grew 
more slowly and that the shPYCR1 CAFs produced less collagen in vivo as well as 
in vitro. Therefore targeting PYCR1 expression has a positive effect on inhibiting 
the tumour stroma as well as tumour cells, and targeting PYCR1 in patients would 
be an effective way to metabolically target both tumour and stroma 
simultaneously. Previously, targeting the tumour stroma has been considered a 
separate endeavour from targeting tumour cells, with combination therapies to 
target tumour and stroma separately. This is especially true in the context of 
metabolism, where many studies have focussed on tumour cells and CAFs having 
opposing but complimentary metabolism, making targeting tumour metabolism 
difficult without conversely activating CAFs or vice versa (Guido et al., 2012, 
Martinez-Outschoorn et al., 2010b, Yang et al., 2016). However, this research has 
provided a target that is relevant both in tumour and in stroma, at least in breast 
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cancer. Furthermore, the decrease in fibrosis caused by targeting stromal PCYR1 
could increase delivery and uptake of other chemotherapies, since high collagen 
density in the TME has been shown to impede drug delivery due to increased 
interstitial pressure and blood vessel compression (Netti et al., 2000, Chauhan et 
al., 2013) 
 
A connection between PYCR1 and collagen production has been demonstrated 
before, although not specifically in CAFs. A recent study showing that PYCR1 
expression is regulated by mechanotransduction through Kindlin-2 in lung 
adenocarcinoma also showed that when kindlin-2 expression was ablated in the 
lungs, there was a decrease in collagen and fibrosis in tumours, and a decrease in 
α-SMA positive CAFs. This suggests that PYCR1 is also required for CAF 
functionality (Guo et al., 2019). However, the study focussed on the role of PYCR1 
in the cancer cells. Whether there was a direct connection between proline 
produced by PYCR1 in CAFs and collagen was unexplored, and would be more 
difficult to prove given that the reduction in the overall number of activated CAFs 
could account for the decrease in collagen in the tumours.  
 
One question that must be addressed is the relevance of the link between proline 
and collagen synthesis in the context of a tumour, since proline is present in serum 
and I have been conducting my experiments in media that does not contain 
proline, with the exception of the SILAC media. Therefore CAFs may not 
experience so great a need to produce proline in the context of a tumour. 
However, the tumour microenvironment is frequently deficient in various 
nutrients due to the leaky vasculature of the TME and also the high demand of the 
cancer cells for nutrients to fuel their continual proliferation. Therefore it is 
reasonable to suppose that proline may be limited in the TME. In support of this, 
it has been shown that cancer cells take up and degrade collagen from the TME to 
provide them with a source of proline, showing that they require more proline 
than they can source from their blood supply (Olivares et al., 2017). Furthermore, 
the abundance of studies showing that PYCR1 is upregulated in cancer cells and is 
required for tumour progression also suggests that proline is limited in the TME 
(Cai et al., 2018, Ding et al., 2017, Hollinshead et al., 2018). From my own in vivo 
experiment, although some of the collagen in the tumours was produced by 
endogenous stroma, quantification of collagen surrounding the transplanted CAFs 
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suggested PYCR1 expression was a limiting factor for collagen production by CAFs 
in the tumour. This further suggests that CAFs are not able to uptake sufficient 
proline from the TME to meet their needs, although I did not quantify proline 
production by these cell lines in vivo.  
 
Since PYCR1 has been shown to be upregulated in many types of tumour, another 
question is whether PYCR1 and proline synthesis is also upregulated in the stroma 
of different types of tumour, since in my PhD I have focussed solely on mammary 
CAFs. We analysed two previously published transcriptome datasets of ovarian 
fibroblasts. In laser capture microdissected stroma from ovarian cancer tissue 
compared to normal fibroblasts (Leung et al., 2014) both PYCR1 and ALDH18A1, 
which is also involved in proline synthesis from glutamate, were upregulated (Fig. 
6-17). OAT, which is involved in proline synthesis from ornithine, was not 
upregulated however, suggesting that the glutamate pathway is more prominent. 
Similarly, transcriptome profiling of TGF-β treated and normal ovarian fibroblasts 
showed upregulation of PYCR1 and ALDH18A1, but not OAT (Fig. 6-18) (Yeung et 
al., 2013). Therefore upregulation of proline synthesis in the stroma is not 
confined to mammary CAFs and could be a more universal pathway to support 
collagen synthesis in CAFs. In the future, it would be useful to investigate PYCR1 
expression in the stroma of more types of tumour with a high stromal content, 
such as PDAC, in order to find out how universal this pathway is and also to further 
stratify which tumours might benefit from treatments targeting PYCR1 to reduce 
fibrosis. 
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Graph shows normalised expression of genes involved in proline synthesis between 
normal and tumour associated fibroblasts isolated from ovarian tissue samples by 
laser capture microdissection. Significance was calculated using a Students t-test 
with Welch’s correction: p≤0.05 *, p≤0.01 **, p≤0.001 *** 
Figure 6-17 Proline synthesis pathway is upregulated in ovarian stroma 
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Graph shows normalised expression of genes involved in proline synthesis between 
control and TGF-β treated ovarian fibroblasts. Significance was calculated using a 
students t-test with Welch’s correction: p≤0.05 *, p≤0.01 **, p≤0.001 *** 
Figure 6-18 Proline synthesis pathway is upregulated in TGF-B treated 
fibroblasts 
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Chapter 7 7 Discussion and Future work 
 
7.1 Discussion 
 
In this thesis I investigated the vital role of metabolism in the maintenance of the 
pro-tumourigenic phenotype in mammary CAFs. Specifically, I showed how CAF 
metabolism influences collagen production, which is a major output of CAFs in the 
TME. Collagen has long been known to play an important role in breast cancer. At 
the clinical level, breast tumours with a high collagen content have a poorer 
prognosis (Conklin et al., 2011, Kauppila et al., 1998). Collagens promote tumour 
growth and metastasis, and induce solid stress that impedes drug delivery to 
tumours (Provenzano et al., 2008, Netti et al., 2000, Kaushik et al., 2016). Indeed, 
targeting fibrotic collagen production with angiotensin inhibition improved 
chemotherapy delivery and reduced hypoxia in breast and pancreatic cancer 
models (Chauhan et al., 2013). Therefore targeting collagen production in breast 
cancer and other tumour types with a desmoplastic TME would be an effective 
way to target tumour growth and metastasis, as well as improving the efficiency 
of conventional anti-cancer therapies. Since CAFs are the major source of collagen 
in the TME, they are most promising target to reduce collagen in tumours. In this 
work, using an unbiased approach, I discovered metabolic pathways supporting 
collagen production in CAFs. Specifically, I uncovered two distinct, but connected, 
metabolic pathways that support collagen synthesis by CAFs: acetyl-coA synthesis 
by PDH and proline synthesis by PYCR1. PDH-derived acetyl-coA controls collagen 
transcription through epigenetic regulation, and PYCR1 supports collagen 
production by providing building blocks for its translation into protein (Fig. 7-1). 
The two metabolic pathways that I have identified as regulators of collagen 
production in CAFs both provide possibilities for developing new ways to 
therapeutically target collagen production by CAFs to inhibit the formation of a 
fibrotic TME. This has the potential to reduce the pro-tumourigenic functions of 
the TME and improve tumour perfusion. 
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Figure 7-1 Working model 
Increased PDH activity leads to increased acetyl-coA production in CAFs. Acetyl-coA 
is exported out of the mitochondria via citrate, and is converted back to acetyl-coA 
by ACLY. In the nucleus, acetyl-coA is used for histone acetylation, leading to 
increased transcription of collagen genes. Simultaneously, PYCR1 expression is also 
upregulated, enabling increased proline production. Proline is then used to support 
translation of collagen mRNA, and collagen is secreted into the ECM to create a pro-
tumourigenic, desmoplastic stroma. 
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I used two models of mammary CAFs and NFs for my research: the iCAFs/iNFs and 
pCAFs/pNFs. Whereas the iCAFs were activated from immortalised NFs isolated 
from a healthy individual by an in vivo co-culture with cancer cells, the pCAFs and 
pNFs were derived separately from breast cancer patient tissue samples. All the 
fibroblasts were immortalised with hTERT (Calvo et al., 2013) to enable in depth 
characterisation without them becoming senescent. Collagen production and high 
levels of aSMA expression are defining features of the activated, myofibroblast 
phenotype (Ronnov-Jessen and Petersen, 1993). My group has previously shown 
that the iCAF have a myofibroblast phenotype and I ensured that the pCAFs 
recapitulated the myofibroblast phenotype by monitoring their αSMA expression. 
All the CAFs expressed high levels of αSMA compared to the NFs, showing that they 
were activated. Further functional characterisation of the fibroblasts carried out 
by other members of the lab has shown that the CAF secretome is more pro-
invasive and pro-angiogenic than their paired NFs, further supporting that both 
the iCAFs and pCAFs are relevant models of the activated, myofibroblast 
phenotype. 
 
The first key finding of my thesis was that PDH phosphorylation at key regulatory 
sites is reduced in CAFs. I found this was due to the reduced expression of the 
kinase PDK2 in CAFs. As a consequence of its reduced phosphorylation, PDH was 
more active in CAFs. Moreover, by increasing or decreasing PDK2 expression in 
CAFs and NFs I could regulate PDH phosphorylation and acetyl-coA production, 
thus showing that, although other PDKs can phosphorylate PDH, PDK2 alone is an 
important regulator of PDH activity in fibroblasts. The role of PDKs and PDH have 
largely been unexplored in CAF metabolism, despite PDH being a central metabolic 
enzyme connecting glycolytic, oxidative and lipid metabolism. A comparison of 
metabolic protein levels by IHC staining in lung tumour and stromal cells showed 
that PDK expression was low and PDH expression high in stromal cells compared 
to the tumour cells (Koukourakis et al., 2014). A further study from the same group 
showed that PDH expression, but not phosphorylation, is upregulated in fibroblasts 
upon co-culture with lung tumour cells (Koukourakis et al., 2017).  While this is 
slightly different from the results from my mammary fibroblasts, in which PDH 
expression is unchanged but the phosphorylation is decreased in CAFs, the end 
result is still that PDH is more active in CAFs. However, neither of these studies 
investigated the functional consequences of PDH activity in the lung stroma. 
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Therefore, the discovery that PDH activity was upregulated in mammary CAFs 
opened up many questions regarding how CAFs might use the resulting acetyl-coA 
to rewire their metabolism or alter protein acetylation levels. 
 
Extensive metabolic profiling and mitochondrial characterisation of the CAFs and 
NFs did not immediately reveal differentially regulated pathways that might be 
affected by PDH activity. Surprisingly, there was no evidence that PDH activity 
affected TCA cycle flux. In proliferating fibroblasts compared to quiescent 
fibroblasts, it has been shown that there is a decrease in citrate conversion to 
alpha-ketoglutarate due to decreased IDH expression, and that citrate is 
preferentially exported to the cytosol (Lemons et al., 2010). IDH3 expression has 
also been found to be downregulated in prostate CAFs, which could further 
exacerbate TCA cycle truncation (Zhang et al., 2015). This is in accordance with 
my metabolic tracing experiments, in which I saw that in CAFs and NFs, which are 
both proliferative, glucose was incorporated into citrate but then was 
incorporated at a much lower ratio into other TCA cycle metabolites. Glutamine 
is then the main source of TCA cycle metabolites, although there was still 
evidence of a lack of transmission of labelled carbon atoms from citrate to α-
ketoglutarate and of some backwards flux from α-ketoglutarate to citrate (citrate 
+5 labelled) when cells were labelled with 13C-glutamine (Fig 4-10). Both CAFs and 
NFs clearly have a truncated TCA cycle, and the increased PDH activity in CAFs 
exacerbated this effect. CAFs contained significantly higher levels of intracellular 
citrate than NFs, yet this difference was not reflected in the levels of other TCA 
cycle metabolites. Furthermore, the increase in citrate in CAFs was also not 
reflected in total cholesterol levels or fatty acid synthesis. Instead, MS analysis of 
the global acetylome of CAFs and NFs suggested that the acetyl-coA produced by 
PDH may be used as an epigenetic regulator to increase histone acetylation. Many 
histone sites were more acetylated in CAFs, but of these H3K27 was the only site 
annotated with a known regulatory function: as a potent activator of transcription 
(Raisner et al., 2018). Since histone acetylation is known to be a general indicator 
of active transcription, I cannot exclude that the other identified acetylated 
histone sites also play a role in regulating gene expression in CAFs. For example, 
H3K18 and H3K23, both of which are also known to be regulated by EP300 and are 
associated with active transcription, were also more acetylated in CAFs. Further 
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investigation into deciphering the histone code is required to uncover the specific 
role of these acetylation sites.  
 
It may therefore be that in proliferating fibroblasts, the mechanism of channelling 
PDH-produced acetyl-coA into the cytoplasm and thence to the nucleus via citrate 
to maintain histone acetylation is shared between CAFs and NFs due to the 
truncated TCA cycle. However, in CAFs this is more pronounced by upregulating 
PDH activity to increase histone acetylation. Furthermore, there is some evidence 
that the levels of nucleocytosolic acetyl-coA influence the site specificity of EP300 
to alter histone acetylation patterns (Henry et al., 2014, Henry et al., 2013). 
Therefore in addition to increasing overall histone acetylation, the increased 
acetyl-coA in CAFs could also regulate which histone sites are more acetylated. 
 
In my thesis I directly connected mitochondrial acetyl-coA production by PDH with 
histone acetylation. Previous works showing that intracellular acetyl-coA levels 
induce histone acetylation have focussed on the synthesis of acetyl-coA in the 
nucleus from acetate or from nuclear PDH rather than mitochondrial PDH 
(Sutendra et al., 2014, Sivanand et al., 2018, Choudhary et al., 2014). The role of 
mitochondrial PDH has previously been studied for the most part as a metabolic 
gatekeeper linking glycolytic, oxidative and lipid metabolism (Randle, 1986, 
Saunier et al., 2016). PDH activity does not affect these metabolic pathways in 
CAFs and NFs, at least when kept in normal culture conditions, so while this is 
undoubtedly a vitally important function of PDH in many cell types, it does not 
appear to have a prominent role in my mammary CAFs. Mitochondrial acetyl-coA 
has been shown to contribute to protein acetylation in the mitochondria (Baeza 
et al., 2016), but whether mitochondrial PDH activity impacts acetylation of 
proteins outside of the mitochondria has not been largely explored. This is perhaps 
surprising given that it is well-known that acetyl-coA can be exported out of the 
mitochondria and it has been shown to impact cytoplasmic metabolic pathways, 
such as lipid synthesis (Mahmood et al., 2016). Indeed, ACLY, which is crucial for 
export of acetyl-coA from the mitochondria has been shown to play an important 
role in protein acetylation (Wellen et al., 2009, Kinnaird et al., 2016). My work 
therefore shows that protein acetylation and in particular histone acetylation 
should be considered along with cellular metabolism during future research into 
the role of PDH in cells. This is especially important when IDH activity is decreased 
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since low IDH activity prevents acetyl-coA from being channelled into the TCA 
cycle and therefore promotes export of acetyl-coA from the mitochondria. 
 
My work provides the first evidence that CAF metabolism regulates the CAF 
epigenetic phenotype through histone acetylation and that a link exists between 
PDH-mediated acetyl-coA production and collagen synthesis. My proteomic 
analysis of CAFs with inhibition of the HAT EP300 suggested that histone 
acetylation in CAFs was involved in activating transcription of ECM genes, which I 
subsequently confirmed with in vitro assays. There have been several studies 
showing that epigenetic changes are responsible for the increase in collagen 
production in myofibroblasts, indicating that a way through which CAFs can 
maintain a significant increase in collagen production is by increasing the 
transcription of the corresponding genes. My research has uncovered that PDH 
activity is an upstream regulator of this mechanism. TGFβ signalling is known to 
induce upregulation of ECM production in CAFs, and studies have shown that TGFβ 
is linked to expression of ECM genes through epigenetic alterations (Sun et al., 
2010, Vizoso et al., 2015). Since my work suggests that collagen expression is 
epigenetically regulated through PDH independently of TGFβ signalling, there may 
therefore be multiple mechanisms that CAFs can use to epigenetically control ECM 
production. Recently, CAF metabolism was shown to contribute to decreased 
H3K27 and H3K4 trimethylation through increased expression of nicotinamide N-
methyltransferase (NNMT) (Eckert et al., 2019). The decrease in histone 
methylation was induced by the depletion of S-adenosyl methionine by NNMT and 
promoted the transcription of markers of CAF activation, including ECM proteins. 
Furthermore, BET inhibitors, which block the response of BRD transcription factors 
to acetylated histones, inhibited the fibrotic phenotype in pancreatic cancer-
associated stellate cells, suggesting that increased histone acetylation is an 
important epigenetic regulator of fibroblast activation (Kumar et al., 2017). 
H3K27 acetylation is a known binding site for BRD4, and a decrease in H3K27me 
could be accompanied by an increase in H3K27ac, however, H3K27ac was not 
specifically investigated in these studies. Therefore my results showing that EP300 
activity and histone acetylation are increased in CAFs further corroborate the 
existence of an epigenetic switch in CAFs to promote ECM production. 
Additionally, also my findings indicate activation of transcription in CAFs, since 
H3K27ac is a well-known marker of active transcription and is often found at 
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enhancer regions (Raisner et al., 2018). It is already known that pathways 
activating transcription factors are upregulated in CAFs, such as TGFβ and NF-κβ 
signalling (Kojima et al., 2010, Pavlides et al., 2010b). Moreover, the CAF 
phenotype involves high levels of protein secretion (Hernandez-Fernaud et al., 
2017). It is therefore likely that overall transcription is upregulated in order to 
maintain an increased protein output, and my finding that overall histones were 
more acetylated supports this possibility. 
 
 In addition to ECM-related proteins, PDGFR, which is a well-known marker of CAF 
activation, was also significantly downregulated in the c646-treated CAF 
proteome. Other proteins that have been previously associated with CAF pro-
tumourigenic functions were also downregulated, such as TAGLN, THY1 and 
ITGA11 (Schliekelman et al., 2017, Navab et al., 2015, Yu et al., 2013). Therefore, 
in addition to regulating ECM production, histone acetylation may regulate other 
aspects of the activated CAF phenotype that might be relevant in cancer and 
therefore interesting to explore in the future. 
 
The second metabolic pathway that I found to regulate collagen production in 
CAFs was proline synthesis by PYCR1. There is increasing interest in how 
metabolites affect collagen synthesis. Amino acid availability clearly plays an 
important role, since glycine synthesis has been recently shown to regulate 
collagen production in fibrosis by maintaining the levels of glycine, which is highly 
abundant in collagens (Selvarajah et al., 2019). My work is the first to demonstrate 
that production and availability of the amino acid proline is important for collagen 
production. Pyruvate metabolism has also been shown to be important for collagen 
deposition. Collagen hydroxylation at proline residues is critical for the production 
of functional collagen molecules, because it stabilises the collagen helix. Pyruvate 
metabolism has been shown to support proline hydroxylation by providing a source 
of alpha-ketoglutarate which is a cofactor required for prolyl hydroxylase activity 
(Elia et al., 2019). Interestingly, the total levels of alpha-ketoglutarate were 
consistently higher in CAFs than in NFs, suggesting that the CAFs could also 
metabolically maintain the increased need of prolyl hydroxylase activity for 
collagen production. Why CAFs have more alpha-ketoglutarate is still an open 
question. The metabolomics tracing experiments that I performed showed that in 
CAFs alpha-ketoglutarate was derived mostly from glutamine rather than pyruvate 
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produced from glucose. I did not assess the contribution of extracellular pyruvate 
to TCA cycle metabolites, as pyruvate can enter the TCA cycle independently from 
the acetyl-coA pathway via conversion to oxaloacetate. Therefore tracing 
experiments using isotope labelled pyruvate should be performed to assess 
whether pyruvate could be a source of alpha-ketoglutarate in CAFs. Alternatively, 
the production of acetyl-coA from citrate by ACLY produces oxaloacetate in the 
cytosol. This oxaloacetate can be then combined with glutamate to make alpha-
ketoglutarate and aspartate (Fig. 7-2). It would therefore be interesting to 
investigate further the roles of extracellular pyruvate and alpha-ketoglutarate 
metabolism in regulating collagen production in CAFs.  
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Diagram showing that oxaloacetate and pyruvate are possible sources of alpha-
ketoglutarate  
Figure 7-2 Sources of alpha-ketoglutarate 
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By showing that PYCR1 expression is downstream of the PDH-induced histone 
acetylation in mammary CAFs, and that an increase in acetyl-coA availability 
corresponds with an increase in the intracellular proline levels, I provided the first 
link between acetyl-coA production by PDH and the proline synthesis pathway. 
Moreover, I have shown that EP300 activity is a key linker of these two pathways.  
However, I have not yet solved the details of the mechanism through which the 
epigenetic regulation triggered by PDH activity in CAFs coordinates the 
downstream increase in ECM and PYCR1 expression. Although, as discussed 
previously, it is already known that collagen synthesis is epigenetically regulated 
in fibroblasts, the regulation of PYCR1 at the epigenetic level has not been 
previously studied. Whilst I provided evidence that PYCR1 expression is controlled 
both by EP300 activity and acetyl-coA availability, it is possible that PYCR1 is not 
directly regulated by H3K27 acetylation, but is upregulated as part of a feedback 
mechanism when proline becomes limiting due to the increase demand of proline 
for collagen synthesis. PYCR1 levels have been shown to be upregulated by a lack 
of proline precursors (Loayza-Puch et al., 2016) and translation of mRNA 
transcripts for biosynthetic enzymes in bacteria is known to be inhibited by 
binding of amino acids to riboswitches, so that, when that amino acid is in short 
supply, translation of the mRNA is activated (Serganov and Patel, 2009). 
Transcription factors can also respond to shortages of amino acids, such as the 
ATF family of transcription factors (Kilberg et al., 2012). Therefore a proline 
sensing mechanism could be in place, so that when collagen production is 
increased and proline is used up more rapidly, more PYCR1 is produced. Since I 
saw upregulation of PYCR1 mRNA expression as well as the protein levels in 
conditions where histone acetylation is upregulated, it seems likely that there is 
a transcriptional or epigenetic component upstream of PYCR1 activation. 
 
I have shown that reduced levels of PYCR1 are sufficient to reduce the amount of 
collagen produced by CAFs, and that treating the cells with exogenous proline 
rescued the phenotype. This strongly points to the use of proline for translation 
as a limiting factor in collagen synthesis. A first indication of the importance of 
this process in vivo was the decreased tumour growth and collagen levels between 
MCF10DCIS.com breast cancer cells xenografts with shPYCR1 CAFs compared to 
the shCTL CAFs. This first in vivo experiment was important to show that reduced 
levels of PYCR1 in CAFs have a positive effect on reducing tumour growth in 
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xenografts, which provides further support for targeting PYCR1 in breast cancer, 
since reducing PYCR1 expression in breast cancer cells has already been 
demonstrated to reduce growth and invasion (Ding et al., 2017). If PYCR1 
inhibition also has a beneficial effect in inhibiting the pro-tumourigenic stroma, 
this could be a very effective strategy for targeting tumours. My data therefore 
suggest that tumours with both high PYCR1 expression and a significant stromal 
component would be good candidates for therapy involving PYCR1 inhibition. 
 
Much of the research on PYCR1 activity has focussed on its role in protecting 
against oxidative stress and apoptosis. In skin fibroblasts taken from cutis laxa 
patients with mutations leading to decreased levels or activity of PYCR1, there is 
an increase in mitochondrial dysfunction and ROS-mediated apoptosis due to the 
loss of protection against oxidative stress given by the activity of the proline cycle. 
(Cai et al., 2018, Reversade et al., 2009). No studies have yet investigated 
whether PYCR1 and proline production also protect against oxidative stress in 
CAFs. CAFs have been shown to have decreased mitochondrial functionality and 
increased ROS production in several studies (Martinez-Outschoorn et al., 2010b, 
Pavlides et al., 2010b). PYCR1 activity could therefore be a means of protecting 
the CAFs from ROS induced apoptosis and alleviating some of the negative effects 
of increased oxidative stress in CAFs. If PYCR1 activity does affect mitochondrial 
functionality in CAFs, inhibiting PYCR1 in the stroma could increase apoptosis in 
CAFs and thus reduce the total amount of pro-tumourigenic stroma in addition to 
targeting collagen production. Surprisingly, in my experiments the shCTL and 
shPCYR1 CAFs proliferated similarly in vitro. This suggests that if there are 
differences in mitochondrial functionality, they do not affect cell survival under 
standard cell culture conditions. These results are consistent with my data 
showing that, although there is a decrease in functional mitochondria in the 
mammary CAFs, this does not affect oxygen consumption rate, mitochondrial 
metabolism or proliferation under basal cell culture conditions, suggesting that a 
certain amount of mitochondrial dysfunction is tolerated by the CAFs. Although 
mitochondrial dysfunction may become a greater vulnerability in the context of 
the TME where nutrients and oxygen are limited, in the two week period that the 
shCTL and shPYCR1 CAFs grew together with the cancer cells in xenografts, I did 
not observe differences in the area of CAFs remaining. This suggests that the 
shPYCR1 CAFs are neither deficient in growth nor more apoptotic due to the loss 
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of PYCR1 in vivo. I cannot, however, exclude the possibility that differences would 
appear over a longer period of time. Further in vivo experiments would be 
required to confirm this. Another possible reason that I did not see differences in 
the amount of CAFs in vivo is that the shRNA against PYCR1 reduced PYCR1 levels 
only by about 50% at the protein level. This reduction could have been sufficient 
to reduce collagen production in culture, but it might not be enough to cause 
mitochondrial dysfunction and increased apoptosis as described in PYCR1 mutant 
cells.  
 
In recent years, the topic of CAF subpopulations and the possibility of targeting 
specific subpopulations have been studied more closely. I was therefore curious 
to investigate whether the metabolic pathways that I have identified are similarly 
regulated in a particular subset of CAFs. Current studies point to at least two 
subpopulations existing, of which one is pro-inflammatory and one is αSMA high 
and myofibroblastic (Bartoschek et al., 2018, Ohlund et al., 2017, Costa et al., 
2018). I analysed the gene expression data from the study by Ohlund et al., which 
focusses on two CAF phenotypes isolated from the KPC mouse model, because this 
study clearly differentiated between the pro-inflammatory and myofibroblastic 
subpopulations. I found that Pdk2 was downregulated and Pycr1 and Aldh18a1 
were upregulated in CAFs from the myofibroblastic subpopulation compared to 
the inflammatory subpopulation (Fig. 7-3) (Ohlund et al., 2017). This provides 
further evidence that the mechanism that I have discovered may be a general 
mechanism activated in myofibroblastic cells and not specific to the mammary 
CAFs I have studied, and also suggests that this pathway might be best targeted 
in tumours with a high proportion of αSMA positive CAFs in the stroma. 
 
To conclude, I have discovered an novel mechanism through which two metabolic 
pathways work together to support increase collagen production in activated CAFs 
both, at gene and protein expression level. Both of these pathways provide 
opportunities for targeting the activated CAF phenotype, with different 
advantages to each. PDH has several times been proposed as a therapeutic target; 
although until recently this has always been in the context of trying to activate 
PDH in tumour cells to mitigate the Warburg effect. However, although individual 
cases have responded to dichloroacetate treatment to inhibit PDK activity, in 
clinical trials no positive effect has been demonstrated (Dunbar et al., 2014, 
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Flavin, 2010b, Powell, 2015). Based on my work, activating PDH to reduce cancer 
cell aggressiveness might conversely increase the pro-tumorigenic and pro-fibrotic 
activity of the stroma, reducing the efficacy of this strategy. Thus, the effects of 
targeting PDH on the stroma should also be taken into account, and possibly 
tumours with a low stromal component would benefit most from PDK inhibitors. 
Furthermore, since PDH activation has a general effect on upregulating histone 
acetylation in CAFs, more pathways will be affected by PDH activation or 
inhibition than just ECM production, the effects of which I have not investigated. 
Therefore further investigation into which tumours might respond to DCA 
treatment is required, and probably tumours with a lower stromal component 
would be a better choice for further clinical testing. The drug CPI-613, which 
inhibits PDH activity, has had much greater success in clinical trials and, for 
example, has shown positive results in PDAC (Alistar, 2018), which is known to 
have a significant stromal component and in which the stroma has been shown to 
be highly pro-tumourigenic. CPI-613 is currently in clinical trials for other tumour 
types including breast, leukaemia, lung and liver cancer. It will be interesting both 
to find out whether CPI-613 is also effective in other tumours with a high stromal 
content, such as breast cancer, and also to investigate whether CPI-613 reduces 
the stromal component in mouse models as this would further support my results 
on the importance of activated PDH in promoting the fibrotic CAF phenotype. 
 
PYCR1 is well known to be upregulated in many tumours, and targeting PYCR1 in 
cancer cells inhibits tumour growth and metastasis (Cai et al., 2018, Ding et al., 
2017, Hollinshead et al., 2018). Here I have shown that PYCR1 is also upregulated 
and plays a pro-tumourigenic role in the stroma, making it an ideal target to 
simultaneously inhibit tumour and stromal cells. A small molecule PYCR1 inhibitor 
has been developed recently (Milne et al., 2019), which will create opportunities 
to test whether general PYCR1 inhibition, rather than specific ablation in cancer 
or stromal cells, is well tolerated in vivo and whether it is an effective anti-cancer 
therapy. The development of an inhibitor is a crucial step in being able to assess 
the impact of targeting PYCR1 in different tumour models and to verify whether 
it is an effective treatment strategy. 
 
The standard treatment for most breast cancers is either surgery or radiotherapy, 
combined with adjuvant or sometimes neoadjuvant chemotherapy or other drug 
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therapies. Targeting collagen synthesis in CAFs, either through PDH or PYCR1 
inhibition, would likely be most effective as a combination therapy with the 
current standard drug treatments. Reducing stromal collagen could improve 
tumour perfusion and thereby drug delivery, enhancing the effectiveness of the 
chemotherapy. Additionally, it could further contribute to reducing growth of the 
primary tumour in addition to any established metastases. In tumours where there 
are not yet detectable metastases, inhibiting collagen production by fibroblasts 
could also reduce the interaction of circulating tumour cells with the pre-
metastatic niche, since increased collagen crosslinking has been shown to be 
important for colony formation by disseminated breast cancer cells (Cox et al., 
2015). 
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Graphs show the log2 fold change in gene expression of PDK1, PDK2, the proline synthesis 
pathway and collagens in myofibroblastic CAFs (myCAFs) compared to inflammatory CAFs 
(iCAFs).  The dataset was taken from Ohlund et al., 2017. 
Figure 7-3 Expression of PDK, proline synthesis and collagen genes in CAF 
subpopulations 
248 
 
 
7.2 Future Work 
 
For the future, several questions remain outstanding which merit further research.  
It would be interesting to discover what lies upstream of PDK2 downregulation in 
CAFs to understand the trigger of the cascade of events that I have described. 
CAFs are known to maintain their activation through autocrine signalling feedback 
loops, such as TGFβ (Kojima et al., 2010). Therefore it is possible that interactions 
with their own ECM stimulate further ECM production by CAFs in another positive 
feedback loop to maintain CAF activation. My initial experiments suggest that CAF-
derived ECM stimulates PDK2 downregulation, possibly via PI3K/Akt signalling. 
Since integrins mediate a vast proportion of cell-ECM interactions, I would first 
carry out experiments in which integrins were inhibited to try and narrow down 
which integrin or integrins might be responsible for this pathway, and to 
investigate further the role of Akt/PI3K signalling in regulating collagen 
production by CAFs. I would also investigate the effects of FAK inhibitors on 
collagen production by CAFs, since FAK mediates integrin signalling and has 
previously been shown to regulate collagen production in fibroblasts (Kinoshita et 
al., 2013, Rajshankar et al., 2017). The PI3K/Akt/mTOR signalling pathway has 
been previously implicated in collagen production during idiopathic pulmonary 
fibrosis (Mercer et al., 2016). In this study the pathway was under the control of 
TGF-β signalling. However, TGF-β signalling does not appear to trigger PDK2 
regulation, because my data showed that TGFβ-1 stimulation did not regulate PDH 
phosphorylation in CAFs. Further experiments using other TGF-B receptor ligands 
would reveal whether TGF-β signalling plays any role at all in regulating PDK2 in 
CAFs. Interestingly, PYCR1 has recently been shown to be upregulated in response 
to ECM interactions in cancer cells (Guo et al., 2019). Therefore there is a 
precedent for ECM interactions regulating proline synthesis enzymes, and it will 
be important to test whether CAF-ECM can also stimulate proline production and 
PYCR1 expression in fibroblasts as this would further corroborate my results 
demonstrating a connection between PDH phosphorylation and PYCR1 expression. 
 
In this work I focussed on the role of histone acetylation and proline production in 
the context of collagen production in CAFs. Interestingly, several other ECM 
proteins were also downregulated in the MS-proteomic analysis of CAFs with EP300 
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inhibition by c646, including fibronectin. Fibronectin is known to contribute a 
significant proportion of CAF-derived ECM and to play important roles in tumour 
progression (Tang et al., 2016, Pickup et al., 2014). Our analysis of the proline 
content of ECM proteins showed that, similarly to collagens, fibronectin is also a 
proline-rich protein. It would therefore be interesting to extend my analysis and 
investigate the role of PDH and PYCR1 activity in the context of fibronectin 
production. It would also be important to do ChIP-Seq for H3K27ac in CAFs and 
NFs or CAFs treated with c646 to uncover which of the proteins that I found to be 
regulated by EP300 activity in my proteomic study are directly regulated by 
changes in H3K27 acetylation on enhancer regions of their genes. This would also 
clarify whether PYCR1 is epigenetically regulated by the same pathway as the 
collagens or whether it is regulated by other signalling downstream of collagen 
production. Moreover, since EP300 regulates acetylation of other histone sites and 
other histone sites were regulated between the acetylomes of CAFs and NFs, an 
unbiased MS-acetylome analysis of fibroblasts expressing different levels of PDK2 
would tell us whether the epigenetic control triggered by PDH activity also 
involves other histone modifications. c646 is also not completely specific for EP300 
(Shrimp et al., 2015), so to verify that my results are EP300 dependent I would 
need to repeat the key experiments with another EP300 inhibitor, such as A-485, 
which has been shown to specifically inhibit the ability of EP300 to acetylate 
H3K27 (Lasko et al., 2017). To explore the mechanism for the epigenetic control 
of collagen in CAFs in more depth, I would also need to investigate which 
transcription factors are regulating the epigenetic control of specific genes by 
EP300. To identify candidate transcription factors, I could use a MS-based 
proteomic approach and perform immunoprecipitation experiments to determine 
which factors interact with EP300 and H3K27ac in the fibroblasts with different 
levels of PDH activity.  
 
The role of proline in maintaining redox homeostasis and protecting against ROS 
and apoptosis has been investigated in the context of cancer cells (Cai et al., 
2018, Hollinshead et al., 2018, Kuo et al., 2016); as yet there have been no studies 
on proline metabolism and oxidative stress in CAFs. Although I did not observe any 
differences in survival between shCtl and shPCYR1 fibroblasts, either in vitro or in 
vivo, it is possible that a stronger depletion of PYCR1 is necessary to see 
differences. To address this, we are currently isolating mouse embryonic 
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fibroblasts (MEFs) from Pycr1 -/- mice which we plan to use for further xenograft 
experiments where they will be co-transplanted with 4T1 or E0771 cancer cells. 
The effect of the PYCR1 KO in these fibroblasts will be much stronger than the 
shPYCR1 cells that I have used for my experiments, so it is possible that we will 
see greater effects on vulnerability to ROS and survival in vitro and in vivo than 
we did with the shPYCR1 CAFs. 
 
Changes in the rate of proline production can also affect other metabolic 
pathways, because a by-product of proline synthesis by PYCR1 is the production 
of NADP+ or NAD+. I did not observe any significant differences in the NADH:NAD+ 
ratio between CAFs and NFs in my metabolomic experiments, with the exception 
of the pCAF3/pNF3 pair (Fig. 4-9). This suggests that the extra NAD+ in CAFs is 
used up in further metabolic reactions. NAD+ is required for production of acetyl-
coA by PDH, so the NAD+ could be used to maintain the increase in PDH activity 
in CAFs. NAD+ can be also be used to fuel glycolysis as it is required for flux through 
GAPDH. I did see an overall increase in intracellular PEP, which is downstream of 
GAPDH, in the CAFs, which could imply that there is an increase in flux through 
this part of the glycolytic pathway. NADP+ is required for the pentose phosphate 
pathway branch of glucose metabolism, which I did not investigate in my 
metabolomic tracing experiments, and PYCR1 activity has been previously shown 
to affect flux through the pentose phosphate pathway (Liu et al., 2015). 
Therefore, to determine whether the CAFs use PYCR1 produced NAD+ and NADP+ 
for glycolysis or the pentose phosphate pathway respectively I could use MS-
metabolomic tracing experiments to compare the flux through glyceraldehyde-3-
phosphate dehydrogenase and enzymes of the pentose phosphate pathway in the 
shCtl and shPYCR1 CAFs. 
 
Another question that is still not entirely answered is whether the proline residues 
produced by PYCR1 directly affect the translation of collagen mRNA into protein. 
I have shown that reducing PYCR1 levels is sufficient to reduce proline production 
and that the level of intracellular proline correlates with the amount of collagen 
deposited in the ECM by CAFs. I also demonstrated by MS-proteomics that proline 
produced by PYCR1 (i.e. 13C-proline labelled collagen) is incorporated into 
collagen, and that there is a decreased amount of collagen produced using 
glutamine-derived proline in the shPYCR1 CAFs. Whether this result is due to a 
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lack of proline for translation has not been conclusively shown. To answer this 
question, we are collaborating with Dr. Fabricio Loayza-Puch from the Deutsches 
Krebsforschung Zentrum in Heidelberg to measure whether there is an increase in 
ribosome stalling at proline codons in CAFs when CAFs express lower levels of 
PYCR1. This will determine whether proline produced by PYCR1 is necessary for 
protein translation. 
 
Finally, the in vivo xenograft experiment provided preliminary evidence that 
reducing levels of PYCR1 in fibroblasts affects collagen production and tumour 
growth in a xenograft model. However, the endogenous murine fibroblasts were 
also present in the stroma of the tumours, making it difficult to conclusively that 
the collagen measured was produced by the human pCAFs that we had 
transplanted. Further experiments are required to answer this question. First, I 
could isolate the transplanted fibroblasts and use qPCR and Western blot analyses 
to determine if the shPYCR1 fibroblasts express less collagen in vivo. Moreover, I 
could use a mouse model where PYCR1 is knocked out in the endogenous murine 
stroma, or perhaps treating tumour bearing mice with the small molecule inhibitor 
of PYCR1 which has recently been developed (Milne et al., 2019).  
 
Whether PDH inhibition in the stroma in vivo would have the same effect as 
inhibiting PYCR1 has not yet been addressed. We are currently working to create 
a model with Pdha1 specifically deleted in fibroblasts through an Fsp1-Cre model 
(Trimboli et al., 2008). In collaboration with the Transgenic Mouse Models team 
we are carrying out the necessary crosses to generate those mice in FVB and 
C57Bl/6 backgrounds for syngeneic orthotopic transplantation of breast cancer 
cells, such as E0771 or lines isolated from the GEM model MMTV-PyMT model. In 
addition to altering PDHA1 activity genetically, we could also target PDHA1 
pharmacologically using the PDH inhibitor CPI-613 in syngeneic orthotopic models 
or the MMTV-PyMT GEM model. CPI-613 is not specific for PDH as it also inhibits α-
ketoglutarate dehydrogenase, however it would be a good starting point to 
investigate the role of PDH activity on collagen production and tumour progression 
in vivo. If we find that CPI-613 and PYCR1 inhibition significantly decrease the 
amount of collagen in the stroma, we will test the effects of the inhibitors on 
tumour perfusion and whether this can improve drug delivery and the efficacy of 
chemotherapy. 
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To conclude, in this thesis I have shown that CAFs metabolically regulate collagen 
production both through increased PDH-mediated acetyl-coA production for 
epigenetic regulation of collagen genes, and through increased proline production 
to support production of collagen proteins. My results open up new possibilities 
for therapeutically targeting the desmoplastic TME to reduce tumour growth and 
metastasis, and to improve tumour perfusion and drug delivery. 
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